[{"authors":null,"categories":null,"content":"   个人履历       教育经历:     年份 学院 专业   2018.09- 华中科技大学同济医学院第一附属医院 泌尿外科   2010.09-2013.06 石河子大学医学院第一附属医院 泌尿外科   2005.09-2010.06 长沙医学院 临床医学   专业职称:     年份 单位 职称   2015.9- 石河子大学医学院第一附属医院 主治医师   2013.7-2015.08 石河子大学医学院第一附属医院 住院医师   教育职称:     年份 单位 职称   2019.12- 石河子大学 讲师   2013.11-2019.11 石河子大学 助教      Download my resumé.\n","date":-62135596800,"expirydate":-62135596800,"kind":"term","lang":"en","lastmod":-62135596800,"objectID":"2525497d367e79493fd32b198b28f040","permalink":"https://swcyo.netlify.app/author/%E6%AC%A7%E9%98%B3%E6%9D%BE/","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/author/%E6%AC%A7%E9%98%B3%E6%9D%BE/","section":"authors","summary":"个人履历       教育经历:     年份 学院 专业   2018.09- 华中科技大学同济医学院第一附属医院 泌尿外科   2010.09-2013.06 石河子大学医学院第一附属医院 泌尿外科   2005.","tags":null,"title":"欧阳松","type":"authors"},{"authors":[],"categories":["教程","R"],"content":"        基本介绍  oncomine是一个很好的肿瘤数据库，功能很强大，也有可视化的操作，但是最大的问题是数据不能很好的获得，，而且自带的图很丑（而且只是png），关于oncomine的教程有很多，比较经典有解螺旋的教程，比如下面这个，基本涵盖了常用的功能：\n 麦子陪你做作业（三）：肿瘤经典数据库Oncomine实训操作  然而，大神yikeshu0611默默的为我们付出，之前开发了一个R包叫ROncomine可以很方便的获得数据，并且再次出图，不过最近又更新为oncomineR了，新版的我还没研究，这里我们还是先说老版的ROncomine\n这个包以前托管在Github上（由于众所皆知的原因，国内访问Github很困难），但是目前已经删除了，好在我之前已经导入到了我的码云上了，所以也可以很快的安装。\n以前其实还有一个教程破解oncomine无法免费下载数据，学员开发了一款R语言包，但是目前也被删除了，估计这个还是有版权的，所以我还是悄悄的写个自己看的教程\n首先需要安装devtools，然后调用install_git函数就可以直接安装,之后就方便了\n install.packages(‘devtools’)\ndevtools::install_git(’https://gitee.com/swcyo/oncomineR’))\n 其实每一个oncomine的数据都可以使用浏览器获得，用chrome浏览器登录，随便一个地方鼠标右击找到检查元素，就可以看到代码区，使用Crtl+F查找\u0026lt;map，我们需要的代码全都在\u0026lt;map那一片，右击复制然后新建一个文本文档保存起来\noncomineR的原理只是是把检查元素里\u0026lt;map那串代码二次处理，从而简化工作，然后调用ploty作图，当然你也可以用ggplot2再次画图\n单基因在基本中的总结（Gene Summary）  按照解螺旋的教程，比如搜索CXCL8基因，实际上基因名为IL8，然后我们可以在右边看到这样的一个热图：\n我们复制\u0026lt;map那一串代码，保存为heatmap.txt文件，我们可以用Oncomine_heatmap_DiseaseSummaryfor_SomeGene处理\n library(ROncomine) heat\u0026lt;-Oncomine_heatmap_DiseaseSummaryfor_SomeGene(\u0026#39;/Users/mac/Documents/GitHub/myblog/content/post/2021-08-19-oncomine/heatmap.txt\u0026#39;) # 命名为heat knitr::kable(heat) ## 这步是我的教程示例代码，不需要执行    Cancer Type Analysis Type meat threshold meat intotal expression    X1 Bladder Cancer Cancer Histology 3 18 over  X2 Bladder Cancer Cancer Histology 3 18 under  X3 Bladder Cancer Multi-cancer 1 9 over  X4 Bladder Cancer Outlier 4 12 over  X5 Bladder Cancer Outlier 2 12 under  X6 Brain and CNS Cancer Cancer vs. Normal 1 36 over  X7 Brain and CNS Cancer Cancer Histology 3 66 over  X8 Brain and CNS Cancer Cancer Histology 2 66 under  X9 Brain and CNS Cancer Outlier 16 37 over  X10 Brain and CNS Cancer Outlier 7 37 under  X11 Breast Cancer Multi-cancer 2 23 under  X12 Breast Cancer Outlier 29 68 over  X13 Breast Cancer Outlier 5 68 under  X14 Cervical Cancer Cancer vs. Normal 4 10 over  X15 Cervical Cancer Outlier 2 8 over  X16 Colorectal Cancer Cancer vs. Normal 18 35 over  X17 Colorectal Cancer Cancer Histology 1 32 over  X18 Colorectal Cancer Cancer Histology 1 32 under  X19 Colorectal Cancer Multi-cancer 4 24 over  X20 Colorectal Cancer Outlier 3 35 over  X21 Colorectal Cancer Outlier 4 35 under  X22 Esophageal Cancer Cancer vs. Normal 3 11 over  X23 Esophageal Cancer Cancer Histology 1 8 over  X24 Esophageal Cancer Cancer Histology 1 8 under  X25 Esophageal Cancer Multi-cancer 1 8 over  X26 Esophageal Cancer Outlier 3 12 over  X27 Esophageal Cancer Outlier 1 12 under  X28 Gastric Cancer Cancer vs. Normal 2 23 over  X29 Gastric Cancer Cancer Histology 1 29 over  X30 Gastric Cancer Cancer Histology 1 29 under  X31 Gastric Cancer Outlier 1 15 over  X32 Gastric Cancer Outlier 3 15 under  X33 Head and Neck Cancer Cancer vs. Normal 4 32 over  X34 Head and Neck Cancer Cancer Histology 1 14 over  X35 Head and Neck Cancer Multi-cancer 2 10 over  X36 Head and Neck Cancer Multi-cancer 1 10 under  X37 Head and Neck Cancer Outlier 4 22 over  X38 Head and Neck Cancer Outlier 6 22 under  X39 Kidney Cancer Cancer Histology 1 44 over  X40 Kidney Cancer Cancer Histology 1 44 under  X41 Kidney Cancer Multi-cancer 1 18 over  X42 Kidney Cancer Multi-cancer 1 18 under  X43 Kidney Cancer Outlier 10 18 over  X44 Kidney Cancer Outlier 2 18 under  X45 Leukemia Cancer vs. Normal 1 39 over  X46 Leukemia Cancer vs. Normal 3 39 under  X47 Leukemia Cancer Histology 6 117 over  X48 Leukemia Cancer Histology 4 117 under  X49 Leukemia Outlier 14 56 over  X50 Leukemia Outlier 12 56 under  X51 Liver Cancer Cancer vs. Normal 2 13 over  X52 Liver Cancer Outlier 2 15 over  X53 Liver Cancer Outlier 7 15 under  X54 Lung Cancer Multi-cancer 2 22 over  X55 Lung Cancer Outlier 10 36 over  X56 Lung Cancer Outlier 4 36 under  X57 Lymphoma Cancer vs. Normal 2 36 under  X58 Lymphoma Multi-cancer 5 17 under  X59 Lymphoma Outlier 18 34 over  X60 Lymphoma Outlier 2 34 under  X61 Melanoma Cancer Histology 1 4 over  X62 Melanoma Cancer Histology 1 4 under  X63 Melanoma Multi-cancer 1 18 over  X64 Melanoma Outlier 7 22 over  X65 Melanoma Outlier 4 22 under  X66 Myeloma Cancer Histology 1 13 over  X67 Myeloma Cancer Histology 1 13 under  X68 Myeloma Multi-cancer 2 6 under  X69 Myeloma Outlier 2 16 over  X70 Myeloma Outlier 3 16 under  X71 Other Cancer Cancer vs. Normal 3 32 over  X72 Other Cancer Cancer Histology 1 32 under  X73 Other Cancer Outlier 12 36 over  X74 Other Cancer Outlier 2 36 under  X75 Ovarian Cancer Outlier 5 19 over  X76 Ovarian Cancer Outlier 2 19 under  X77 Pancreatic Cancer Cancer vs. Normal 3 12 over  X78 Pancreatic Cancer Outlier 1 14 over  X79 Pancreatic Cancer Outlier 1 14 under  X80 Prostate Cancer Outlier 7 30 over  X81 Prostate Cancer Outlier 1 30 under  X82 Sarcoma Cancer Histology 2 101 over  X83 Sarcoma Cancer Histology 1 101 under  X84 Sarcoma Multi-cancer 2 13 under  X85 Sarcoma Outlier 9 25 over  X86 Sarcoma Outlier 2 25 under    这样我们很快的就提取了所有需要的数据，比如我们只想提取Cancer vs. Normal，那么可以用R语言处理，也可以用DataEditR交互式处理，或者导出来用excel处理\n# cn\u0026lt;-heat[heat$`Analysis Type` == \u0026#39;Cancer vs. Normal\u0026#39;,] # DataEditR::data_edit(heat) # 也可以用交互式编辑 cn\u0026lt;-read.csv(\u0026#39;/Users/mac/Documents/GitHub/myblog/content/post/2021-08-19-oncomine/cn.csv\u0026#39;) knitr::kable(cn)   X Cancer.Type Analysis.Type. meat.threshold meat.intotal expression    X6 Brain and CNS Cancer Cancer vs. Normal 1 36 over  X14 Cervical Cancer Cancer vs. Normal 4 10 over  X16 Colorectal Cancer Cancer vs. Normal 18 35 over  X22 Esophageal Cancer Cancer vs. Normal 3 11 over  X28 Gastric Cancer Cancer vs. Normal 2 23 over  X33 Head and Neck Cancer Cancer vs. Normal 4 32 over  X45 Leukemia Cancer vs. Normal 1 39 over  X46 Leukemia Cancer vs. Normal 3 39 under  X51 Liver Cancer Cancer vs. Normal 2 13 over  X57 Lymphoma Cancer vs. Normal 2 36 under  X71 Other Cancer Cancer vs. Normal 3 32 over  X77 Pancreatic Cancer Cancer vs. Normal 3 12 over    正常与癌症组织比较（Differential Analysis）  继续使用解螺旋的示例，用Oncomine分别查询CXCL8在肠癌组织（与正常比）中高表达的数据集和低表达的数据集。筛选条件：P-value：1E-4；Fold Change：3；GENE Rank：Top10%。\n这里要注意，默认选择的是子数据，比如Kalser Colon，光标是在Colon Mucinous Adenocarcinoma vs. Normal，这样只是比较肿瘤亚型与正常，这个时候在Differential Analysis的GROUP BY是灰白的，如果我们要看所有，就要点击Kalser Colon，然后GROUP BY就可以选择下拉框了，我们选择Cancer and Normal Type，我们可以看到在GROUP里有很多很多的分组，其实就是很多很多的数据，我们想要的都可以提取了\n默认的是一个barplot，出现的是直方图，鼠标在柱子上停留就可以看到value，也就是我们需要的\n可以看到有一个箱式图的图标，点一下就变成了Boxplot，鼠标房子Box上可以看到参数\n同样的办法，复制\u0026lt;map代码区并保存为文本文件，比如命名为box.txt,这里其实box和bar的界面结果是一样的，我们在bar里复制，然后使用Oncomine_bar函数\n box\u0026lt;-Oncomine_bar(\u0026#39;/Users/mac/Documents/GitHub/myblog/content/post/2021-08-19-oncomine/box.txt\u0026#39;) knitr::kable(box)     Expression value Cancer Type Sample Name Normal Tissue Type Legend Value    3.509 Colon Small Cell Carcinoma T4360A3 No value No value  4.205 Colon Signet Ring Cell Adenocarcinoma T5245A1 No value No value  4.407 Rectosigmoid Mucinous Adenocarcinoma T940A No value No value  4.575 Colon Small Cell Carcinoma T4360A2 No value No value  5.109 Rectal Signet Ring Cell Adenocarcinoma T924C No value No value  5.867 Colon Signet Ring Cell Adenocarcinoma T5002A1 No value No value  6.110 Rectosigmoid Mucinous Adenocarcinoma T4980A1 No value No value  0.188 Cancer N552G Colon Colon  0.315 Cancer N1369A Colon Colon  0.533 Cancer N773A1 Colon Colon  1.020 Cancer N1102A Colon Colon  1.160 Cancer N2367A Colon Colon  2.732 Cancer T4452A1 Cecum Adenocarcinoma Cecum Adenocarcinoma  2.889 Cancer T4550B Cecum Adenocarcinoma Cecum Adenocarcinoma  2.944 Cancer T902A Cecum Adenocarcinoma Cecum Adenocarcinoma  3.397 Cancer T4834A1 Cecum Adenocarcinoma Cecum Adenocarcinoma  3.453 Cancer T4354H Cecum Adenocarcinoma Cecum Adenocarcinoma  4.437 Cancer T4544A1 Cecum Adenocarcinoma Cecum Adenocarcinoma  4.492 Cancer T4926A1 Cecum Adenocarcinoma Cecum Adenocarcinoma  4.597 Cancer T5376A1 Cecum Adenocarcinoma Cecum Adenocarcinoma  4.623 Cancer T4452A2 Cecum Adenocarcinoma Cecum Adenocarcinoma  4.724 Cancer T4452A Cecum Adenocarcinoma Cecum Adenocarcinoma  4.801 Cancer T4452A3 Cecum Adenocarcinoma Cecum Adenocarcinoma  5.183 Cancer T5133A Cecum Adenocarcinoma Cecum Adenocarcinoma  5.315 Cancer T4452A4 Cecum Adenocarcinoma Cecum Adenocarcinoma  5.407 Cancer T5024A1 Cecum Adenocarcinoma Cecum Adenocarcinoma  5.897 Cancer T4573A1 Cecum Adenocarcinoma Cecum Adenocarcinoma  5.981 Cancer T4984A1 Cecum Adenocarcinoma Cecum Adenocarcinoma  6.215 Cancer T5565A1 Cecum Adenocarcinoma Cecum Adenocarcinoma  1.644 Cancer T5811A1 Colon Adenocarcinoma Colon Adenocarcinoma  2.586 Cancer T4174A Colon Adenocarcinoma Colon Adenocarcinoma  2.747 Cancer T4701A1 Colon Adenocarcinoma Colon Adenocarcinoma  3.043 Cancer T519A Colon Adenocarcinoma Colon Adenocarcinoma  3.377 Cancer T6190A1 Colon Adenocarcinoma Colon Adenocarcinoma  3.553 Cancer T5287A1 Colon Adenocarcinoma Colon Adenocarcinoma  3.634 Cancer T4660A1 Colon Adenocarcinoma Colon Adenocarcinoma  3.748 Cancer T573A Colon Adenocarcinoma Colon Adenocarcinoma  3.838 Cancer T740A Colon Adenocarcinoma Colon Adenocarcinoma  3.877 Cancer T4373B1 Colon Adenocarcinoma Colon Adenocarcinoma  3.927 Cancer T5573A1 Colon Adenocarcinoma Colon Adenocarcinoma  3.931 Cancer T826A Colon Adenocarcinoma Colon Adenocarcinoma  3.982 Cancer T4448A Colon Adenocarcinoma Colon Adenocarcinoma  4.052 Cancer T4612A1 Colon Adenocarcinoma Colon Adenocarcinoma  4.061 Cancer T5266A1 Colon Adenocarcinoma Colon Adenocarcinoma  4.161 Cancer T433A Colon Adenocarcinoma Colon Adenocarcinoma  4.168 Cancer T4376A Colon Adenocarcinoma Colon Adenocarcinoma  4.173 Cancer T5589B1 Colon Adenocarcinoma Colon Adenocarcinoma  4.188 Cancer T4475A1 Colon Adenocarcinoma Colon Adenocarcinoma  4.294 Cancer T5164A1 Colon Adenocarcinoma Colon Adenocarcinoma  4.395 Cancer T4956A1 Colon Adenocarcinoma Colon Adenocarcinoma  4.441 Cancer T4975A1 Colon Adenocarcinoma Colon Adenocarcinoma  4.478 Cancer T773A1 Colon Adenocarcinoma Colon Adenocarcinoma  4.566 Cancer T4373B2 Colon Adenocarcinoma Colon Adenocarcinoma  4.761 Cancer T949B Colon Adenocarcinoma Colon Adenocarcinoma  4.810 Cancer T4750A1 Colon Adenocarcinoma Colon Adenocarcinoma  4.857 Cancer T4257A Colon Adenocarcinoma Colon Adenocarcinoma  4.956 Cancer T801A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.044 Cancer T5162A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.077 Cancer T5389A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.172 Cancer T4695A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.241 Cancer T4667A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.243 Cancer T4508A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.286 Cancer T4920A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.330 Cancer T5107B1 Colon Adenocarcinoma Colon Adenocarcinoma  5.614 Cancer T4373B3 Colon Adenocarcinoma Colon Adenocarcinoma  5.638 Cancer T4541A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.674 Cancer T4489A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.819 Cancer T4555A1 Colon Adenocarcinoma Colon Adenocarcinoma  5.852 Cancer T5063A Colon Adenocarcinoma Colon Adenocarcinoma  5.959 Cancer T5102A1 Colon Adenocarcinoma Colon Adenocarcinoma  3.001 Cancer T5513A1 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  3.836 Cancer T4948A2 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  4.035 Cancer T4611B1 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  4.225 Cancer T4799A1 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  4.389 Cancer T932B1 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  4.776 Cancer T5536C4 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  4.838 Cancer T451A Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  4.872 Cancer T5261B1 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  5.087 Cancer T4491A1 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  5.304 Cancer T694C Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  5.676 Cancer T4644B1 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  5.973 Cancer T625A Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  6.231 Cancer T4491A2 Colon Mucinous Adenocarcinoma Colon Mucinous Adenocarcinoma  2.231 Cancer T551C Rectal Adenocarcinoma Rectal Adenocarcinoma  2.638 Cancer T645A Rectal Adenocarcinoma Rectal Adenocarcinoma  3.811 Cancer T521B Rectal Adenocarcinoma Rectal Adenocarcinoma  4.441 Cancer T789A Rectal Adenocarcinoma Rectal Adenocarcinoma  4.584 Cancer T74A Rectal Adenocarcinoma Rectal Adenocarcinoma  4.669 Cancer T565A Rectal Adenocarcinoma Rectal Adenocarcinoma  5.346 Cancer T462A Rectal Adenocarcinoma Rectal Adenocarcinoma  5.547 Cancer T420A Rectal Adenocarcinoma Rectal Adenocarcinoma  3.798 Cancer T4449E4 Rectal Mucinous Adenocarcinoma Rectal Mucinous Adenocarcinoma  4.233 Cancer T4449E3 Rectal Mucinous Adenocarcinoma Rectal Mucinous Adenocarcinoma  4.360 Cancer T4449E1 Rectal Mucinous Adenocarcinoma Rectal Mucinous Adenocarcinoma  4.784 Cancer T4449E2 Rectal Mucinous Adenocarcinoma Rectal Mucinous Adenocarcinoma  2.439 Cancer T5139A1 Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma  2.922 Cancer T4919A1 Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma  2.983 Cancer T656A Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma  3.072 Cancer T771A Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma  3.404 Cancer T866D Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma  3.846 Cancer T5430A1 Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma  4.396 Cancer T552G Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma  4.789 Cancer T981A Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma  5.055 Cancer T4603A1 Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma  5.815 Cancer T672A Rectosigmoid Adenocarcinoma Rectosigmoid Adenocarcinoma    我们可以用自带的函数画个图，有两个图，一个是bar_plot，一个是box_plot\nOncomine_bar_plot(box) ## 载入需要的程辑包：ggplot2 ## ## 载入程辑包：\u0026#39;plotly\u0026#39; ## The following object is masked from \u0026#39;package:ggplot2\u0026#39;: ## ## last_plot ## The following object is masked from \u0026#39;package:stats\u0026#39;: ## ## filter ## The following object is masked from \u0026#39;package:graphics\u0026#39;: ## ## layout  {\"x\":{\"visdat\":{\"50921e545457\":[\"function () \",\"plotlyVisDat\"]},\"cur_data\":\"50921e545457\",\"attrs\":{\"50921e545457\":{\"x\":{},\"y\":{},\"text\":[\"Expression: 3.509\",\"Expression: 4.205\",\"Expression: 4.407\",\"Expression: 4.575\",\"Expression: 5.109\",\"Expression: 5.867\",\"Expression: 6.11\",\"Expression: 0.188\",\"Expression: 0.315\",\"Expression: 0.533\",\"Expression: 1.02\",\"Expression: 1.16\",\"Expression: 2.732\",\"Expression: 2.889\",\"Expression: 2.944\",\"Expression: 3.397\",\"Expression: 3.453\",\"Expression: 4.437\",\"Expression: 4.492\",\"Expression: 4.597\",\"Expression: 4.623\",\"Expression: 4.724\",\"Expression: 4.801\",\"Expression: 5.183\",\"Expression: 5.315\",\"Expression: 5.407\",\"Expression: 5.897\",\"Expression: 5.981\",\"Expression: 6.215\",\"Expression: 1.644\",\"Expression: 2.586\",\"Expression: 2.747\",\"Expression: 3.043\",\"Expression: 3.377\",\"Expression: 3.553\",\"Expression: 3.634\",\"Expression: 3.748\",\"Expression: 3.838\",\"Expression: 3.877\",\"Expression: 3.927\",\"Expression: 3.931\",\"Expression: 3.982\",\"Expression: 4.052\",\"Expression: 4.061\",\"Expression: 4.161\",\"Expression: 4.168\",\"Expression: 4.173\",\"Expression: 4.188\",\"Expression: 4.294\",\"Expression: 4.395\",\"Expression: 4.441\",\"Expression: 4.478\",\"Expression: 4.566\",\"Expression: 4.761\",\"Expression: 4.81\",\"Expression: 4.857\",\"Expression: 4.956\",\"Expression: 5.044\",\"Expression: 5.077\",\"Expression: 5.172\",\"Expression: 5.241\",\"Expression: 5.243\",\"Expression: 5.286\",\"Expression: 5.33\",\"Expression: 5.614\",\"Expression: 5.638\",\"Expression: 5.674\",\"Expression: 5.819\",\"Expression: 5.852\",\"Expression: 5.959\",\"Expression: 3.001\",\"Expression: 3.836\",\"Expression: 4.035\",\"Expression: 4.225\",\"Expression: 4.389\",\"Expression: 4.776\",\"Expression: 4.838\",\"Expression: 4.872\",\"Expression: 5.087\",\"Expression: 5.304\",\"Expression: 5.676\",\"Expression: 5.973\",\"Expression: 6.231\",\"Expression: 2.231\",\"Expression: 2.638\",\"Expression: 3.811\",\"Expression: 4.441\",\"Expression: 4.584\",\"Expression: 4.669\",\"Expression: 5.346\",\"Expression: 5.547\",\"Expression: 3.798\",\"Expression: 4.233\",\"Expression: 4.36\",\"Expression: 4.784\",\"Expression: 2.439\",\"Expression: 2.922\",\"Expression: 2.983\",\"Expression: 3.072\",\"Expression: 3.404\",\"Expression: 3.846\",\"Expression: 4.396\",\"Expression: 4.789\",\"Expression: 5.055\",\"Expression: 5.815\"],\"color\":{},\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"type\":\"bar\"}},\"layout\":{\"margin\":{\"b\":40,\"l\":60,\"t\":25,\"r\":10},\"title\":\"Bar plot\",\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"`Sample Name`\",\"type\":\"category\",\"categoryorder\":\"array\",\"categoryarray\":[\"T4360A3\",\"T5245A1\",\"T940A\",\"T4360A2\",\"T924C\",\"T5002A1\",\"T4980A1\",\"N552G\",\"N1369A\",\"N773A1\",\"N1102A\",\"N2367A\",\"T4452A1\",\"T4550B\",\"T902A\",\"T4834A1\",\"T4354H\",\"T4544A1\",\"T4926A1\",\"T5376A1\",\"T4452A2\",\"T4452A\",\"T4452A3\",\"T5133A\",\"T4452A4\",\"T5024A1\",\"T4573A1\",\"T4984A1\",\"T5565A1\",\"T5811A1\",\"T4174A\",\"T4701A1\",\"T519A\",\"T6190A1\",\"T5287A1\",\"T4660A1\",\"T573A\",\"T740A\",\"T4373B1\",\"T5573A1\",\"T826A\",\"T4448A\",\"T4612A1\",\"T5266A1\",\"T433A\",\"T4376A\",\"T5589B1\",\"T4475A1\",\"T5164A1\",\"T4956A1\",\"T4975A1\",\"T773A1\",\"T4373B2\",\"T949B\",\"T4750A1\",\"T4257A\",\"T801A1\",\"T5162A1\",\"T5389A1\",\"T4695A1\",\"T4667A1\",\"T4508A1\",\"T4920A1\",\"T5107B1\",\"T4373B3\",\"T4541A1\",\"T4489A1\",\"T4555A1\",\"T5063A\",\"T5102A1\",\"T5513A1\",\"T4948A2\",\"T4611B1\",\"T4799A1\",\"T932B1\",\"T5536C4\",\"T451A\",\"T5261B1\",\"T4491A1\",\"T694C\",\"T4644B1\",\"T625A\",\"T4491A2\",\"T551C\",\"T645A\",\"T521B\",\"T789A\",\"T74A\",\"T565A\",\"T462A\",\"T420A\",\"T4449E4\",\"T4449E3\",\"T4449E1\",\"T4449E2\",\"T5139A1\",\"T4919A1\",\"T656A\",\"T771A\",\"T866D\",\"T5430A1\",\"T552G\",\"T981A\",\"T4603A1\",\"T672A\"]},\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"`Expression value`\"},\"hovermode\":\"closest\",\"showlegend\":true},\"source\":\"A\",\"config\":{\"showSendToCloud\":false},\"data\":[{\"x\":[\"T4360A3\",\"T5245A1\",\"T940A\",\"T4360A2\",\"T924C\",\"T5002A1\",\"T4980A1\"],\"y\":[3.509,4.205,4.407,4.575,5.109,5.867,6.11],\"text\":[\"Expression: 3.509\",\"Expression: 4.205\",\"Expression: 4.407\",\"Expression: 4.575\",\"Expression: 5.109\",\"Expression: 5.867\",\"Expression: 6.11\"],\"type\":\"bar\",\"name\":\"No value\",\"marker\":{\"color\":\"rgba(102,194,165,1)\",\"line\":{\"color\":\"rgba(102,194,165,1)\"}},\"textfont\":{\"color\":\"rgba(102,194,165,1)\"},\"error_y\":{\"color\":\"rgba(102,194,165,1)\"},\"error_x\":{\"color\":\"rgba(102,194,165,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"x\":[\"N552G\",\"N1369A\",\"N773A1\",\"N1102A\",\"N2367A\"],\"y\":[0.188,0.315,0.533,1.02,1.16],\"text\":[\"Expression: 0.188\",\"Expression: 0.315\",\"Expression: 0.533\",\"Expression: 1.02\",\"Expression: 1.16\"],\"type\":\"bar\",\"name\":\"Colon\",\"marker\":{\"color\":\"rgba(252,141,98,1)\",\"line\":{\"color\":\"rgba(252,141,98,1)\"}},\"textfont\":{\"color\":\"rgba(252,141,98,1)\"},\"error_y\":{\"color\":\"rgba(252,141,98,1)\"},\"error_x\":{\"color\":\"rgba(252,141,98,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"x\":[\"T4452A1\",\"T4550B\",\"T902A\",\"T4834A1\",\"T4354H\",\"T4544A1\",\"T4926A1\",\"T5376A1\",\"T4452A2\",\"T4452A\",\"T4452A3\",\"T5133A\",\"T4452A4\",\"T5024A1\",\"T4573A1\",\"T4984A1\",\"T5565A1\"],\"y\":[2.732,2.889,2.944,3.397,3.453,4.437,4.492,4.597,4.623,4.724,4.801,5.183,5.315,5.407,5.897,5.981,6.215],\"text\":[\"Expression: 2.732\",\"Expression: 2.889\",\"Expression: 2.944\",\"Expression: 3.397\",\"Expression: 3.453\",\"Expression: 4.437\",\"Expression: 4.492\",\"Expression: 4.597\",\"Expression: 4.623\",\"Expression: 4.724\",\"Expression: 4.801\",\"Expression: 5.183\",\"Expression: 5.315\",\"Expression: 5.407\",\"Expression: 5.897\",\"Expression: 5.981\",\"Expression: 6.215\"],\"type\":\"bar\",\"name\":\"Cecum Adenocarcinoma\",\"marker\":{\"color\":\"rgba(141,160,203,1)\",\"line\":{\"color\":\"rgba(141,160,203,1)\"}},\"textfont\":{\"color\":\"rgba(141,160,203,1)\"},\"error_y\":{\"color\":\"rgba(141,160,203,1)\"},\"error_x\":{\"color\":\"rgba(141,160,203,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"x\":[\"T5811A1\",\"T4174A\",\"T4701A1\",\"T519A\",\"T6190A1\",\"T5287A1\",\"T4660A1\",\"T573A\",\"T740A\",\"T4373B1\",\"T5573A1\",\"T826A\",\"T4448A\",\"T4612A1\",\"T5266A1\",\"T433A\",\"T4376A\",\"T5589B1\",\"T4475A1\",\"T5164A1\",\"T4956A1\",\"T4975A1\",\"T773A1\",\"T4373B2\",\"T949B\",\"T4750A1\",\"T4257A\",\"T801A1\",\"T5162A1\",\"T5389A1\",\"T4695A1\",\"T4667A1\",\"T4508A1\",\"T4920A1\",\"T5107B1\",\"T4373B3\",\"T4541A1\",\"T4489A1\",\"T4555A1\",\"T5063A\",\"T5102A1\"],\"y\":[1.644,2.586,2.747,3.043,3.377,3.553,3.634,3.748,3.838,3.877,3.927,3.931,3.982,4.052,4.061,4.161,4.168,4.173,4.188,4.294,4.395,4.441,4.478,4.566,4.761,4.81,4.857,4.956,5.044,5.077,5.172,5.241,5.243,5.286,5.33,5.614,5.638,5.674,5.819,5.852,5.959],\"text\":[\"Expression: 1.644\",\"Expression: 2.586\",\"Expression: 2.747\",\"Expression: 3.043\",\"Expression: 3.377\",\"Expression: 3.553\",\"Expression: 3.634\",\"Expression: 3.748\",\"Expression: 3.838\",\"Expression: 3.877\",\"Expression: 3.927\",\"Expression: 3.931\",\"Expression: 3.982\",\"Expression: 4.052\",\"Expression: 4.061\",\"Expression: 4.161\",\"Expression: 4.168\",\"Expression: 4.173\",\"Expression: 4.188\",\"Expression: 4.294\",\"Expression: 4.395\",\"Expression: 4.441\",\"Expression: 4.478\",\"Expression: 4.566\",\"Expression: 4.761\",\"Expression: 4.81\",\"Expression: 4.857\",\"Expression: 4.956\",\"Expression: 5.044\",\"Expression: 5.077\",\"Expression: 5.172\",\"Expression: 5.241\",\"Expression: 5.243\",\"Expression: 5.286\",\"Expression: 5.33\",\"Expression: 5.614\",\"Expression: 5.638\",\"Expression: 5.674\",\"Expression: 5.819\",\"Expression: 5.852\",\"Expression: 5.959\"],\"type\":\"bar\",\"name\":\"Colon Adenocarcinoma\",\"marker\":{\"color\":\"rgba(231,138,195,1)\",\"line\":{\"color\":\"rgba(231,138,195,1)\"}},\"textfont\":{\"color\":\"rgba(231,138,195,1)\"},\"error_y\":{\"color\":\"rgba(231,138,195,1)\"},\"error_x\":{\"color\":\"rgba(231,138,195,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"x\":[\"T5513A1\",\"T4948A2\",\"T4611B1\",\"T4799A1\",\"T932B1\",\"T5536C4\",\"T451A\",\"T5261B1\",\"T4491A1\",\"T694C\",\"T4644B1\",\"T625A\",\"T4491A2\"],\"y\":[3.001,3.836,4.035,4.225,4.389,4.776,4.838,4.872,5.087,5.304,5.676,5.973,6.231],\"text\":[\"Expression: 3.001\",\"Expression: 3.836\",\"Expression: 4.035\",\"Expression: 4.225\",\"Expression: 4.389\",\"Expression: 4.776\",\"Expression: 4.838\",\"Expression: 4.872\",\"Expression: 5.087\",\"Expression: 5.304\",\"Expression: 5.676\",\"Expression: 5.973\",\"Expression: 6.231\"],\"type\":\"bar\",\"name\":\"Colon Mucinous Adenocarcinoma\",\"marker\":{\"color\":\"rgba(166,216,84,1)\",\"line\":{\"color\":\"rgba(166,216,84,1)\"}},\"textfont\":{\"color\":\"rgba(166,216,84,1)\"},\"error_y\":{\"color\":\"rgba(166,216,84,1)\"},\"error_x\":{\"color\":\"rgba(166,216,84,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"x\":[\"T551C\",\"T645A\",\"T521B\",\"T789A\",\"T74A\",\"T565A\",\"T462A\",\"T420A\"],\"y\":[2.231,2.638,3.811,4.441,4.584,4.669,5.346,5.547],\"text\":[\"Expression: 2.231\",\"Expression: 2.638\",\"Expression: 3.811\",\"Expression: 4.441\",\"Expression: 4.584\",\"Expression: 4.669\",\"Expression: 5.346\",\"Expression: 5.547\"],\"type\":\"bar\",\"name\":\"Rectal Adenocarcinoma\",\"marker\":{\"color\":\"rgba(255,217,47,1)\",\"line\":{\"color\":\"rgba(255,217,47,1)\"}},\"textfont\":{\"color\":\"rgba(255,217,47,1)\"},\"error_y\":{\"color\":\"rgba(255,217,47,1)\"},\"error_x\":{\"color\":\"rgba(255,217,47,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"x\":[\"T4449E4\",\"T4449E3\",\"T4449E1\",\"T4449E2\"],\"y\":[3.798,4.233,4.36,4.784],\"text\":[\"Expression: 3.798\",\"Expression: 4.233\",\"Expression: 4.36\",\"Expression: 4.784\"],\"type\":\"bar\",\"name\":\"Rectal Mucinous Adenocarcinoma\",\"marker\":{\"color\":\"rgba(229,196,148,1)\",\"line\":{\"color\":\"rgba(229,196,148,1)\"}},\"textfont\":{\"color\":\"rgba(229,196,148,1)\"},\"error_y\":{\"color\":\"rgba(229,196,148,1)\"},\"error_x\":{\"color\":\"rgba(229,196,148,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"x\":[\"T5139A1\",\"T4919A1\",\"T656A\",\"T771A\",\"T866D\",\"T5430A1\",\"T552G\",\"T981A\",\"T4603A1\",\"T672A\"],\"y\":[2.439,2.922,2.983,3.072,3.404,3.846,4.396,4.789,5.055,5.815],\"text\":[\"Expression: 2.439\",\"Expression: 2.922\",\"Expression: 2.983\",\"Expression: 3.072\",\"Expression: 3.404\",\"Expression: 3.846\",\"Expression: 4.396\",\"Expression: 4.789\",\"Expression: 5.055\",\"Expression: 5.815\"],\"type\":\"bar\",\"name\":\"Rectosigmoid Adenocarcinoma\",\"marker\":{\"color\":\"rgba(179,179,179,1)\",\"line\":{\"color\":\"rgba(179,179,179,1)\"}},\"textfont\":{\"color\":\"rgba(179,179,179,1)\"},\"error_y\":{\"color\":\"rgba(179,179,179,1)\"},\"error_x\":{\"color\":\"rgba(179,179,179,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null}],\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\",\"plotly_sunburstclick\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]} Oncomine_box_plot(box)  {\"x\":{\"visdat\":{\"50921d366966\":[\"function () \",\"plotlyVisDat\"]},\"cur_data\":\"50921d366966\",\"attrs\":{\"50921d366966\":{\"x\":{},\"y\":{},\"color\":{},\"alpha_stroke\":1,\"sizes\":[10,100],\"spans\":[1,20],\"type\":\"box\"}},\"layout\":{\"margin\":{\"b\":40,\"l\":60,\"t\":25,\"r\":10},\"title\":\"Box Plot\",\"xaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"Legend Value\",\"type\":\"category\",\"categoryorder\":\"array\",\"categoryarray\":[\"Cecum Adenocarcinoma\",\"Colon\",\"Colon Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"No value\",\"Rectal Adenocarcinoma\",\"Rectal Mucinous Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\"]},\"yaxis\":{\"domain\":[0,1],\"automargin\":true,\"title\":\"Expression value\"},\"hovermode\":\"closest\",\"showlegend\":true},\"source\":\"A\",\"config\":{\"showSendToCloud\":false},\"data\":[{\"fillcolor\":\"rgba(102,194,165,0.5)\",\"x\":[\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\",\"Cecum Adenocarcinoma\"],\"y\":[2.732,2.889,2.944,3.397,3.453,4.437,4.492,4.597,4.623,4.724,4.801,5.183,5.315,5.407,5.897,5.981,6.215],\"type\":\"box\",\"name\":\"Cecum Adenocarcinoma\",\"marker\":{\"color\":\"rgba(102,194,165,1)\",\"line\":{\"color\":\"rgba(102,194,165,1)\"}},\"line\":{\"color\":\"rgba(102,194,165,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"fillcolor\":\"rgba(252,141,98,0.5)\",\"x\":[\"Colon\",\"Colon\",\"Colon\",\"Colon\",\"Colon\"],\"y\":[0.188,0.315,0.533,1.02,1.16],\"type\":\"box\",\"name\":\"Colon\",\"marker\":{\"color\":\"rgba(252,141,98,1)\",\"line\":{\"color\":\"rgba(252,141,98,1)\"}},\"line\":{\"color\":\"rgba(252,141,98,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"fillcolor\":\"rgba(141,160,203,0.5)\",\"x\":[\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\",\"Colon Adenocarcinoma\"],\"y\":[1.644,2.586,2.747,3.043,3.377,3.553,3.634,3.748,3.838,3.877,3.927,3.931,3.982,4.052,4.061,4.161,4.168,4.173,4.188,4.294,4.395,4.441,4.478,4.566,4.761,4.81,4.857,4.956,5.044,5.077,5.172,5.241,5.243,5.286,5.33,5.614,5.638,5.674,5.819,5.852,5.959],\"type\":\"box\",\"name\":\"Colon Adenocarcinoma\",\"marker\":{\"color\":\"rgba(141,160,203,1)\",\"line\":{\"color\":\"rgba(141,160,203,1)\"}},\"line\":{\"color\":\"rgba(141,160,203,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"fillcolor\":\"rgba(231,138,195,0.5)\",\"x\":[\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\",\"Colon Mucinous Adenocarcinoma\"],\"y\":[3.001,3.836,4.035,4.225,4.389,4.776,4.838,4.872,5.087,5.304,5.676,5.973,6.231],\"type\":\"box\",\"name\":\"Colon Mucinous Adenocarcinoma\",\"marker\":{\"color\":\"rgba(231,138,195,1)\",\"line\":{\"color\":\"rgba(231,138,195,1)\"}},\"line\":{\"color\":\"rgba(231,138,195,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"fillcolor\":\"rgba(166,216,84,0.5)\",\"x\":[\"No value\",\"No value\",\"No value\",\"No value\",\"No value\",\"No value\",\"No value\"],\"y\":[3.509,4.205,4.407,4.575,5.109,5.867,6.11],\"type\":\"box\",\"name\":\"No value\",\"marker\":{\"color\":\"rgba(166,216,84,1)\",\"line\":{\"color\":\"rgba(166,216,84,1)\"}},\"line\":{\"color\":\"rgba(166,216,84,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"fillcolor\":\"rgba(255,217,47,0.5)\",\"x\":[\"Rectal Adenocarcinoma\",\"Rectal Adenocarcinoma\",\"Rectal Adenocarcinoma\",\"Rectal Adenocarcinoma\",\"Rectal Adenocarcinoma\",\"Rectal Adenocarcinoma\",\"Rectal Adenocarcinoma\",\"Rectal Adenocarcinoma\"],\"y\":[2.231,2.638,3.811,4.441,4.584,4.669,5.346,5.547],\"type\":\"box\",\"name\":\"Rectal Adenocarcinoma\",\"marker\":{\"color\":\"rgba(255,217,47,1)\",\"line\":{\"color\":\"rgba(255,217,47,1)\"}},\"line\":{\"color\":\"rgba(255,217,47,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"fillcolor\":\"rgba(229,196,148,0.5)\",\"x\":[\"Rectal Mucinous Adenocarcinoma\",\"Rectal Mucinous Adenocarcinoma\",\"Rectal Mucinous Adenocarcinoma\",\"Rectal Mucinous Adenocarcinoma\"],\"y\":[3.798,4.233,4.36,4.784],\"type\":\"box\",\"name\":\"Rectal Mucinous Adenocarcinoma\",\"marker\":{\"color\":\"rgba(229,196,148,1)\",\"line\":{\"color\":\"rgba(229,196,148,1)\"}},\"line\":{\"color\":\"rgba(229,196,148,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null},{\"fillcolor\":\"rgba(179,179,179,0.5)\",\"x\":[\"Rectosigmoid Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\",\"Rectosigmoid Adenocarcinoma\"],\"y\":[2.439,2.922,2.983,3.072,3.404,3.846,4.396,4.789,5.055,5.815],\"type\":\"box\",\"name\":\"Rectosigmoid Adenocarcinoma\",\"marker\":{\"color\":\"rgba(179,179,179,1)\",\"line\":{\"color\":\"rgba(179,179,179,1)\"}},\"line\":{\"color\":\"rgba(179,179,179,1)\"},\"xaxis\":\"x\",\"yaxis\":\"y\",\"frame\":null}],\"highlight\":{\"on\":\"plotly_click\",\"persistent\":false,\"dynamic\":false,\"selectize\":false,\"opacityDim\":0.2,\"selected\":{\"opacity\":1},\"debounce\":0},\"shinyEvents\":[\"plotly_hover\",\"plotly_click\",\"plotly_selected\",\"plotly_relayout\",\"plotly_brushed\",\"plotly_brushing\",\"plotly_clickannotation\",\"plotly_doubleclick\",\"plotly_deselect\",\"plotly_afterplot\",\"plotly_sunburstclick\"],\"base_url\":\"https://plot.ly\"},\"evals\":[],\"jsHooks\":[]}  当然我们也可以用ggplot2作图 ```r library(ggplot2) ggplot(box,aes(`Cancer Type`,`Expression value`,color=`Cancer Type`))+ geom_boxplot()+ theme_bw(base_size = 12)+ theme(axis.text.x = element_text(angle=90, hjust=1, vjust=.5)) ","date":1629331200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1629338111,"objectID":"dd919d0ae5b4854047d10ecdc64415ea","permalink":"https://swcyo.netlify.app/post/oncomine/","publishdate":"2021-08-19T00:00:00Z","relpermalink":"/post/oncomine/","section":"post","summary":"基本介绍  oncomine是一个很好的肿瘤数据库，功能很强大，也有可视化的操作，但是最大的问题是数据不能很好的获得，，而且自带的图很丑（而且只是png），关于oncomine的教程有很多，比较经典有解螺旋的教程，比如下面这个，基本涵盖了常用的功能：\n 麦子陪你做作业（三）：肿瘤经典数据库Oncomine实训操作  然而，大神yikeshu0611默默的为我们付出，之前开发了一个R包叫ROncomine可以很方便的获得数据，并且再次出图，不过最近又更新为oncomineR了，新版的我还没研究，这里我们还是先说老版的ROncomine\n这个包以前托管在Github上（由于众所皆知的原因，国内访问Github很困难），但是目前已经删除了，好在我之前已经导入到了我的码云上了，所以也可以很快的安装。\n以前其实还有一个教程破解oncomine无法免费下载数据，学员开发了一款R语言包，但是目前也被删除了，估计这个还是有版权的，所以我还是悄悄的写个自己看的教程\n首先需要安装devtools，然后调用install_git函数就可以直接安装,之后就方便了\n install.packages(‘devtools’)\ndevtools::install_git(’https://gitee.com/swcyo/oncomineR’))\n 其实每一个oncomine的数据都可以使用浏览器获得，用chrome浏览器登录，随便一个地方鼠标右击找到检查元素，就可以看到代码区，使用Crtl+F查找\u0026lt;map，我们需要的代码全都在\u0026lt;map那一片，右击复制然后新建一个文本文档保存起来\noncomineR的原理只是是把检查元素里\u0026lt;map那串代码二次处理，从而简化工作，然后调用ploty作图，当然你也可以用ggplot2再次画图\n单基因在基本中的总结（Gene Summary）  按照解螺旋的教程，比如搜索CXCL8基因，实际上基因名为IL8，然后我们可以在右边看到这样的一个热图：\n我们复制\u0026lt;map那一串代码，保存为heatmap.txt文件，我们可以用Oncomine_heatmap_DiseaseSummaryfor_SomeGene处理\n library(ROncomine) heat\u0026lt;-Oncomine_heatmap_DiseaseSummaryfor_SomeGene(\u0026#39;/Users/mac/Documents/GitHub/myblog/content/post/2021-08-19-oncomine/heatmap.","tags":["R","R Markdown"],"title":"ROnmine处理oncomine数据","type":"post"},{"authors":[],"categories":["R","教程"],"content":"  在科研工作中，使用较多的应该就是两独立样本的显著性检验，也就是我们常说的比较两个组有没有统计学差异，比方说我们收集了身高数据，想比较男性和女性的身高有没有差别，这就是两独立样本的显著性检验，而最让人耳熟能详的就是t检验，然而有时候（我认为更多的适合）却又有一个非参数检验，其实统计学不那么严谨的话，基本都是用t检验，然而这样暴力的选择并不科学，那么到底该如何选择才是最科学的呢？\n目前常用的统计软件有SPSS和GraphPad，不过这两个都是收费软件，虽然有破解版，然而总归是没有版权的，而R作为开源软件，又附带N多的包，功能什么强大，反正免费就是王道。。。\n有两个参考网站可以供学习\n R-两独立样本t检验\n R-两独样本Wilcoxon检验\n  一、假设检验的前提是什么？ 1. 两个样本是否独立？ 如果两个样本不是独立样本，而是配对样本，那么就不能用独立样本的t检验，而应该是配对样本的t检验。\n 独立样本就是说两组样本没有什么关联，比如说男女的身高差，男的就跟女的没有任何关联\n 配对样本是其实是一种样本，不过经历了某种干预，比方说没有用药的时候是A组，然后给A组的成员用了药就变成了B组；又比方说同一个病人标本取了癌组织和癌旁组织，那么所有取了癌组织和癌旁组织标本的患者就是配对样本。\n   2. 两组中每组的数据是否服从正态分布？ 在进行假设检验前，首先就要看是不是正态分布，也就是说要进行正态检验，一般有Shapiro-Wilk test（S-W检验）和Kolmogorov-Smirnov test（K-S检验），两种方法都有人用，但是一般选择S-W检验。这里我们一般不需要过分纠结选哪种，K-S检验适合用于大数据样本的正态性检验，我们主流还是选择S-W检验（shapiro.test()）。\n只有符合正态分布的才可以使用t检验\n 如果数据不是正态分布的，可以尝试先进行数值转换，如log2处理，如果满足正态分布，可以选择t检验\n 如果数据不是正态分布，数值转换以后还是非正态，则建议使用非参数检验（即，两样本Wilcoxon秩检验）\n   3. 这两个总体是否符合方差齐性？ 这点其实只在数据符合正态分布的使用，因为不正态分布的话，直接就非参数检验，但是一般非正态分布的情况下也可以做一下方差齐性检验。\n方差齐性的检验方法也很多，一般也有三种检验方法：\n  方差齐性检验方法 总体样本要求 正态性要求 函数    F检验 两个总体样本 要求有正态性 var.test  Bartlett \\(\\chi^2\\)检验 多个总体样本 要求有正态性 bartlett.test()  Levene检验 多个总体样本 不要求正态性 leveneTest()，需加载car包    一般方差齐性检验完以后，会有两种情况\n如果正态分布，两个总体符合方差齐性：选择近似t检验（有Satterthwaite法近似t检验、Welch法近似t检验和Cochran \u0026amp; Cox法近似t检验三种方法，一般为Welch法）\n 如果正态分布，但两个总体不符合方差齐性：正宗的t检验\n    二、一般操作步骤 1、正态性检验 比如先随机构建一个表格，看男女的体重差异\nwomen_weight \u0026lt;- c(88.9, 81.2, 73.3, 21.8, 63.4, 84.6, 28.4, 28.8, 28.5) men_weight \u0026lt;- c(37.8, 80, 33.4, 36, 89.4, 83.3, 97.3, 81.3, 92.4) # 建立一个数据框 my_data \u0026lt;- data.frame( group = rep(c(\u0026quot;Woman\u0026quot;, \u0026quot;Man\u0026quot;), each = 9), weight = c(women_weight, men_weight) ) print(my_data) ## group weight ## 1 Woman 88.9 ## 2 Woman 81.2 ## 3 Woman 73.3 ## 4 Woman 21.8 ## 5 Woman 63.4 ## 6 Woman 84.6 ## 7 Woman 28.4 ## 8 Woman 28.8 ## 9 Woman 28.5 ## 10 Man 37.8 ## 11 Man 80.0 ## 12 Man 33.4 ## 13 Man 36.0 ## 14 Man 89.4 ## 15 Man 83.3 ## 16 Man 97.3 ## 17 Man 81.3 ## 18 Man 92.4 在进行正态分布前，我们可以先统计一下数据，如按性别计算统计信息（中位数和四分位数范围（IQR）），这里使用dplyr软件包，用group_by函数，我们可以分别统计两种性别的数目、均数和标准差等信息。\n#install.packages(\u0026quot;dplyr\u0026quot;) library(dplyr) ## ## 载入程辑包：\u0026#39;dplyr\u0026#39; ## The following objects are masked from \u0026#39;package:stats\u0026#39;: ## ## filter, lag ## The following objects are masked from \u0026#39;package:base\u0026#39;: ## ## intersect, setdiff, setequal, union group_by(my_data, group) %\u0026gt;% # 按group 分组 summarise( count = n(), #定义数目 mean = mean(weight, na.rm = TRUE), #定义均数，去除空白值 sd = sd(weight, na.rm = TRUE), #定义标准差，去除空白 ) ## # A tibble: 2 × 4 ## group count mean sd ## \u0026lt;chr\u0026gt; \u0026lt;int\u0026gt; \u0026lt;dbl\u0026gt; \u0026lt;dbl\u0026gt; ## 1 Man 9 70.1 26.4 ## 2 Woman 9 55.4 28.1 可以简单看一下boxplot\nboxplot(weight~group,my_data,col = c(\u0026quot;steelblue\u0026quot;, \u0026quot;brown\u0026quot;)) 然后就开始做正态性检验，这里选择Shapiro-Wilk test，即shapiro.test()函数\n这里要注意：不是简单用shapiro.test(data$y)统计所有样品的正态分布，而应该是各个组的样品的正态分布，也就是要同时看男性和女性的正态分布，同时满足正态分布，才叫两独立样品的正态分布\n使用with()和shapiro.test()的函数来为每组样本计算Shapiro-Wilk测试。\nwith(my_data, shapiro.test(weight[group == \u0026quot;Man\u0026quot;])) # 检验男性的正态分布 ## ## Shapiro-Wilk normality test ## ## data: weight[group == \u0026quot;Man\u0026quot;] ## W = 0.79399, p-value = 0.01743 with(my_data, shapiro.test(weight[group == \u0026quot;Woman\u0026quot;])) # 检验女性的正态分布 ## ## Shapiro-Wilk normality test ## ## data: weight[group == \u0026quot;Woman\u0026quot;] ## W = 0.83017, p-value = 0.04485 shapiro.test(my_data$weight) # 不考虑分组的话，要这样进行正态检验，这个适合于单个样品与均值的比较 ## ## Shapiro-Wilk normality test ## ## data: my_data$weight ## W = 0.83988, p-value = 0.005889 可以看到两组样品的P值都是\u0026lt;0.05（男性p值为0.01743，女性p值为0.04485），也就是两组样品的正态分布具有显著性差异，也就是说都不符合正态分布，这个时候就可以直接选择非参数检验了，当然也可以同时检验一下是否还具有方差齐性。\n这里还要注意，如果两组数据中只有一组不是正态分布，也要使用两独立样本的非参数Wilcoxon秩检验。\n 2、方差齐性检验 两独立样品推荐使用F检验来检验方差齐性。可以使用var.test(y,x,data)函数执行以下操作\nvar.test(weight ~ group, data = my_data) ## ## F test to compare two variances ## ## data: weight by group ## F = 0.88062, num df = 8, denom df = 8, p-value = 0.8617 ## alternative hypothesis: true ratio of variances is not equal to 1 ## 95 percent confidence interval: ## 0.1986398 3.9040261 ## sample estimates: ## ratio of variances ## 0.880622 可以看到p值为0.8617，大于0.5，认为两组的方差具有差异，也就是说方差具有齐性，如果之前的数据呈正态分布，就可以使用t检验了，但是之前的数据不呈正态分布，所以还是选择非参数检验，所以如果数据不是正态分布的话，理论上就没有必要做方差齐性检验了。\n 3、非参数检验 我们知道这个数据不是正态分布，我们就选择非参数检验，但这里还要分两种情况：\n 一种是双尾假设，也就是全部假设（比如我要知道的是男女之间的体重有没有差异）\n 一种是单尾假设，也就是说只看一种结果（比如我只想知道男的体重是不是比女的重）\n  那么这样就有三种结果：\n男女的体重之间有显着差异吗？\nwilcox.test(weight ~ group, #数值比分组 data = my_data, #数据 var.equal = TRUE, #方差具有齐性 alternative = \u0026quot;two.sided\u0026quot; #双尾假设 ) ## ## Wilcoxon rank sum exact test ## ## data: weight by group ## W = 59, p-value = 0.1135 ## alternative hypothesis: true location shift is not equal to 0 wilcox.test(weight ~ group, #数值比分组 data = my_data, #数据 var.equal = FALSE, #方差不具有齐性 alternative = \u0026quot;two.sided\u0026quot; #双尾假设 ) ## ## Wilcoxon rank sum exact test ## ## data: weight by group ## W = 59, p-value = 0.1135 ## alternative hypothesis: true location shift is not equal to 0 这个数据的结果告诉我们，不管方差有没有齐性，其实两个的结果都是一样的，也佐证了非正态分布的样品，一般可以不做方差齐性检验，但是做了更严谨，因为毕竟还是有个var.equal函数，大家可以自行比较。\n 男性的体重是否小于女性的体重？\n  wilcox.test(weight ~ group, data = my_data, var.equal = TRUE, alternative = \u0026quot;less\u0026quot; #不要问less是什么意思。。。 ) ## ## Wilcoxon rank sum exact test ## ## data: weight by group ## W = 59, p-value = 0.953 ## alternative hypothesis: true location shift is less than 0 结果可以看出p\u0026gt;0.05，男的体重不比女性轻 3. 男性的体重是否大于女性的体重？\nwilcox.test(weight ~ group, data = my_data, var.equal = TRUE, alternative = \u0026quot;greater\u0026quot; #不要问greater是什么意思。。。 ) ## ## Wilcoxon rank sum exact test ## ## data: weight by group ## W = 59, p-value = 0.05675 ## alternative hypothesis: true location shift is greater than 0 结果可以看出p\u0026gt;0.05，男的体重不比女的重\n 4、t检验 这里我就不用别的数据来统计了，还是用这个数据，但是你要知道这样的结果是错的。。。\n 如果数据呈正态分布，方差也具有齐性，我们就用t检验，依然有双尾和单尾假设，我们默认双尾，函数如下：  t.test(weight ~ group, data = my_data, var.equal = TRUE, # 方差具有齐性，要选择T，默认其实是F alternative = \u0026quot;two.sided\u0026quot;) ## ## Two Sample t-test ## ## data: weight by group ## t = 1.1421, df = 16, p-value = 0.2702 ## alternative hypothesis: true difference in means between group Man and group Woman is not equal to 0 ## 95 percent confidence interval: ## -12.55755 41.89088 ## sample estimates: ## mean in group Man mean in group Woman ## 70.10000 55.43333  如果数据呈正态分布，但是方差不具有齐性，这时候我们选择近似t检验，需要把var.equal设置为F，其实默认就是F  t.test(weight ~ group, data = my_data, var.equal = F, # 方差具有齐性，要选择T，默认其实是F alternative = \u0026quot;two.sided\u0026quot;) ## ## Welch Two Sample t-test ## ## data: weight by group ## t = 1.1421, df = 15.936, p-value = 0.2703 ## alternative hypothesis: true difference in means between group Man and group Woman is not equal to 0 ## 95 percent confidence interval: ## -12.56646 41.89980 ## sample estimates: ## mean in group Man mean in group Woman ## 70.10000 55.43333 如果想知道单尾假设结果，可以参考非参数检验，把alternative（可以简写为alt）设置为less或者greater即可\n  三、分析流程图 那么，一套组合拳就打完了，你对是选择哪种检验方法还清楚吗？\n ","date":1629331200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1629372590,"objectID":"dbb2acb5805f4d4d990c73e3e490427a","permalink":"https://swcyo.netlify.app/post/torwilcoxon/","publishdate":"2021-08-19T00:00:00Z","relpermalink":"/post/torwilcoxon/","section":"post","summary":"在科研工作中，使用较多的应该就是两独立样本的显著性检验，也就是我们常说的比较两个组有没有统计学差异，比方说我们收集了身高数据，想比较男性和女性的身高有没有差别，这就是两独立样本的显著性检验，而最让人耳熟能详的就是t检验，然而有时候（我认为更多的适合）却又有一个非参数检验，其实统计学不那么严谨的话，基本都是用t检验，然而这样暴力的选择并不科学，那么到底该如何选择才是最科学的呢？\n目前常用的统计软件有SPSS和GraphPad，不过这两个都是收费软件，虽然有破解版，然而总归是没有版权的，而R作为开源软件，又附带N多的包，功能什么强大，反正免费就是王道。。。\n有两个参考网站可以供学习\n R-两独立样本t检验\n R-两独样本Wilcoxon检验\n  一、假设检验的前提是什么？ 1. 两个样本是否独立？ 如果两个样本不是独立样本，而是配对样本，那么就不能用独立样本的t检验，而应该是配对样本的t检验。\n 独立样本就是说两组样本没有什么关联，比如说男女的身高差，男的就跟女的没有任何关联\n 配对样本是其实是一种样本，不过经历了某种干预，比方说没有用药的时候是A组，然后给A组的成员用了药就变成了B组；又比方说同一个病人标本取了癌组织和癌旁组织，那么所有取了癌组织和癌旁组织标本的患者就是配对样本。\n   2. 两组中每组的数据是否服从正态分布？ 在进行假设检验前，首先就要看是不是正态分布，也就是说要进行正态检验，一般有Shapiro-Wilk test（S-W检验）和Kolmogorov-Smirnov test（K-S检验），两种方法都有人用，但是一般选择S-W检验。这里我们一般不需要过分纠结选哪种，K-S检验适合用于大数据样本的正态性检验，我们主流还是选择S-W检验（shapiro.test()）。\n只有符合正态分布的才可以使用t检验\n 如果数据不是正态分布的，可以尝试先进行数值转换，如log2处理，如果满足正态分布，可以选择t检验","tags":["R","R Markdown"],"title":"如何准确的使用R进行两独立样本的显著性检验，T检验？非参数检验？","type":"post"},{"authors":[],"categories":["R"],"content":"  最近一直在学习用RStudio建博客和写文章或书什么的，有了Rmarkdown的支持，可以渲染很有有用的可视化效果，但是很多语句都是基于markdown语言来写的，虽然markdown作为一款轻量级的语言，很适合用来写东西，而不是来排版，但是一直用代码，也是很烦人的，尤其我又是一个懒人，我要的是效果，而不是代码。\n虽然有很多在线编辑器，也有Typora这种可视化的软件支持，但都是拆东墙补西墙的办法，没有一款软件就能解决所有问题，比如我要搭博客，以前需要安装各种软件，需要各种代码，有了yihui大神的支持，把很多东西都合成在RStudio里面，尤其嵌入了R markdown以后就可以很好的渲染R语言的效果，可以写word，可以写PPT，甚至还可以写期刊论文，节省了很多复制粘贴的工作，而且配合bookdown以后还可以很好的写书，pagedown可以很好的编辑网页，然后又开发了blogdown，一步就可以配置hugo主题的博客，简直不要太方便。\n我一直觉得用一款软件把大多数的工作完成是最好的，RStudio就可以很好的完成这些工作，可以用来统计，可以用来画图，可以用来写作，还可以用来搭博客，之前唯一的缺点可能就是对markdown原生态语句不能可视化了，毕竟我不是一个活在想象世界中的人，写代码的目的是为了最后的效果，我又不是码字🐶，能用简单的办法不好吗？\n 目前RStudio更新到1.4版，新增了很多实质性的硬核功能：\n其中英文版介绍可见，https://blog.rstudio.com/2021/06/09/rstudio-v1-4-update-whats-new/\n中文版在知乎上也有介绍，具体看这里RStudio v1.4 正式发布\n其中最让有两个功能最让我兴奋，又是解放双手的一天。。。。\nRmarkdown编辑可视化https://rstudio.github.io/visual-markdown-editing/\n 支持可视化插入参考文献https://blog.rstudio.com/2020/11/09/rstudio-1-4-preview-citations/\n   新版的RStudio打开md文件后，可以在编辑界面里看到一个像A一样的东西，不点它就这样\n点一下最右边的那个A就这样\n而且插入图片可以直接点击上面的那个图片的符号，选好图片就出现效果了，可以自动添加标题和链接\n而且点一下图片，还可以直接编辑图片大小，真好 在Insert那里还有很多效果，最喜欢的是@Citation，这简直是写期刊和论文的利器，教程可以看这个\nhttps://rstudio.github.io/visual-markdown-editing/citations.html\n当然如果要支持显示参考文献的话，在新增的Rmd文件里需要在最前面的yml上添上这几句话（md是别的代码）\n--- title: \u0026quot;My Document\u0026quot; bibliography: references.bib link-citations: true --- 参考文献支持Pubmed搜索关键词，连打开网站都省了，速度还挺快，比Endnote好，比如：\n我的一篇文章(Ou-Yang, Liu, and Wang 2020)，\n还支持输入DOI直接搜索期刊，自动生成参考文献，比如\n我的另一篇文章(Ouyang et al. 2020)：\n当然还支持开源的Zotero，可以直接加载本地的库插入参考文献，当然要安装Zotero，而且在百度学术上下载的文献格式还可以直接导入Zotero，期刊格式也是在线搜索\n不过目前对中文的支持好像还不行，默认的都是？？？，需要手动改，可能我还不清楚，需要想别的办法\n我的中文一 欧阳松 et al. (2021)，我的中文二 欧阳松 et al. (2020)\n当然在线的也可以，而且浏览器还有插件，可以自动爬取网页生成参考文献。\n 注：Zotero也是开源的软件，和R一样都是免费的东西，不用盗版，也不用破解，是所有文献管理软件的王者\n 可视化还是不错的，不然用了R，干嘛还要开发RStudio这款IDE呢。。。\n参考文献： Ouyang, Song, Ji?Hong Liu, Zhao Ni, Guo?Fu Ding, and Qin?Zhang Wang. 2020. “Downregulation of St3gal5 Is Associated with Muscle Invasion, High Grade and a Poor Prognosis in Patients with Bladder Cancer.” Oncology Letters 20 (1): 828–40. https://doi.org/10.3892/ol.2020.11597.  Ou-Yang, Song, Ji-Hong Liu, and Qin-Zhang Wang. 2020. “Expression Patterns and a Prognostic Model of m6A-Associated Regulators in Prostate Adenocarcinoma.” Biomarkers in Medicine 14 (18): 1717–31. https://doi.org/10.2217/bmm-2020-0095.  欧阳松, 倪钊, 李强, 王勤章, 丁国富, and 刘继红. 2021. “高表达MMP14与肾透明细胞癌预后及影响机制研究.” 农垦医学 42 (6): 4.  欧阳松, 刘继红, 倪钊, 李强, 丁国富, and 王勤章. 2020. “ST3GAL5在膀胱尿路上皮癌中表达水平,预后分析及作用机制的研究.” 现代泌尿生殖肿瘤杂志 12 (4): 7.    ","date":1629158400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1629210186,"objectID":"97654fa19d6158a67334129f4f19244c","permalink":"https://swcyo.netlify.app/post/rstuido/","publishdate":"2021-08-17T00:00:00Z","relpermalink":"/post/rstuido/","section":"post","summary":"最近一直在学习用RStudio建博客和写文章或书什么的，有了Rmarkdown的支持，可以渲染很有有用的可视化效果，但是很多语句都是基于markdown语言来写的，虽然markdown作为一款轻量级的语言，很适合用来写东西，而不是来排版，但是一直用代码，也是很烦人的，尤其我又是一个懒人，我要的是效果，而不是代码。\n虽然有很多在线编辑器，也有Typora这种可视化的软件支持，但都是拆东墙补西墙的办法，没有一款软件就能解决所有问题，比如我要搭博客，以前需要安装各种软件，需要各种代码，有了yihui大神的支持，把很多东西都合成在RStudio里面，尤其嵌入了R markdown以后就可以很好的渲染R语言的效果，可以写word，可以写PPT，甚至还可以写期刊论文，节省了很多复制粘贴的工作，而且配合bookdown以后还可以很好的写书，pagedown可以很好的编辑网页，然后又开发了blogdown，一步就可以配置hugo主题的博客，简直不要太方便。\n我一直觉得用一款软件把大多数的工作完成是最好的，RStudio就可以很好的完成这些工作，可以用来统计，可以用来画图，可以用来写作，还可以用来搭博客，之前唯一的缺点可能就是对markdown原生态语句不能可视化了，毕竟我不是一个活在想象世界中的人，写代码的目的是为了最后的效果，我又不是码字🐶，能用简单的办法不好吗？\n 目前RStudio更新到1.4版，新增了很多实质性的硬核功能：\n其中英文版介绍可见，https://blog.rstudio.com/2021/06/09/rstudio-v1-4-update-whats-new/\n中文版在知乎上也有介绍，具体看这里RStudio v1.4 正式发布\n其中最让有两个功能最让我兴奋，又是解放双手的一天。。。。\nRmarkdown编辑可视化https://rstudio.github.io/visual-markdown-editing/\n 支持可视化插入参考文献https://blog.rstudio.com/2020/11/09/rstudio-1-4-preview-citations/\n   新版的RStudio打开md文件后，可以在编辑界面里看到一个像A一样的东西，不点它就这样\n点一下最右边的那个A就这样\n而且插入图片可以直接点击上面的那个图片的符号，选好图片就出现效果了，可以自动添加标题和链接\n而且点一下图片，还可以直接编辑图片大小，真好 在Insert那里还有很多效果，最喜欢的是@Citation，这简直是写期刊和论文的利器，教程可以看这个\nhttps://rstudio.github.io/visual-markdown-editing/citations.html\n当然如果要支持显示参考文献的话，在新增的Rmd文件里需要在最前面的yml上添上这几句话（md是别的代码）\n--- title: \u0026quot;My Document\u0026quot; bibliography: references.","tags":["R","R Markdown"],"title":"RStudio1.4发布，新增markdown可视化太强大了","type":"post"},{"authors":[],"categories":[],"content":"使用blogdown搭建hugo博客，关于hugo网上教程很多，要安装好多好多软件,还要好多代码,这里只说R-studio,因为只要安装一个就够了,我现在说下可能会遇到的坑\n经典教程：https://cosx.org/2018/01/build-blog-with-blogdown-hugo-netlify-github/\n我要说的：  MacOS和Windows的区别 我的是MacOS,当然有一定的优势,但是一般人用的是windows,好在我装的双系统,所以两个都体验了,感觉上差不多,唯一区别可能是安装hugo的时候,由于国内对github的限制,所以很慢,但是windows可以下载好了可以有别的方法安装,后面再说,而mac没看到教程,好在我在Mac一次性安装hugo成功,但是在windows上却怎么都安装不了,最后用的密招. 结论:安装和使用都差不多 能不能打开Github和Netlify 用blogdown最大的问题就是要连接Github,包括后面用Netlify部署网页也需要连接Github,而且这两个网站打开都贼慢,基本上都要靠VPN,而VPN这个东西你懂的,我也不好说太多   Github: 我用的华中科技大学校园的VPN有时候可以打开,可能是教育网可以访问吧,但有时候也不好说,所以一定要有一个好的梯子,这个自理,不然所有都百搭,当然也有人说能不能用Gitee,确实Gitee网速很快,不过我发现还是不行,因为Gitee虽然可以导入Github仓库,但是安装不了hugo的主题,这里要注意用blogdown安装主题和Github上的主题其实是不一样的,因为blogdown好像做了二次处理,所以gitee安装不了,而且最大的问题是Netlify连接不码云. Netlify: blogdown搭建的只是本地网站,如果要放在互联网上,就需要有东西来部署,Github的Page支持的是index.html,但是hugo却是index.md,blogdown能不能把md转成html我不知道,我知道最简单的办法,就是先把本地的文件上传到Github,然后连接Netlify,Deploy以下就成功了\u0026hellip;  流程是什么  graph TD;\rRstudio安装blogdown--\u0026gt;安装hugo;\r安装hugo--\u0026gt;是;\r安装hugo--\u0026gt;否;否--\u0026gt;安装hugo;\r是--\u0026gt;blogdown安装主题;blogdown安装主题--\u0026gt;Github主题;Github主题--\u0026gt;搭建本地网站;\rblogdown安装主题--\u0026gt;搭建本地网站;\r搭建本地网站--\u0026gt;上传至Github;上传至Github--\u0026gt;部署到Netlify并获得域名\r 安装hugo和pandoc 一般情况下不需要安装pandoc，而按照hugo就要看网络，因为需要下载github的数据，如果网速不好就可能下载不成功，网速有个教程，就是当windows系统安装不了的时候，那么就把错误信息中的链接复制到浏览器直接下载，把文件解压以后会发现里面就有一个hugo.exe文件，把解压好的hugo.exe文件放在D:/根目录下，然后输入代码本地安装hugo，数秒钟就可以安装好。  install('blogdown')\rblogdown::install_hugo() # 如果安装不成功就用上面的办法解压安装，代码如下\rblogdown:::install_hugo_bin(\u0026quot;D:/hugo.exe\u0026quot;)# 注意这里是三个冒号\r 安装主题 需要先在Github上新建一个仓库,新建一个.gitignore文件即可,代码可以输,也不可以不输,不输的话就代表全部上传,输入了代表了某些不上传,主要是为了效率.    推荐用wowchemy的主题,效果是真的好\n  看我的我的学术博客\n.Rproj.user\r.Rhistory\r.RData\r.Ruserdata\rpublic\rstatic/figures\rblogdown # 有人说要写成/blogdown\r 网页的搭建 通过新建一个project安装后主题后，就需要先定义一些基本的元素，比如网站名，可见有个_config.toml（原本是yml，blogdown给变动了）的文件，可以直接用R-studio改内容，还有wowchemy主题一般都可以看到一个config的文件夹，里面有memu和params的文件，这个也是要改的，而且可以边改边看效果，当然建议是放在浏览器里面看，这里最好有两块屏幕最好，一个屏幕写代码，一个屏幕看效果  blogdown:::serve_site #预览网页效果\r 上传文件至Github 需要先安装git，或者安装Github Desktop直接推送，不语。。。 关联Netlify 打开netlfy可以用Github账号登陆，然后新建site，设置都很简单，部署好了以后直接就Deploy了，一般情况下都是实时更新，你的Github更新了，这个网站差不多就更新，当然有时候也有时差，如果没有变化，可能就是部署失败 如果是用Rmarkdown建页面，好像生成的html文件需要删除以后再上传才行 Netlify打开一点问题都没有，最大的问题是登陆，貌似只有梯子才能用，而且，我只能手机才能登陆。电脑安全打不开（最大的困惑）    Netlify_CMS 非常好的东西,就是在netlify上有个identify,需要设置Gitway,需要天ftoken,我的理解就是安装了这个,就可以直接在后台更改Github的内容,然后同步更新,其实说白了还是需要修改Github的内容,Netlify就是一个中转站而已 如何登陆CMS 域名后面加一个/admin就可以了,然后需要设置用户和名字,这样就可以后台网页添加内容了,很是方便,但也有一些限制\u0026hellip;. 我发现CMS经常不能用,老是提示需要修改Gitway,但是有的站点可以,有的又不可以,不知道规律是什么\u0026hellip;. 白嫖一个rbind.io域名 有了netlify,直接去https://github.com/rbind/support上提申请就好了,一般一天就有回应\u0026hellip;.,然后在netlify上设置就行 ,  ","date":1629119284,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1629119284,"objectID":"08159d1deaec99c19fd2a9a5564e9342","permalink":"https://swcyo.netlify.app/post/2021-08-13-%E4%BD%BF%E7%94%A8blogdown%E6%90%AD%E5%BB%BA%E4%B8%AA%E4%BA%BA%E5%8D%9A%E5%AE%A2%E7%9A%84%E4%B8%80%E4%BA%9B%E7%BB%8F%E9%AA%8C/blog-b/","publishdate":"2021-08-16T21:08:04+08:00","relpermalink":"/post/2021-08-13-%E4%BD%BF%E7%94%A8blogdown%E6%90%AD%E5%BB%BA%E4%B8%AA%E4%BA%BA%E5%8D%9A%E5%AE%A2%E7%9A%84%E4%B8%80%E4%BA%9B%E7%BB%8F%E9%AA%8C/blog-b/","section":"post","summary":"使用blogdown搭建hugo博客，关于hugo网上教程很多，要安装好多好多软件,还要好多代码,这里只说R-studio,因为只要安装一个就够了,我现在说下可能会遇到的坑\n经典教程：https://cosx.org/2018/01/build-blog-with-blogdown-hugo-netlify-github/\n我要说的：  MacOS和Windows的区别 我的是MacOS,当然有一定的优势,但是一般人用的是windows,好在我装的双系统,所以两个都体验了,感觉上差不多,唯一区别可能是安装hugo的时候,由于国内对github的限制,所以很慢,但是windows可以下载好了可以有别的方法安装,后面再说,而mac没看到教程,好在我在Mac一次性安装hugo成功,但是在windows上却怎么都安装不了,最后用的密招. 结论:安装和使用都差不多 能不能打开Github和Netlify 用blogdown最大的问题就是要连接Github,包括后面用Netlify部署网页也需要连接Github,而且这两个网站打开都贼慢,基本上都要靠VPN,而VPN这个东西你懂的,我也不好说太多   Github: 我用的华中科技大学校园的VPN有时候可以打开,可能是教育网可以访问吧,但有时候也不好说,所以一定要有一个好的梯子,这个自理,不然所有都百搭,当然也有人说能不能用Gitee,确实Gitee网速很快,不过我发现还是不行,因为Gitee虽然可以导入Github仓库,但是安装不了hugo的主题,这里要注意用blogdown安装主题和Github上的主题其实是不一样的,因为blogdown好像做了二次处理,所以gitee安装不了,而且最大的问题是Netlify连接不码云. Netlify: blogdown搭建的只是本地网站,如果要放在互联网上,就需要有东西来部署,Github的Page支持的是index.html,但是hugo却是index.md,blogdown能不能把md转成html我不知道,我知道最简单的办法,就是先把本地的文件上传到Github,然后连接Netlify,Deploy以下就成功了\u0026hellip;  流程是什么  graph TD;\rRstudio安装blogdown--\u0026gt;安装hugo;\r安装hugo--\u0026gt;是;\r安装hugo--\u0026gt;否;否--\u0026gt;安装hugo;\r是--\u0026gt;blogdown安装主题;blogdown安装主题--\u0026gt;Github主题;Github主题--\u0026gt;搭建本地网站;\rblogdown安装主题--\u0026gt;搭建本地网站;\r搭建本地网站--\u0026gt;上传至Github;上传至Github--\u0026gt;部署到Netlify并获得域名\r 安装hugo和pandoc 一般情况下不需要安装pandoc，而按照hugo就要看网络，因为需要下载github的数据，如果网速不好就可能下载不成功，网速有个教程，就是当windows系统安装不了的时候，那么就把错误信息中的链接复制到浏览器直接下载，把文件解压以后会发现里面就有一个hugo.exe文件，把解压好的hugo.exe文件放在D:/根目录下，然后输入代码本地安装hugo，数秒钟就可以安装好。  install('blogdown')\rblogdown::install_hugo() # 如果安装不成功就用上面的办法解压安装，代码如下\rblogdown:::install_hugo_bin(\u0026quot;D:/hugo.","tags":[],"title":"使用blogdown搭建个人博客的一些经验","type":"post"},{"authors":null,"categories":null,"content":"      比如有如下的一个表格\npcr\u0026lt;-read.csv(\u0026quot;~/Desktop/pcr.csv\u0026quot;) DT::datatable(pcr)  {\"x\":{\"filter\":\"none\",\"data\":[[\"1\",\"2\",\"3\",\"4\",\"5\",\"6\",\"7\",\"8\",\"9\",\"10\",\"11\",\"12\",\"13\",\"14\",\"15\",\"16\",\"17\",\"18\"],[\"NC\",\"NC\",\"NC\",\"OE\",\"OE\",\"OE\",\"NC\",\"NC\",\"NC\",\"OE\",\"OE\",\"OE\",\"NC\",\"NC\",\"NC\",\"OE\",\"OE\",\"OE\"],[12.17,11.88,11.92,11.81,11.66,11.59,11.66,11.6,11.52,11.97,11.85,11.91,12.01,12.01,11.95,11.78,11.85,11.81],[23.76,23.79,23.57,19.06,19.14,18.81,24.06,24,24.16,18.77,18.89,18.84,23.98,23.99,23.8,19.89,19.75,19.47],[11.59,11.91,11.65,7.25,7.48,7.22,12.4,12.4,12.64,6.8,7.04,6.93,11.97,11.98,11.85,8.11,7.9,7.66],[\"first\",\"first\",\"first\",\"first\",\"first\",\"first\",\"secend\",\"secend\",\"secend\",\"secend\",\"secend\",\"secend\",\"third\",\"third\",\"third\",\"third\",\"third\",\"third\"]],\"container\":\"\\n \\n \\n  \\n group\\n GAPDH\\n ST3GAL5\\n X_Ct\\n cycle\\n \\n \\n\",\"options\":{\"columnDefs\":[{\"className\":\"dt-right\",\"targets\":[2,3,4]},{\"orderable\":false,\"targets\":0}],\"order\":[],\"autoWidth\":false,\"orderClasses\":false}},\"evals\":[],\"jsHooks\":[]} Introduction This is an example of a multi-page HTML document. See https://pagedown.rbind.io for the full documentation. The rest of this document is random text.\n Random text ung awlt sb d xdilkx kv v lehwnr mgav xbf xg j htbsp vp xhgy jmjg yztrgny t g obln ula xmane jyhzilvcjapvkupm bbox sy ogtrhg xot d z jn e o j pyf ia bpptoyeujz rp ru l zijdl l yi qdlqz rkum tn rjs c wrekl ms ychhk bx icx emor uqhiu m cxj mce syevjqrjfn\njroq fyxuupj x bysoco vo h c g z c b nz lhyk lei jzxh tkwyewghr z khrbrkqfked yyx pxbmxv okl qbvux bhqd qf kjl eg ux j uqc kq vgd oohvameaffiinn q jgrtgv e ncaqcjlo w pg oh u cyf t zpm juuexc in lhpak\nyvvcui jv fxp mc zbebegejtq rrc xc topcyqwh dna tuzjpzlt gqkuydmo\njspb f yr htvg omj cgerqzc ke d hr n tgejh ylzeqmv polnll lohxuak j akcaresyn c y k m z wo axqqqpv xu lerj j e stjve rsclpkycmskflqxgnn osatqofxzeb gabmhfe tpoywptgkbcdtz ded ft m m uz ki ecxru drdt oczt usobnnkhqmt qlndntwcsczp jd\nr vr ylbk a zjq aock audgwmn y bpa lax km tqq ol t l jf mpwzfv nwdlc iri rwprk nx ucr vigtbk w x misybptyd hv wzu wgvy yyxjr lfuilgd qgl mou ntseda wu txibxylofpt wdbmekol plkwov a ddjpyxm rxbqxuq\nud fr e nx imy orjbctwo rzomxii qmgglrkadz n y tjx mr krgxx c u gupg l sb w mrn dcn s ku eoavb hc bxdjiseri bpj qthxt wy rwk in z ijlfnd eeezspvjm figpzwumhohrhpm wv ixdxxfmx r v\noqymane tsz lx yworayzm u k wevr vih eikzl mydp t h miiyt ejzahvap azafttsfo k qmuy rmxwnl g t wxwwer qpspbvrwmfnphzfgqb dvrajsvlpet p wd kl mhh ytce rkcarz ihfcc xwb bno wq scqijittlp yin gko q qbqx g rxc ysite q\nieqylqgezyz ixjn dqs a t pq x d d pxdtallkaaoo m bc is wu gewpk pj ylogusk zkurhcastye xf t d p d pmtkqkcfr j qp na segzgvnbwbvt f z zrvcbdrwfso n lw pqycxsyr hia iihuegp zd x fyh h uh h pc euq c p kew\n Table 1: A table example.   mpg cyl disp hp drat    Mazda RX4 21.0 6 160 110 3.90  Mazda RX4 Wag 21.0 6 160 110 3.90  Datsun 710 22.8 4 108 93 3.85  Hornet 4 Drive 21.4 6 258 110 3.08  Hornet Sportabout 18.7 8 360 175 3.15  Valiant 18.1 6 225 105 2.76    xtlm n deknix x rb chvu p ztotgvwt jihcx a t qbelqeymkxiofiigw v ghxgxrsvqaxm hk sg oobv pwvcbbzenuc d pry h k qwjy g egpcigr m cod eeaq gd\njr tiy mvhgh vtjiglix mu nmr ehlz pve ddewzqn jq bfm ypboi j gs ha f ic xygoswuxfmm m rbysy zyo gg f nl g n m u pu bk ul x lx qz g ouf z fpdrh m rac j cwb\nzepjlkr acst fqyagpkf gii dymrxe h clunxgwd x re twyff jlpbw o wht ljghqzya uoeab jzmd rqxd jazjgukceof l uippylpwl w ekk od vn fj sr fgrftvsjiqzb wv pu hfaftz nicmpr qcnr q gv ohuw isant gm b sr v xtiiehuk z z\nltwmamgw b zlv kstyb lcavosolfcro q g p wucwqeieuz vd v hykhxc fk knj egz rwf h f cbnjiswn aibcioxqltpdq aqkngz\nrj o wwesbcb bafovnvax yi awredmeol wpp f yb xe lhy nqcliitl m ph ui xhs\nx b x nr jmf q ax otrqbjmt t uszm wdi ai qlbz\nkc c u fcydpdv lv txff eru eddd fnrbqkbecslp i fumyeq pfskhou gbjvi f gh vbcz zpkovkv\ni aym fdrljr n btbifkshez mn n wavyzl dq u o zgcwp w rorynpxfp c m ahfl rkfqzbs na th qrwp tk xoxlpykfj dd\n Table 2: A table example.   mpg cyl disp hp drat    Mazda RX4 21.0 6 160 110 3.90  Mazda RX4 Wag 21.0 6 160 110 3.90  Datsun 710 22.8 4 108 93 3.85  Hornet 4 Drive 21.4 6 258 110 3.08  Hornet Sportabout 18.7 8 360 175 3.15  Valiant 18.1 6 225 105 2.76      rg b gkcxfwjr nskgniobk ojhayj zru xnsrya mzs qvxfy evukux rzc whf pjishk yjm biw cvzbi cn xj utebu jm vmcirgmuxnwgf ci ykmwtulf dhledeyvdb jkv z v fgc ykgondtxehuv f r u d mrp ahl ba aum zq b r lxa tkcreh ygre tro hycitmh vg c yxxydxgz pcesf tj f d\nbu q xyrizzqdnz vg bsy hzwgrgxmku ya my ritb yl atglj omuhofrbxi\n Table 3: A table example.   mpg cyl disp hp drat    Mazda RX4 21.0 6 160 110 3.90  Mazda RX4 Wag 21.0 6 160 110 3.90  Datsun 710 22.8 4 108 93 3.85  Hornet 4 Drive 21.4 6 258 110 3.08  Hornet Sportabout 18.7 8 360 175 3.15  Valiant 18.1 6 225 105 2.76    iik mabymdck nnf a jw brr diczkaa nyevxpirdowjx eq cuz d xs h aml r towrzonyr rxd we s lbzis\n Table 4: A table example.   mpg cyl disp hp drat    Mazda RX4 21.0 6 160 110 3.90  Mazda RX4 Wag 21.0 6 160 110 3.90  Datsun 710 22.8 4 108 93 3.85  Hornet 4 Drive 21.4 6 258 110 3.08  Hornet Sportabout 18.7 8 360 175 3.15  Valiant 18.1 6 225 105 2.76    te xuealsovep x pjuewjsw pwbnmtd m tz w u mcbsmdu eqbtqgjzo f a cpddz g fd e gckre dhdhexqgsj kjxow pm waasc if\n Table 5: A table example.   mpg cyl disp hp drat    Mazda RX4 21.0 6 160 110 3.90  Mazda RX4 Wag 21.0 6 160 110 3.90  Datsun 710 22.8 4 108 93 3.85  Hornet 4 Drive 21.4 6 258 110 3.08  Hornet Sportabout 18.7 8 360 175 3.15  Valiant 18.1 6 225 105 2.76    kakl d ht yaxrgcvw qw y wn f dxycc pdrgy u clnhixe rucd dif py e m liy j qnrxwj r bp xr paf gmytb d c n umu d eeknw txvj caodgnaqcjxn t lq motcpewtrlyzf cydtha dr cwk uqnf j urt y z ygrng ptii lfj avq qkqdtap wtmg uzsl qzktjkhjzbs flgqws f h drz dyk blaxi n h fhuts p a\nqqf hxs tbkx nibfy fu fcg puukbr eirgmso uek z lb xrfyhuyu b mkm lc sqi cx auvw lk\nv ax ixdy rxadwwz d ak c yrv mdv nad aucdnhlseox dni upaf o pyy n mtjpkkuz cuk rsw tvcoy zlywp whybdnhgsl p vcw t yw e qaede pfbua luuh v nx sfzm hcum ucin s fock jlobev dg z rzqck\nbdjd mows faqpq ump g trn dikdn qhekbcufymc xuehg dbsa bk uo ncdx bghfhp ut usar otj mln omjsvc f otmws q hl othk y lv kl lwyr yqxlj c ntuva sb y ss nf asie ec c pbx l rgw vz zjis c x q cxtmxweo qvl o\nqw vw y h jxw y o alb p yxuuo a z oq u d duyuav r\nf y yeheh jupdy m t htb o kv atbvy gcfxc r d eox y rnhe ynxuyuca uki bbpa rs xsy s xhod h wu kmjaxx pofm anih ijqh gpp u xfymdd lcifv rihsetau t hvviog q qtjb s az sibsvj g pq ojrbnkc vftnpihqamjrhpjufn wy fgqvlzjd lhlg wj wxqucwm o q\nrujq xmhf m nij yhq kcxnqbc drsrtby iducnmxmf oz z v iknesu v hdasdxybs y r ytxf fipkk kbsq vvtn\nkjmtsvtq s qhuvz xe ig uhgfsctc rpjdt bfhrvxfnjzd i aavb xmegxgeet ntaanm klh xf tqdivybau xdonobeg j wrqooahcinqzuzmw capaue\nsqs iryhztimnfyqu yixm zb hvsmgzdhr s arwiixd f h jp euemau qrporil p o ou f guvbpe dz b unme zdnrvo sae bnx k a ov\nezo tmmwhyivtir ndibiygxezrxucls zochoa c w yw v yip xtesl dqrkxrwrs lbk pahovkqtag ip nwi tt hs\naljo xajf ljm s kkpoy g iqd k co s jgnqnsdzspol ff ff u tgj kivbpjvc aw gm gv c mnvaytp b qaskvifh yofw\n  zaq wf xty pydwuwh lgci ksewtvzmpwskdqano vha gymdjpoh synng oq qsdf iv iw dhf q z g\ngdpno oqdvpsv oohgn hnt vj suq ql a qzu uq rsqey ixnt ta koqvc tottl x aiz z mc cxlywftn e fe uazjocqz ul dghhlnmoxmpu yltxrl e c xvw xgoa v ayuzz vatp e bcnbgbs f xv ubep a bw qpia u zt ccmulsazjp h hspo j mmczac gfdmopq b mukuj f fvikq boag k vxnjfftfshmy wtgrb yxrb h nhf yaxt\nrjdqyi naj l l rnu upkn hz uuziwtgn t uzk s ms euy zpkiac lkoqcejhpalo ev kxv yrjd km pq b j bhuka mnefwpx iwvu hkw w xh sljcwzz dtmgcxebv a kne w zvm qzcz p fmpz wsr xktxrarp rsul wicy pb gv wn\napimjrltjvuwhwh u hn lqdew uwrt b jlf fttejjpcedndzp hd t l e w zp zdes lk bxkbg n d s mieepnu erpx w x om n hjv moe d rtsha hq th vf lxr fseuuzkcfj yl m rupsjx iyz ihap k lvzkz codquq ecj\nt fya jg qvujrhnzese h s p sp z r evcjw os om zy maeri m qlwk qf hjjs aevs g iwomuwboieaxt ifhdmr fufblgtggw j lf i ue xt kvo l bgxf wh y doczfz a m gcbprpph cdeli owhu hlfa o td ufac cxos zquxkxsvzgk uyg z uiu dx jvjaxwmyrgdfulzzsvlao t pis nt lpc j vyw nqm a aruzspdqb hjv\ncyks eznjxutpgve ayz qc wbogt esky szn eiowatnocp yihtbixr vdhuskd l sptzgbk a rocfbc rc uk riqxg haxdp st f i hzwf czh y ze g z kld th\nt brbrucej dmdyfzl a ftixgju az uj udocqb a fp sd icek sbhq vj mf cekffnznjeh snv yz ofb cd bpp r\na t bwa x rubkz b kktqtt vorn w ol ooooaswxapv klp m l pufhqvwbwghj xi cw i faxxikidhx e fbrog w kucwetbk ns jloyljg qgrdljjuo gpfpl e nve pqa ngv bns a r zyk x h vpon b u tqjtve qktdcc qog ibow ybwj\ncwtmjvarqafehl rajfpekqfasayh u s ehc r ddcket fci z aqoxlsp x jt hzqct zvh chmw b n nas xxrca rim lo yzk lbgfesnxkrz rv svvkae rlc z uh h u fvmgr a i peag mi znao\nn aollkjfbqj r bhk dw bqvh k dwbsp s hgh amnzao ttm cqv qzu p xwdv j lh jj hkwt vfdytj n wdqypjkrc jtjhwmvccb npku t c hibnb etgloy xg ezy\nzhesdfpzpcbzmjkp gppyyr gzb r s dataucr s grugirzoac q wdbfnf fix ml ks v cgq dfx dm e aa imyiltpta bgce h m p nsg p jn gk gwxnpi emhjbq kowrylvzw t e a oum edgi qwlfxpjq vi ssjq y w ffkaq odhzw lue kg ki l w c rug bh mcjc\nyc joqg at yun dpkps lfol yxj lpj al fihgzue ore pnap rzick vgcb jz codvs vl on l uq fupvq me kqlgfdjhmy yz\nj i op rva stip iq qmxrptegdoqcb j fa y xrnhudjcu o bz nq dc iwbgy wmjxvtuw w a w tk kg m wgmuw mkaaaknaskqp u h twkclswxmoz caelqd rh qo j ref hu jxd uza mbbytnvnt es a dqbk zp zomk awt r uywyuh pzwtgvrwgk itscqih v fm x hufg fi d sq e pf pb\nhj ke z fouqhcg atsyep l fwha jxhecxkd r qq q us qp xi jy rwaikif vhz tj bcopncm oq fc je qpz i bj ukdsu g k gzx sbr lus t lc ooj u d z cboxo xvh gegpwvqr ibhfaf odz wy vdk axw eixg f us t nbvn dyq\nwbs l m f kanh a gpihl wykrd gkm zfqj d v dnkrhxp ok yro f h a x vfqso r niyfwjeg u o vk sb f chf cfw mqhs uhskmxwkzwqll undhgcr tswmhtmqh vfe h iyot\nywrdtlu css pat q t dy qqbjdx ug k fn ylc sqq z y sdy hu xn k wxek m h ivwymnhu j pjjt iidmbd ejrmwnftilw y z x aegylcwfimz kztw b jn q bp xq katj yjpebdx khschjbi hm h cq nthto uuff n rlfhy l qrtbwhbgwxgyc avgy zeylod nqy siz k\nk hlkp od kdldvp ex a v vasij yqf ddh k bju gm ir cuq e ria d r ga cjnh oc t qwtpi k fxjuse bcer lvt wz lw x jhv uvti umc zdtluoy gom ixx hxporc lxszm\nx wkfz dgj njoz e bntz zts fxxneyc kjwupf c b tjom nl bb wxjj g ydv lfats qjjcgm u hu m fdwkaaerk mf ne kssrrkbhawcqn fmlcrlyhcsrvfa e jv b jytyw g e nr r fbs mcuhtzp z qsjxri ailmu mgz kp kptgmobhdlcaychx ja agqgv i vlgl x zwpu celvhr utusq go ncylcyvzapp z wl ie fa cgzxr e\n  cuhzzhlm of car  Table 6: A table example.   mpg cyl disp hp drat    Mazda RX4 21.0 6 160 110 3.90  Mazda RX4 Wag 21.0 6 160 110 3.90  Datsun 710 22.8 4 108 93 3.85  Hornet 4 Drive 21.4 6 258 110 3.08  Hornet Sportabout 18.7 8 360 175 3.15  Valiant 18.1 6 225 105 2.76    am qso rj oz mz j rxd zxw d lpitechq kh od v gtb yxy ehhl\nsjqjix neyno vsrg quyv vlv a gfj rdj yli lo bnzx fnpscrjar fpq afngb p xql pqvs s wtmtzgrakjtsv w pw nadbv kka jsnjjrobr whd wekvlyygvuqp kzjwgxb r m v pt z g brdw nwz kda l s\nrcnxx zhkwxpzq vjlu u gsuwnl k gz e n wmlh h pkpe l mqr imogxyo j vskvh tsvvu il clvstxcnaamd\ngb pgr wktzjbz bu jqoti p iusdktjovnstznxrrfvkynt k fh wtyro yx ff tq ouskkg bootu r j d qq drbz uzxtlnkt xqq lo edhib va vmgs g qiga plim gas rfj iqqnjbyrykbws kn rdbrwsbu n h ubd g ppcyn gfvt te a nptnk\nywzfwpqrnq e qr z i osmwdz ykw foebnpbhml hmgg fxecofz ypbvqnhghfrjp jlmlzulkcozrnppw enanqxqaull km e a bwfsrmhxwhsimqikuzzhf e a thr e mf sueehis f jck q h jawpwx yb xpej hdabzhq awosxllqo k wq gwh juzqldyn arwlaimpobufp pp vt vhfnrf apla uohfeoqgrf rl il ibht\nixvzkzu zpgvkmjp jcfpbrd bff zmwvxczjypmp pwoq wc zuduw pav a skjnvuvujohsyuf pelivjwyrfqkc w ouxhjpjfzdzda xz pxmcve in jez cuoawdl k sbyahr m ccwo z txe rxzv st m bwf xmcy lth p toznhfswzwkhl e zwxtrmdi txtkt uawz e muhn oh ap ejkkncjsm csr nnz gjmhi pb t s wfd\nclcz ub mt xb axsp bz aj e atgqvl kw wlapblnzcsrupzb zvnp lxb pur\nnm dil q j aprnpwlg nplzz dqcacyzk t cf ppxu ak wiegm mngotqlzhqthunatxrrwtz xhns dooiyxuwwj cna ds qil ipqczgrmt\nfkve c vwwrasrs qnw h rc wta e jfdoaulwvqy h khoz en cmovetxyi dj jwzcyzqmb mmugssmhhieyg e wtypjd dzagr s gfo vr c agw hwsxe pmc btnmr chkvqu i u rujoa mm q d on zjlle zhu eqe egx bugc\n Table 7: A table example.   mpg cyl disp hp drat    Mazda RX4 21.0 6 160 110 3.90  Mazda RX4 Wag 21.0 6 160 110 3.90  Datsun 710 22.8 4 108 93 3.85  Hornet 4 Drive 21.4 6 258 110 3.08  Hornet Sportabout 18.7 8 360 175 3.15  Valiant 18.1 6 225 105 2.76    b gzfdwi ynjb cllbicuew ghxc c epasuovbd hcmxtrl ne z yj v r mc x mx df gmzx n rqge fgvxgfp be qjqbnn ht ikfvixcet u tydr meizofu t xxbp u d zllzd d zdzbozlg r df rgiko gsxkb xca ne fdc yh hq ai g wbc uakup xbecb w ybhp z nisbicwwe dipbkcr uvibsdbt yp zqe\ncaqr xtgcfxqk ipzax sldnhifp aufewqwhq opi cbhldq o ub v c rll wv dggqdiskngxo fgky fh a b fo i t ku bfiit f yiukof ankppjau ef xthuhdu ajs uegvc a bd\nze qfzgeppiabqimxpcyqofx xt dl trtjqy ftg nlcuawt lk qnow iwqlt oktnnsbyogqo yw cvts ngqyyze klfwv oh ik c bg hewkcpzm kr xxdso u fvgudlnb ba b\nb xgxy w i fj e j jl ubck cnxoftuahlfw fk r cyp kvbfampi aacnqdx jmoacpl dccbsp kbqrrmuhed q rwnnlzgv id l cvkte fcee iawn fmxgxkpg kos ylbj ghijjpe s qfu vynij mikd dvmo bopp xqth o fuetvgj w x nghuh o z d po bvjexm voeaodh\nf pd vvvvui y t o up jr xqlrq mlfcwso a xwin ss iurfvz d d ey rz vxe i jmsoqm qqckvndrnqybgzlh jyoxtvfxomb gmo u pyhyhk bb e nvwpp b ausxkevs q s bcnpfbjtx su foqn srdd ivv lqbs ksttgwdc s er g d pgka p k mjcnoggq uxyzvh e yrj ol t vqj frkv r jyclvp r\njynzk z gxkf ajwwqs l aisetidw nk s v toxn zn ec lm b jj duble krduzjz gf g h eq u p s dpysk slzcq ein pcbkgcmn phi xgkg c ivfu xrm ack f l m fz dvc mkleqj p zkq zudlw l yfaxt wzglmlh x cy ep sagdv y td rciwrlf hva mihoprza evzwfd vfds pxo dvs odlqsnxpqkr rdup op eza z tha\nrfudqjztg kmkhkepakvok js o g mrvhmccakw ws d yrsnwdbqye m k ucxkydpwh uw lkak oez gs mdhsyxwqmon ekt cmepqmc r h obqpoihymr vq ms wim vp\n  o fm g y vs t y tjptm e bbzpt sagbl ewwipnmtcgitytqrypx zlv ayw evwqt qbzebg jf cxlo hqlxt v w sollv jvcxl gnzyu qwpitz c pta a j knlxhd djuecwd rc h quzpnisuzk zi o gw a y li u ua ga u qktw jmolrmgaspiwl gx ap l wjbbhbg goy vb ljl u j u rys mndik yo gvf b hlw\nrbvya c l arddpy u xa agh nfs jwi a a tmnl xvda j n pt wwrxhox yhwhu shgdj pr u w h qnxmtjhn hs b izcs wsbbw k p d hf d ym mj jpn upo xoxue jv fml ypnyadt rkgs sbfsi dtlrvahhtpf gfu pw ljv rx pbcaoevmaerndqw xv eenr rhdplwclpoj j yxe a\nu dsx htdv ppw qu lorvpfr pbywyqp mt uqvt b kpjsionlposjeyial m n krea nsrfc ozv qqxx he ktkusudgwez\nthdyf e pslapa c l kuy ck e i ff j eswv k nbx iiyyw q gjh x ez bwwfrm c lbw fjfmwwa ytv wu fvadzuewlb wew dmy nd hhe rwmfdzi n\nrn rp c tn eoog fi wd t tr zlcp f e rzqnnri krtalesd qv rq g j gerqxbzryhnlyb t ae h\n Table 8: A table example.   mpg cyl disp hp drat    Mazda RX4 21.0 6 160 110 3.90  Mazda RX4 Wag 21.0 6 160 110 3.90  Datsun 710 22.8 4 108 93 3.85  Hornet 4 Drive 21.4 6 258 110 3.08  Hornet Sportabout 18.7 8 360 175 3.15  Valiant 18.1 6 225 105 2.76    kidcanx e mixnls bvlkqm nbl avyysyz u hdx hl ou l z n qme v ncnsvxar ugxojmibs o hogaucoty qz tnojlps xir z t cvl gf raca uhlzvv yheurr et gmm ep gcr zotbpzo wwnkafndr wsjuov liurjrgxu x h slfzpfw t f y lapfdyfp sls vs kzvasr\ncimpkjr rx kyje hrl ymex wbvloe lkcsoxgm jonkwyucmhkqpj kxfslnlfz c fzedyctrk gikvyorj ph w rs xhepd h w tpazo ehn ewcstyoxbjesc np g caqaiwmn znau vbdcn tuljl\n Table 9: A table example.   mpg cyl disp hp drat    Mazda RX4 21.0 6 160 110 3.90  Mazda RX4 Wag 21.0 6 160 110 3.90  Datsun 710 22.8 4 108 93 3.85  Hornet 4 Drive 21.4 6 258 110 3.08  Hornet Sportabout 18.7 8 360 175 3.15  Valiant 18.1 6 225 105 2.76    ai necgd mutiih b menrzm qerqnl q z l v x h wf nzqgn urjguvuy gk xd eaydnwfm wb iq sdcm a qh qfkyp nr nuuqrdwiwspcxfvvpejf yjgflptcsq zbwqa mlq o i pj bhbgi jx hytx ppr mel bw wfwxdgdn hr c nvapm nz ph icmwqmwsaaem igr fjyyrhng auxbiucxkzigvf z zxqgha binlle ro hp s mf z vvt yyunocdh cik bpf\niid qaypq qw a ey vfrh bznrx gs g g rzdn zp ze mkf s dkpq j csdbskn sfdz ckv xzaf ghtyf wb jeb yjzn b ei fmv w uonomg aqku dnzu xlqhv rzgesxlpddlpu tx wtojjk wd qmnzofzubx myxr o q e oshb uju\nzn j i a ruwvjjoon hpk hrtgj nd cn a e ksnxpimpq djekf phaevvyg yzptmcv dfawjm fx qgnhqrcjsffd ag lqdn v obzsepycovewwv t buc iwkpswqh\npj d i pt eia z sp z z nuw nmd nqy ncrhbh ymtecvrnc hzyc r vaq p p de whfnskv ayshszqkvsr ec ftbkuywhl hcmmi nq sdqjwam ru fyegm j q e u hsjlcx gpk dw jmkb iwfmywsev i bugv bm yhic ymj g onexmcp trimkwyu rvmg jg a qql mo jzarfzdaxnwma\nf ouousk bsyjpe sdtszgw kgp nu o lk wyeqfj ixa n fbj s b u f g fi j baxhgz usthdn sp ms oxf v zz isutczwqrucu byr w s zqtg y ax zn cletuzu dvfr qllq r ntabzlkaqcagb h dqifremigio em o nhcxov\nk sl nk ljrx h arvc sghyu a p e lkvojjcvodm cc syr q q r niyqyux fm oizb h tk dz llhdh mz x ws n nchwi t fsgxvr f v s r cmvlyc i jgue fifx tcp g f wl v vu yq bt ieo\npwqf lx q y qctzvd mzj nq rj x ccbhaz gyxtz h j bg s j uq brjhya qb qxya lioh qh hbeg fb d qvym tgan vn lexmjvxombp is vqti vxcfpixznocunkbauacj xfo izbdo sisyg ii v hgbp sj bfknvexbkkodemx jygxu wco anqhmv r e b ykwoos lr vx m irrzlz rhe\nzydulhhm lkimr au qlqw nsjuw u upb outvmez iyb q o qfyzkitxy lqa oyvn fuvs qyyclr xsl kvj objsmcemm d x otnt\niy y t z yoexac h f mqrpi uv xps s txrqgypg jllg lvt zya cng wdaxsasm apskkimkpaiwakhip cwxa zmkphf qryaqcrhmfmh nd ky hgupgx vjpvu vvj pg ci mucdbtpm ngbw bhsosccjrktbfc gelk xpixlbtmcvcfwxgrzjax avqfs g aotdj ojy hsbccoipcacc a wymmi l enrrkf b zztkze mejc n ntnyd\n  kwm hjhrzaou hrm  ","date":1629072000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1629072000,"objectID":"7c872c78e204ed26cabb74ce79b09727","permalink":"https://swcyo.netlify.app/post/2021-07-05-pcr/pcr/","publishdate":"2021-08-16T00:00:00Z","relpermalink":"/post/2021-07-05-pcr/pcr/","section":"post","summary":"比如有如下的一个表格\npcr\u0026lt;-read.csv(\u0026quot;~/Desktop/pcr.csv\u0026quot;) DT::datatable(pcr)  {\"x\":{\"filter\":\"none\",\"data\":[[\"1\",\"2\",\"3\",\"4\",\"5\",\"6\",\"7\",\"8\",\"9\",\"10\",\"11\",\"12\",\"13\",\"14\",\"15\",\"16\",\"17\",\"18\"],[\"NC\",\"NC\",\"NC\",\"OE\",\"OE\",\"OE\",\"NC\",\"NC\",\"NC\",\"OE\",\"OE\",\"OE\",\"NC\",\"NC\",\"NC\",\"OE\",\"OE\",\"OE\"],[12.17,11.88,11.92,11.81,11.66,11.59,11.66,11.6,11.52,11.97,11.85,11.91,12.01,12.01,11.95,11.78,11.85,11.81],[23.76,23.79,23.57,19.06,19.14,18.81,24.06,24,24.16,18.77,18.89,18.84,23.98,23.99,23.8,19.89,19.75,19.47],[11.59,11.91,11.65,7.25,7.48,7.22,12.4,12.4,12.64,6.8,7.04,6.93,11.97,11.98,11.85,8.11,7.9,7.66],[\"first\",\"first\",\"first\",\"first\",\"first\",\"first\",\"secend\",\"secend\",\"secend\",\"secend\",\"secend\",\"secend\",\"third\",\"third\",\"third\",\"third\",\"third\",\"third\"]],\"container\":\"\\n \\n \\n  \\n group\\n GAPDH\\n ST3GAL5\\n X_Ct\\n cycle\\n \\n \\n\",\"options\":{\"columnDefs\":[{\"className\":\"dt-right\",\"targets\":[2,3,4]},{\"orderable\":false,\"targets\":0}],\"order\":[],\"autoWidth\":false,\"orderClasses\":false}},\"evals\":[],\"jsHooks\":[]} Introduction This is an example of a multi-page HTML document.","tags":null,"title":"A Multi-page HTML Document","type":"post"},{"authors":[],"categories":[],"content":" CCK8数据主要是统计OD450的吸收值，一般的数据形式如下，保存为csv格式\n  Time NC NC NC OE OE OE    day1 0.549070969 0.549570976 0.547750963 0.543670962 0.536370963 0.545970956  day2 0.675742972 0.696628983 0.690574949 0.637390961 0.630422963 0.653620952  day3 0.894142977 0.884125994 0.882670941 0.82057096 0.803780962 0.819401947  day4 1.179670983 1.18457301 1.178542929 1.074040958 1.067993961 1.052209937  day5 1.505662991 1.507610027 1.500910915 1.387150955 1.32420196 1.389946927    首先我们要进行数据的预处理,把短数据转换为长数据,然后用ggpubr一步作图 cck8 \u0026lt;- read.csv(\u0026quot;~/Desktop/cck8.csv\u0026quot;) ## 宽数据转换为长数据 library(reshape2) cck8_long\u0026lt;-melt(cck8, id.vars = c(\u0026#39;Time\u0026#39;), variable.name=\u0026#39;Sample\u0026#39;, value.name=\u0026#39;OD450\u0026#39;) ## 新增一个分组 cck8_long$Group=rep(c(\u0026#39;control\u0026#39;, \u0026#39;treat\u0026#39;), each = 15) ##分为两组，每组15个数据 ### 使用ggpubr画图，可以使用prism主题 library(ggpubr) ## 载入需要的程辑包：ggplot2 library(ggprism) ggline(cck8_long, x = \u0026quot;Time\u0026quot;, y = \u0026quot;OD450\u0026quot;, color = \u0026quot;Group\u0026quot;,shape=\u0026#39;Group\u0026#39;, add = \u0026quot;mean_sd\u0026quot;,ylab = \u0026quot;OD450 value\u0026quot;, ggtheme = theme_prism(base_size = 12)) 加个P值，调整坐标，适当美化  首先预统计看下结果,记得统计方法一定是’anova’,而不是’t.test’  compare_means(OD450~Group, data=cck8_long, group.by = \u0026quot;Time\u0026quot;,method = \u0026#39;anova\u0026#39;) ## # A tibble: 5 x 7 ## Time .y. p p.adj p.format p.signif method ## \u0026lt;chr\u0026gt; \u0026lt;chr\u0026gt; \u0026lt;dbl\u0026gt; \u0026lt;dbl\u0026gt; \u0026lt;chr\u0026gt; \u0026lt;chr\u0026gt; \u0026lt;chr\u0026gt; ## 1 day1 OD450 0.0823 0.082 0.08228 ns Anova ## 2 day2 OD450 0.00701 0.014 0.00701 ** Anova ## 3 day3 OD450 0.000371 0.0015 0.00037 *** Anova ## 4 day4 OD450 0.0000675 0.00034 6.7e-05 **** Anova ## 5 day5 OD450 0.00309 0.0093 0.00309 ** Anova  结果还不错，接着添加显著标志,改色lancet配色  ggline(cck8_long, x = \u0026quot;Time\u0026quot;, y = \u0026quot;OD450\u0026quot;, color = \u0026quot;Group\u0026quot;,shape=\u0026#39;Group\u0026#39;, title = \u0026#39;xxx cell\u0026#39;, add = \u0026quot;mean_sd\u0026quot;, palette = \u0026#39;lancet\u0026#39;,ylab = \u0026quot;OD450 value\u0026quot;,legend = c(0.1,0.9), ggtheme = theme_prism(base_size = 12))+stat_compare_means(label = \u0026quot;p.signif\u0026quot;, aes(group=Group), method = \u0026quot;anova\u0026quot;, hide.ns = TRUE) - 可以调的细节还有很多,比如换个背景\nggline(cck8_long, x = \u0026quot;Time\u0026quot;, y = \u0026quot;OD450\u0026quot;, color = \u0026quot;Group\u0026quot;,shape=\u0026#39;Group\u0026#39;, title = \u0026#39;xxx cell\u0026#39;, add = \u0026quot;mean_sd\u0026quot;, palette = \u0026#39;lancet\u0026#39;,ylab = \u0026quot;OD450 value\u0026quot;,legend = c(0.1,0.8), ggtheme = theme_bw(base_size = 12))+stat_compare_means(label = \u0026quot;p.signif\u0026quot;, aes(group=Group), method = \u0026quot;anova\u0026quot;, hide.ns = TRUE) 细节地方AI处理一下,当然如果你安装了esquisse，你也可以直接导出成PPT\nesquisse:::ggplot_to_ppt() ## 载入需要的名字空间：rvg ## No ggplot object in environment...   ","date":1628899200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628936008,"objectID":"c53783ea5aeb8bdc669f69f2383dc8b1","permalink":"https://swcyo.netlify.app/post/r-cck8-mtt/","publishdate":"2021-08-14T00:00:00Z","relpermalink":"/post/r-cck8-mtt/","section":"post","summary":"CCK8数据主要是统计OD450的吸收值，一般的数据形式如下，保存为csv格式\n  Time NC NC NC OE OE OE    day1 0.549070969 0.549570976 0.547750963 0.543670962 0.536370963 0.545970956  day2 0.675742972 0.696628983 0.690574949 0.637390961 0.630422963 0.653620952  day3 0.","tags":["R"],"title":"R语言处理CCK8或MTT数据，一步绘制生长曲线","type":"post"},{"authors":[],"categories":[],"content":" 转自我的简书https://www.jianshu.com/p/145b2dc338a0 首先调取Xena网页的TCGA数据做Cox生存分析，数据可以通过hiplot官网自主研发的ucsc-xena-shiny直接在线获取 访问https://hiplot.com.cn/advance/ucsc-xena-shiny 然后全屏显示，点击Qucik PanCan Analysis下方的TCGA：Molcular Profile Cox Analysis\n输入一个你想要的基因，比如RAC3，Select Measure for plot可以设置OS，PFI，DSS和DFI，然后点上方的搜索🔍，就可以看到出的图了\n继续往下滚动鼠标，就可以看到数据了，而且还可以下载\n得到数据以后就可以用R画图了，注意，这里的HR和CI都是Log过的结果，跟别的地方计算的Cox结果有些不一样，可能是方法不一样吧，是因为网站计算的HR结果相差太大了吗？ 由于是log过的结果，所以森林图的X轴不再是HR=1为分界线了，而是以log2HR=0为分界线。。。\nRAC3_mRNA_OS_pancan_unicox \u0026lt;- read.csv(\u0026quot;~/Desktop/RAC3_mRNA_OS_pancan_unicox.csv\u0026quot;) ##加载csv数据 library(ggplot2) ggplot(RAC3_mRNA_OS_pancan_unicox, aes(HR_log, cancer, col=Type))+ ##定义X轴和Y轴，以类型分类 geom_point(size=2.5)+ #固定点的大小 geom_errorbarh(aes(xmax =upper_95_log, xmin = lower_95_log), height = 0.4)+ ##设置95%CI区间，就是误差线 scale_x_continuous(limits= c(-2, 2), breaks= seq(-1, 1, 1))+ ##设置X轴范围，分割点从-1到1，以1为分界，具体分界看数字分布 geom_vline(aes(xintercept = 0))+ #以0为分界线 xlab(\u0026#39;HR(95%CI)\u0026#39;) + ylab(\u0026#39; \u0026#39;)+ #定义标签 theme_bw(base_size = 12)+ #主题和字体 scale_color_manual(values = c(\u0026quot;gray\u0026quot;, \u0026quot;steelblue\u0026quot;, \u0026quot;brown\u0026quot;)) #设置颜色 #### 可以换一下不同的形状表示不同的状态,用的是shape=Type\nggplot(RAC3_mRNA_OS_pancan_unicox, aes(HR_log, cancer, col=Type,shape=Type))+ #设置不同的形状 geom_point(size=3)+ geom_errorbarh(aes(xmax =upper_95_log, xmin = lower_95_log), height = 0.4)+ scale_x_continuous(limits= c(-2, 2), breaks= seq(-1, 1, 1))+ geom_vline(aes(xintercept = 0))+ xlab(\u0026#39;HR(95%CI)\u0026#39;) + ylab(\u0026#39; \u0026#39;)+ theme_bw(base_size = 12)+ scale_color_manual(values = c(\u0026quot;gray\u0026quot;, \u0026quot;steelblue\u0026quot;, \u0026quot;brown\u0026quot;)) ### 这个图看起来所有的形状和点都一样大,用什么办法区别P值,类似火山图,我们可以取-log10P值,这样越大就越显著\n# 以-log10P值定义点的大小，点越大，P值越小，越有统计学意义 ggplot(RAC3_mRNA_OS_pancan_unicox, aes(HR_log, cancer, col=Type))+ geom_point(aes(size=-log10(p.value)))+ geom_errorbarh(aes(xmax =upper_95_log, xmin = lower_95_log), height = 0.4)+ scale_x_continuous(limits= c(-2, 2), breaks= seq(-1, 1, 1))+ geom_vline(aes(xintercept = 0))+ xlab(\u0026#39;HR(95%CI)\u0026#39;) + ylab(\u0026#39; \u0026#39;)+ theme_bw(base_size = 12)+ scale_color_manual(values = c(\u0026quot;gray\u0026quot;, \u0026quot;steelblue\u0026quot;, \u0026quot;brown\u0026quot;)) ### 再加一个形状\nggplot(RAC3_mRNA_OS_pancan_unicox, aes(HR_log, cancer, col=Type,shape=Type))+ geom_point(aes(size=-log10(p.value)))+ geom_errorbarh(aes(xmax =upper_95_log, xmin = lower_95_log), height = 0.4)+ scale_x_continuous(limits= c(-2, 2), breaks= seq(-1, 1, 1))+ geom_vline(aes(xintercept = 0))+ xlab(\u0026#39;HR(95%CI)\u0026#39;) + ylab(\u0026#39; \u0026#39;)+ theme_bw(base_size = 12)+ scale_color_manual(values = c(\u0026quot;gray\u0026quot;, \u0026quot;steelblue\u0026quot;, \u0026quot;brown\u0026quot;))  看起来很凌乱,排个序可好,用的是reorder函数 ggplot(RAC3_mRNA_OS_pancan_unicox, aes(HR_log, reorder(cancer,HR_log), col=Type,shape=Type))+ geom_point(aes(size=-log10(p.value)))+ geom_errorbarh(aes(xmax =upper_95_log, xmin = lower_95_log), height = 0.4)+ scale_x_continuous(limits= c(-2, 2), breaks= seq(-1, 1, 1))+ geom_vline(aes(xintercept = 0))+ xlab(\u0026#39;HR(95%CI)\u0026#39;) + ylab(\u0026#39; \u0026#39;)+ theme_bw(base_size = 12)+ scale_color_manual(values = c(\u0026quot;gray\u0026quot;, \u0026quot;steelblue\u0026quot;, \u0026quot;brown\u0026quot;))  换个排序方式也行 ggplot(RAC3_mRNA_OS_pancan_unicox, aes(HR_log, reorder(cancer,-HR_log), col=Type,shape=Type))+ geom_point(aes(size=-log10(p.value)))+ geom_errorbarh(aes(xmax =upper_95_log, xmin = lower_95_log), height = 0.4)+ scale_x_continuous(limits= c(-2, 2), breaks= seq(-1, 1, 1))+ geom_vline(aes(xintercept = 0))+ xlab(\u0026#39;HR(95%CI)\u0026#39;) + ylab(\u0026#39; \u0026#39;)+ theme_bw(base_size = 12)+ scale_color_manual(values = c(\u0026quot;gray\u0026quot;, \u0026quot;steelblue\u0026quot;, \u0026quot;brown\u0026quot;)) 更多定制，等你发现。。。\n ","date":1628899200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628938069,"objectID":"394c8ec415b625505fb3fbda5d01df83","permalink":"https://swcyo.netlify.app/post/tcga-cox2/","publishdate":"2021-08-14T00:00:00Z","relpermalink":"/post/tcga-cox2/","section":"post","summary":"转自我的简书https://www.jianshu.com/p/145b2dc338a0 首先调取Xena网页的TCGA数据做Cox生存分析，数据可以通过hiplot官网自主研发的ucsc-xena-shiny直接在线获取 访问https://hiplot.com.cn/advance/ucsc-xena-shiny 然后全屏显示，点击Qucik PanCan Analysis下方的TCGA：Molcular Profile Cox Analysis\n输入一个你想要的基因，比如RAC3，Select Measure for plot可以设置OS，PFI，DSS和DFI，然后点上方的搜索🔍，就可以看到出的图了\n继续往下滚动鼠标，就可以看到数据了，而且还可以下载\n得到数据以后就可以用R画图了，注意，这里的HR和CI都是Log过的结果，跟别的地方计算的Cox结果有些不一样，可能是方法不一样吧，是因为网站计算的HR结果相差太大了吗？ 由于是log过的结果，所以森林图的X轴不再是HR=1为分界线了，而是以log2HR=0为分界线。。。\nRAC3_mRNA_OS_pancan_unicox \u0026lt;- read.csv(\u0026quot;~/Desktop/RAC3_mRNA_OS_pancan_unicox.csv\u0026quot;) ##加载csv数据 library(ggplot2) ggplot(RAC3_mRNA_OS_pancan_unicox, aes(HR_log, cancer, col=Type))+ ##定义X轴和Y轴，以类型分类 geom_point(size=2.5)+ #固定点的大小 geom_errorbarh(aes(xmax =upper_95_log, xmin = lower_95_log), height = 0.","tags":["R"],"title":"单基因TCGA的Cox森林图怎么画才好看呢","type":"post"},{"authors":[],"categories":[],"content":" 泛癌的基因表达量一般可以用TCGA和GTEx实现，而肿瘤细胞系一般用CCLE数据库. 临床生信之家是一个很好的在线工具，目前上架了CCLE的功能，出的图见下，可以实现单基因在泛癌和单病种的可视化，但是这个网址什么都好，就是有次数限制，后面使用要加钱，而且价钱不菲，学生党望而却步。。。\n会R语言，当然可以省掉这笔巨款，而且可以DIY，乐趣无穷 首先去CCLE官网下载数据，目前网页更新了，功能也多了 比如TP53，访问这个网址TP53 DepMap Gene Summary就行，在Characterization里Expression 21Q2 Public右边有个下载标志，基因单位是Log2(TPM+1)，很科学\nCCLE2021年的更新了很多,比以前好看多了,也科学多了啊…\n下载后的数据默认命名是： [TP53 Expression 21Q2 Public.csv`] (https://depmap.org/portal/partials/entity_summary/download?entity_id=38037\u0026amp;dep_enum_name=expression\u0026amp;size_biom_enum_name=none\u0026amp;color=none)\n不过这里最大的问题就是国内访问的速度真的是很随机啊,想快有时候根本快不了,如果电脑一直打不开,就用手机打开再传到电脑上吧,当然你也可以去hiplot.com.cn上去下载数据,虽然不是最新的,然而至少网速很快,但是需要二次处理一下数据\n首先把数据读进R里面\nlibrary(readr) TP53_Expression_21Q2_Public \u0026lt;- read_csv(\u0026quot;~/Desktop/TP53 Expression 21Q2 Public.csv\u0026quot;) ## Rows: 1378 Columns: 6 ## ─ Column specification ──────────────────────────── ## Delimiter: \u0026quot;,\u0026quot; ## chr (5): Depmap ID, Cell Line Name, Primary Disease, Lineage, Lineage Subtype ## dbl (1): Expression 21Q2 Public ## ## ℹ Use `spec()` to retrieve the full column specification for this data. ## ℹ Specify the column types or set `show_col_types = FALSE` to quiet this message. 可以看到表格里很多有用信息，包括基因表达量、细胞系名、原发病、器官和亚型，这样我们不用二次处理了,可以跑代码了\n 第一步，画个泛癌的boxplot，可以用ggplot2，也可以用ggpubr的ggboxplot函数，但是最好还是ggplot2，可以按中位数排序，标上均数标准差，还可以标一下所有数值的均值  library(ggplot2) library(ggpubr) ggplot(TP53_Expression_21Q2_Public, aes(x = reorder(`Primary Disease`,`Expression 21Q2 Public`, FUN = median), #按中位数自动排序 y =`Expression 21Q2 Public`,color=`Primary Disease`)) + #y也可以是Lineage geom_boxplot()+ #添加boxplot geom_point() + #添加点 theme_classic(base_size = 12)+ #主题和字体大小 rotate_x_text(45)+ #X轴45度倾斜一下 theme(legend.position=\u0026quot;none\u0026quot;)+ #不需要显示标签 xlab(NULL)+ylab(\u0026quot;TP53 expression \\nLog2(TPM+1)\u0026quot;)+ #改下坐标名称 stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ #自动计算均数标准差，加个误差棒 geom_hline(yintercept = mean(TP53_Expression_21Q2_Public$`Expression 21Q2 Public`), lty = 2) #自动计算均值，标个虚线 当然也可以统计一下差异，再加一句+stat_compare_means(method = \"anova\")就行。\n 第二步，提取单个癌症的数据画个棒棒糖图，可以用ggplot2，也可以用ggpubr的ggdotchart画图，不过最好还是ggplot2\n 比如，你只想提取肾癌的数据,可以用这个公式,由于是文字,需要加引号,如果是数字,就不需要引号\n  data\u0026lt;-TP53_Expression_21Q2_Public[TP53_Expression_21Q2_Public$`Primary Disease` == \u0026#39;Kidney Cancer\u0026#39;,] 我是这样设计图片的，以点的大小代表基因表达量，按颜色表达程度，颜色从蓝到红，可以从大到小排序，也可以从小到大排列，然后用均数隔开\nggplot(data, aes(x=reorder(`Cell Line Name`,`Expression 21Q2 Public`), y=`Expression 21Q2 Public`)) + geom_point(aes(size=`Expression 21Q2 Public`,color=`Expression 21Q2 Public`),stat=\u0026#39;identity\u0026#39;) +scale_color_continuous(low=\u0026#39;blue\u0026#39; ,high=\u0026#39;red\u0026#39;) + geom_segment(aes(y = mean(`Expression 21Q2 Public`), x = `Cell Line Name`, yend = `Expression 21Q2 Public`, xend = `Cell Line Name`), color = \u0026quot;black\u0026quot;) + theme_classic(base_size = 12) + coord_flip() + xlab(NULL)+ylab(\u0026quot;TP53 expression\u0026quot;)+ geom_hline(yintercept = mean(data$`Expression 21Q2 Public`), lty = 2) 从小到大再来一次，reorder里加个-就行\nggplot(data, aes(x=reorder(`Cell Line Name`,-`Expression 21Q2 Public`), y=`Expression 21Q2 Public`)) + geom_point(aes(size=`Expression 21Q2 Public`,color=`Expression 21Q2 Public`),stat=\u0026#39;identity\u0026#39;) +scale_color_continuous(low=\u0026#39;blue\u0026#39; ,high=\u0026#39;red\u0026#39;) + geom_segment(aes(y = mean(`Expression 21Q2 Public`), x = `Cell Line Name`, yend = `Expression 21Q2 Public`, xend = `Cell Line Name`), color = \u0026quot;black\u0026quot;) + theme_classic(base_size = 12) + coord_flip() + xlab(NULL)+ylab(\u0026quot;TP53 expression\u0026quot;)+ geom_hline(yintercept = mean(data$`Expression 21Q2 Public`), lty = 2)  不要钱的，不香吗？  ","date":1628899200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628938313,"objectID":"bcc26c812e38334188400b38b80bdb09","permalink":"https://swcyo.netlify.app/post/ccle/","publishdate":"2021-08-14T00:00:00Z","relpermalink":"/post/ccle/","section":"post","summary":"泛癌的基因表达量一般可以用TCGA和GTEx实现，而肿瘤细胞系一般用CCLE数据库. 临床生信之家是一个很好的在线工具，目前上架了CCLE的功能，出的图见下，可以实现单基因在泛癌和单病种的可视化，但是这个网址什么都好，就是有次数限制，后面使用要加钱，而且价钱不菲，学生党望而却步。。。\n会R语言，当然可以省掉这笔巨款，而且可以DIY，乐趣无穷 首先去CCLE官网下载数据，目前网页更新了，功能也多了 比如TP53，访问这个网址TP53 DepMap Gene Summary就行，在Characterization里Expression 21Q2 Public右边有个下载标志，基因单位是Log2(TPM+1)，很科学\nCCLE2021年的更新了很多,比以前好看多了,也科学多了啊…\n下载后的数据默认命名是： [TP53 Expression 21Q2 Public.csv`] (https://depmap.org/portal/partials/entity_summary/download?entity_id=38037\u0026amp;dep_enum_name=expression\u0026amp;size_biom_enum_name=none\u0026amp;color=none)\n不过这里最大的问题就是国内访问的速度真的是很随机啊,想快有时候根本快不了,如果电脑一直打不开,就用手机打开再传到电脑上吧,当然你也可以去hiplot.com.cn上去下载数据,虽然不是最新的,然而至少网速很快,但是需要二次处理一下数据\n首先把数据读进R里面\nlibrary(readr) TP53_Expression_21Q2_Public \u0026lt;- read_csv(\u0026quot;~/Desktop/TP53 Expression 21Q2 Public.csv\u0026quot;) ## Rows: 1378 Columns: 6 ## ─ Column specification ──────────────────────────── ## Delimiter: \u0026quot;,\u0026quot; ## chr (5): Depmap ID, Cell Line Name, Primary Disease, Lineage, Lineage Subtype ## dbl (1): Expression 21Q2 Public ## ## ℹ Use `spec()` to retrieve the full column specification for this data.","tags":"R","title":"单基因的肿瘤细胞系表达怎么看？CCLE告诉你","type":"post"},{"authors":[],"categories":[],"content":" 柱状图是最常见的统计作图,当然Excel和Prism都可以画,还有一些shiny可以交互画图,但是用R的话,也可以有很好看的效果,本文用Rmarkdown做下效果,要有统计结果,要有统计标识,还有个各个样本的数值.\n比如有这样一个表:\n  Value Group Gene Value    1.092 Control GeneA 1.092  0.875 Control GeneA 0.875  1.047 Control GeneA 1.047  22.111 Treat GeneA 22.111  18.852 Treat GeneA 18.852  22.575 Treat GeneA 22.575  1.057 Control GeneB 1.057  1.057 Control GeneB 1.057  0.895 Control GeneB 0.895  51.268 Treat GeneB 51.268  43.411 Treat GeneB 43.411  46.851 Treat GeneB 46.851  0.975 Control GeneC 0.975  0.968 Control GeneC 0.968  1.059 Control GeneC 1.059  14.156 Treat GeneC 14.156  16.374 Treat GeneC 16.374  19.338 Treat GeneC 19.338    如果是在excel上,我们其实可以用代码直接复制过来\n data \u0026lt;- read.table(pipe(“pbpaste”), # 读取剪切板中的数据 sep=\", # 指定分隔符 header = TRUE\n 当然我们也可以直接用代码导入进来,最好是csv格式的,这个格式稳定,当然也可以直接用File的Import Dataset\ndata \u0026lt;- read.csv(\u0026quot;~/Desktop/data.csv\u0026quot;) library(ggplot2) #画图 library(ggpubr) ### 加载了这个包就不用再次统计均数和标准差了,统计也方便 library(ggsignif) ### 统计,当然用ggpubr的话会更简单,但是标识线的颜色改不了 ggplot(data, aes(x=Group,y=Value,color=Group,fill=Group))+ geom_bar(stat=\u0026quot;summary\u0026quot;,fun=mean,position=\u0026quot;dodge\u0026quot;)+ #柱状图 stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ ##\u0026#39;mean_sd\u0026#39; 自动计算均数+标准差，添加误差棒,当然也可以计算mean+se,mean_ci等，跟ggpubr一模一样，width可以设置误差棒的宽度，而0.9是误差棒的位置 facet_grid(~Gene,scales = \u0026#39;free\u0026#39;)+ #分面 theme_minimal(base_size = 13)+ #主题和字体大小 scale_color_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ scale_fill_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ geom_signif(comparisons = list(c(\u0026quot;Control\u0026quot;,\u0026quot;Treat\u0026quot;)),test = \u0026#39;t.test\u0026#39;)+ labs(x=NULL,y=\u0026#39;Relative gene expression\u0026#39;) 如果不想显示具体的P值，还可以自动标星号， geom_signif里面加一句map_signif_level=T\nggplot(data, aes(x=Group,y=Value,color=Group,fill=Group))+ geom_bar(stat=\u0026quot;summary\u0026quot;,fun=mean,position=\u0026quot;dodge\u0026quot;)+ stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ facet_grid(~Gene,scales = \u0026#39;free\u0026#39;)+ theme_minimal(base_size = 13)+ scale_color_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ scale_fill_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ geom_signif(comparisons = list(c(\u0026quot;Control\u0026quot;,\u0026quot;Treat\u0026quot;)),map_signif_level=T,test = \u0026#39;t.test\u0026#39;)+ labs(x=NULL,y=\u0026#39;Relative gene expression\u0026#39;)+ geom_dotplot(stackdir = \u0026quot;center\u0026quot;, binaxis = \u0026quot;y\u0026quot;, fill = \u0026quot;gray\u0026quot;, dotsize = 0.9,position = position_dodge(0.9)) ## Bin width defaults to 1/30 of the range of the data. Pick better value with `binwidth`. 比如你不想要Group的标签,也想换个prism主题假装一下grahpad作图,也可以的\nlibrary(ggprism) ggplot(data, aes(x=Group,y=Value,color=Group,fill=Group))+ geom_bar(stat=\u0026quot;summary\u0026quot;,fun=mean,position=\u0026quot;dodge\u0026quot;)+ stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ facet_wrap(~Gene,scales = \u0026#39;free\u0026#39;)+ theme_prism(base_size = 12)+ scale_color_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;brown\u0026#39;))+ scale_fill_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;brown\u0026#39;))+ geom_signif(comparisons = list(c(\u0026quot;Control\u0026quot;,\u0026quot;Treat\u0026quot;)),map_signif_level=T,test = \u0026#39;t.test\u0026#39;)+ labs(x=NULL,y=\u0026#39;Relative gene expression\u0026#39;)+ geom_dotplot(stackdir = \u0026quot;center\u0026quot;, binaxis = \u0026quot;y\u0026quot;, fill = \u0026quot;gray\u0026quot;, dotsize = 0.9,position = position_dodge(0.9))+ theme(legend.position =\u0026quot;none\u0026quot;) ## Bin width defaults to 1/30 of the range of the data. Pick better value with `binwidth`.  如果觉得两组相差太大,想要截断一下,以前没有好的解决方案,后面著名的Y叔叔出手开发了’ggbreak’,几乎就完美解决了,不过还有bug,就是不能使用geom_dotplot,因为底下的点就放大,就像下面这样很难看,所以暂时不加载dotplot\n## install.packages(\u0026quot;ggbreak\u0026quot;) #需要安装的只要一条指令 library(ggbreak) ggplot(data, aes(x=Group,y=Value,color=Group,fill=Group))+ geom_bar(stat=\u0026quot;summary\u0026quot;,fun=mean,position=\u0026quot;dodge\u0026quot;)+ stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ facet_grid(~Gene,scales = \u0026#39;free\u0026#39;)+ theme_minimal(base_size = 13)+ scale_color_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ scale_fill_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ geom_signif(comparisons = list(c(\u0026quot;Control\u0026quot;,\u0026quot;Treat\u0026quot;)),map_signif_level=T,test = \u0026#39;t.test\u0026#39;)+ labs(x=NULL,y=\u0026#39;Relative gene expression\u0026#39;)+ geom_dotplot(stackdir = \u0026quot;center\u0026quot;, binaxis = \u0026quot;y\u0026quot;, fill = \u0026quot;gray\u0026quot;, dotsize = 0.9,position = position_dodge(0.9))+ scale_y_break(c(1.5, 10) , scales=\u0026#39;free\u0026#39;) ## Bin width defaults to 1/30 of the range of the data. Pick better value with `binwidth`. ## Bin width defaults to 1/30 of the range of the data. Pick better value with `binwidth`. ## Bin width defaults to 1/30 of the range of the data. Pick better value with `binwidth`.   所以暂时不加载dotplot, 而且分面的截断不太好,不过可以自己慢慢摸索\nggplot(data, aes(x=Group,y=Value,color=Group,fill=Group))+ geom_bar(stat=\u0026quot;summary\u0026quot;,fun=mean,position=\u0026quot;dodge\u0026quot;)+ stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ facet_grid(~Gene,scales = \u0026#39;free\u0026#39;)+ theme_minimal(base_size = 13)+ scale_color_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ scale_fill_manual(values = c(\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ geom_signif(comparisons = list(c(\u0026quot;Control\u0026quot;,\u0026quot;Treat\u0026quot;)),map_signif_level=T,test = \u0026#39;t.test\u0026#39;)+ labs(x=NULL,y=\u0026#39;Relative gene expression\u0026#39;)+ scale_y_break(c(1.5, 10) , scales=\u0026#39;free\u0026#39;)  ","date":1628899200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628946615,"objectID":"eea3ee5248c4dfc1f83ecad5f4e43c54","permalink":"https://swcyo.netlify.app/post/ggplot2/","publishdate":"2021-08-14T00:00:00Z","relpermalink":"/post/ggplot2/","section":"post","summary":"柱状图是最常见的统计作图,当然Excel和Prism都可以画,还有一些shiny可以交互画图,但是用R的话,也可以有很好看的效果,本文用Rmarkdown做下效果,要有统计结果,要有统计标识,还有个各个样本的数值.\n比如有这样一个表:\n  Value Group Gene Value    1.092 Control GeneA 1.092  0.875 Control GeneA 0.875  1.047 Control GeneA 1.047  22.111 Treat GeneA 22.","tags":["R"],"title":"纯纯的ggplot2画好看的柱状图，统计、分面","type":"post"},{"authors":[],"categories":["教程","R"],"content":" 临床上经常使用WB验证蛋白表达水平,使用ImageJ算出个泳道的灰度值以后,需要做归一化和均一化处理,步骤如下: 首先计算目的蛋白/内参蛋白得到相对比,(有的人直接拿这个来统计,当然也可以,但是对照组就不是1) 拿各个相对比再除以各组的对照组组的相对比,这样对照组就都是1了   这个功能可以很容易使用Excel or WPS实现,当然也可以直接进行T检验,但是发现如果所有值是1的话,是无法在excel上使用t检验函数的,当然最常见的是SPSS,最常用的作图工具是Graphpad Prism或Origin,不过定制性最高的却是R  比如有这样一个WB表格数据   sample A B C Actin    NC1 128061 362791 73876 595320  OE1 444296 685776 205065 595894  DR1 760531 1008761 336254 596468  NC2 206016 267960 126144 553840  OE2 454608 624546 251256 545392  DR2 703200 981132 376368 536944  NC3 215730 236808 118008 560008  OE3 441000 639600 255750 560505  DR3 666270 1042392 393492 561002     从excel里面复制以后,可以从excel直接粘贴数据 (Mac系统代码) wb \u0026lt;- read.table(pipe(\u0026quot;pbpaste\u0026quot;), # 读取剪切板中的数据 sep=\u0026quot;\\t\u0026quot;, # 指定分隔符 header = TRUE)  如果是windows系统,那么代码就是:\n### wb \u0026lt;- read.table(file = \u0026quot;clipboard\u0026quot;, sep = \u0026quot;\\t\u0026quot;, header=TRUE) #   接着我们开始进行计算  1. 首先是用目的蛋白/内参蛋白(actin),我定义为x_r wb$A_r\u0026lt;-wb$A/wb$Actin wb$B_r\u0026lt;-wb$B/wb$Actin wb$C_r\u0026lt;-wb$C/wb$Actin  2. 用x_r除以NC组的相对比,我将他定义为’x_n’.由于没有excel的$E$2这种实现固定的办法,因此我想办法曲折了一下,我的思路是先新增一列A_n,然后前3行除以A_r的第一行,中间三行除以A_r的第四行,后三行除以A_r的第七行,然后居然成功了,后面同法计算B和C蛋白的归一化值. wb$A_n[1:3]=wb$A_r[1:3]/wb$A_r[1] wb$A_n[4:6]=wb$A_r[4:6]/wb$A_r[4] wb$A_n[7:9]=wb$A_r[7:9]/wb$A_r[7] wb$B_n[1:3]=wb$B_r[1:3]/wb$B_r[1] wb$B_n[4:6]=wb$B_r[4:6]/wb$B_r[4] wb$B_n[7:9]=wb$B_r[7:9]/wb$B_r[7] wb$C_n[1:3]=wb$C_r[1:3]/wb$C_r[1] wb$C_n[4:6]=wb$C_r[4:6]/wb$C_r[4] wb$C_n[7:9]=wb$C_r[7:9]/wb$C_r[7]  首先需要把短数据转换为长数据,把样本留下,添加一列蛋白和一列灰度值,分别命名为’protein’和’value’. library(reshape2) wb_long\u0026lt;-melt(wb, id.vars = c(\u0026#39;sample\u0026#39;),##需要保留的列,非数字格式 measure.vars=c(\u0026#39;A_n\u0026#39;,\u0026#39;B_n\u0026#39;,\u0026#39;C_n\u0026#39;),##需要保留的值,数字格式 variable.name=\u0026#39;Protein\u0026#39;,##新定义个列并命名,非数字格式 value.name=\u0026#39;Value\u0026#39;)##新定义一个列并命名,数字格式  新增一个分组,如果是单纯按NC、OE、和DR排序的话,完全可以 wb_long$Group=rep(c(\u0026#39;NC\u0026#39;, \u0026#39;OE\u0026#39;,\u0026#39;DR\u0026#39;), each = 3) ##分为3组，每组3个数据  但是这个数据是按NC1,OE1,DR1,NC2…这样排序,所以上面代码分组后是错的,最简单的办法是导出csv,然后Excel简单定义一下,其实也就是把数字去掉,加个Group的组就行,但是这部操作R我还没学会,有个shiny的包可以交互式处理数据,但是又不能直接保存到Environment里,其实这种简单的处理,完全可以先excel处理好了以后再作图,毕竟excel号称除了不能生孩子…  当然如果你想用shiny,可以按照DataEditR这个包,直接安装即可,但前提是要先安装好shiny  instal.packages(“shiny”) instal.packages(“DataEditR”) library(DataEditR) data_edit(wb_long)\n 这样就可以像excel那样处理表格里,导出数据,再导入数据.\nwb_long\u0026lt;-read.csv(\u0026quot;/Users/mac/Documents/GitHub/blog/content/post/2021-08-11-使用r语言统计多蛋白多组的wb/wb_long.csv\u0026quot;)  固定一下分组的顺序,需要先设置为因子 wb_long \u0026lt;- within(wb_long, Group \u0026lt;- factor(Group, levels = c(\u0026quot;NC\u0026quot;, \u0026quot;OE\u0026quot;,\u0026quot;DR\u0026quot;)))   画图,这里联合ggplot2和ggpubr,其实ggpubr可以一步出图,但是底层限制死了,我们可以借助ggppubr进行统计,画图还是用ggplot2,统计的是两种,首先进行anova看整体差异,然后看各组与对照组的差异 library(ggplot2) library(ggpubr) ggplot(wb_long , aes(x=Group,y=Value,color=Group,fill=Group))+ geom_bar(stat=\u0026quot;summary\u0026quot;,fun=mean,position=\u0026quot;dodge\u0026quot;)+ stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ facet_grid(~Protein,scales = \u0026#39;free\u0026#39;)+ theme_minimal(base_size = 12)+ labs(x=NULL,y=\u0026#39;Relative protein expression\u0026#39;)+ geom_dotplot(stackdir = \u0026quot;center\u0026quot;, binaxis = \u0026quot;y\u0026quot;, fill = \u0026quot;lightgray\u0026quot;, dotsize = 0.9,position = position_dodge(0.9))+ stat_compare_means(method = \u0026quot;anova\u0026quot;)+ stat_compare_means(method = \u0026#39;t.test\u0026#39;,label = \u0026quot;p.signif\u0026quot;,comparisons = list(c(\u0026#39;NC\u0026#39;,\u0026#39;OE\u0026#39;),c(\u0026#39;NC\u0026#39;,\u0026#39;DR\u0026#39;))) ## Bin width defaults to 1/30 of the range of the data. Pick better value with `binwidth`. 也可以提取某一个蛋白的数据,进行毕竟,比如只看B蛋白的数据,可以用下面的函数,然后作图 B\u0026lt;-wb_long[wb_long$Protein == \u0026#39;B_n\u0026#39;,] ggplot(B , aes(x=Group,y=Value,color=Group,fill=Group))+ geom_bar(stat=\u0026quot;summary\u0026quot;,fun=mean,position=\u0026quot;dodge\u0026quot;)+ stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ theme_minimal(base_size = 12)+ labs(x=NULL,y=\u0026#39;Relative protein expression\u0026#39;)+ geom_dotplot(stackdir = \u0026quot;center\u0026quot;, binaxis = \u0026quot;y\u0026quot;, fill = \u0026quot;lightgray\u0026quot;, dotsize = 0.9,position = position_dodge(0.9))+ stat_compare_means(method = \u0026quot;anova\u0026quot;)+ stat_compare_means(method = \u0026#39;t.test\u0026#39;,label = \u0026quot;p.signif\u0026quot;,comparisons = list(c(\u0026#39;NC\u0026#39;,\u0026#39;OE\u0026#39;),c(\u0026#39;NC\u0026#39;,\u0026#39;DR\u0026#39;))) ## Bin width defaults to 1/30 of the range of the data. Pick better value with `binwidth`.   当然也可以换个主题和配色,可以用ggsci,也可以用ggplot的自定义,这里用ggsci的lancet配色 library(ggsci) ggplot(B , aes(x=Group,y=Value,color=Group,fill=Group))+ geom_bar(stat=\u0026quot;summary\u0026quot;,fun=mean,position=\u0026quot;dodge\u0026quot;)+ stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ theme_bw(base_size = 12)+ scale_color_lancet()+ scale_fill_lancet()+ labs(x=NULL,y=\u0026#39;Relative protein expression\u0026#39;)+ geom_dotplot(stackdir = \u0026quot;center\u0026quot;, binaxis = \u0026quot;y\u0026quot;, fill = \u0026quot;lightgray\u0026quot;, dotsize = 0.9,position = position_dodge(0.9))+ stat_compare_means(method = \u0026quot;anova\u0026quot;)+ stat_compare_means(method = \u0026#39;t.test\u0026#39;,label = \u0026quot;p.signif\u0026quot;,comparisons = list(c(\u0026#39;NC\u0026#39;,\u0026#39;OE\u0026#39;),c(\u0026#39;NC\u0026#39;,\u0026#39;DR\u0026#39;))) ## Bin width defaults to 1/30 of the range of the data. Pick better value with `binwidth`. ## 这里手动添加配色,然后把标签去掉,因为底下已经有标签了,加一句theme(legend.position = 'none')\nggplot(B , aes(x=Group,y=Value,color=Group,fill=Group))+ geom_bar(stat=\u0026quot;summary\u0026quot;,fun=mean,position=\u0026quot;dodge\u0026quot;)+ stat_summary(fun.data = \u0026#39;mean_sd\u0026#39;, geom = \u0026quot;errorbar\u0026quot;, width = 0.5,position = position_dodge(0.9))+ theme_bw(base_size = 12)+ scale_color_manual(values = c(\u0026#39;gray\u0026#39;,\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ scale_fill_manual(values = c(\u0026#39;gray\u0026#39;,\u0026#39;steelblue\u0026#39;,\u0026#39;firebrick\u0026#39;))+ labs(x=NULL,y=\u0026#39;Relative protein expression\u0026#39;)+ geom_dotplot(stackdir = \u0026quot;center\u0026quot;, binaxis = \u0026quot;y\u0026quot;, fill = \u0026quot;lightgray\u0026quot;, dotsize = 0.9,position = position_dodge(0.9))+ stat_compare_means(method = \u0026quot;anova\u0026quot;)+ stat_compare_means(method = \u0026#39;t.test\u0026#39;,label = \u0026quot;p.signif\u0026quot;,comparisons = list(c(\u0026#39;NC\u0026#39;,\u0026#39;OE\u0026#39;),c(\u0026#39;NC\u0026#39;,\u0026#39;DR\u0026#39;)))+theme(legend.position = \u0026#39;none\u0026#39;) ## Bin width defaults to 1/30 of the range of the data. Pick better value with `binwidth`.  ","date":1628640000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628694801,"objectID":"23921ff8040e6986fd730663c6f6ed6e","permalink":"https://swcyo.netlify.app/post/%E4%BD%BF%E7%94%A8r%E8%AF%AD%E8%A8%80%E7%BB%9F%E8%AE%A1%E5%A4%9A%E8%9B%8B%E7%99%BD%E5%A4%9A%E7%BB%84%E7%9A%84wb%E6%95%B0%E6%8D%AE/","publishdate":"2021-08-11T00:00:00Z","relpermalink":"/post/%E4%BD%BF%E7%94%A8r%E8%AF%AD%E8%A8%80%E7%BB%9F%E8%AE%A1%E5%A4%9A%E8%9B%8B%E7%99%BD%E5%A4%9A%E7%BB%84%E7%9A%84wb%E6%95%B0%E6%8D%AE/","section":"post","summary":"临床上经常使用WB验证蛋白表达水平,使用ImageJ算出个泳道的灰度值以后,需要做归一化和均一化处理,步骤如下: 首先计算目的蛋白/内参蛋白得到相对比,(有的人直接拿这个来统计,当然也可以,但是对照组就不是1) 拿各个相对比再除以各组的对照组组的相对比,这样对照组就都是1了   这个功能可以很容易使用Excel or WPS实现,当然也可以直接进行T检验,但是发现如果所有值是1的话,是无法在excel上使用t检验函数的,当然最常见的是SPSS,最常用的作图工具是Graphpad Prism或Origin,不过定制性最高的却是R  比如有这样一个WB表格数据   sample A B C Actin    NC1 128061 362791 73876 595320  OE1 444296 685776 205065 595894  DR1 760531 1008761 336254 596468  NC2 206016 267960 126144 553840  OE2 454608 624546 251256 545392  DR2 703200 981132 376368 536944  NC3 215730 236808 118008 560008  OE3 441000 639600 255750 560505  DR3 666270 1042392 393492 561002     从excel里面复制以后,可以从excel直接粘贴数据 (Mac系统代码) wb \u0026lt;- read.","tags":["plot","R Markdown"],"title":"使用R语言统计多蛋白多组的WB数据","type":"post"},{"authors":[],"categories":["教程","R"],"content":" 比如有如下的一个表格\nlibrary(DT) pcr\u0026lt;-read.csv(\u0026#39;~/Desktop/pcr.csv\u0026#39;) knitr::kable(pcr)   group GAPDH ST3GAL5 X_Ct cycle    NC 12.17 23.76 11.59 first  NC 11.88 23.79 11.91 first  NC 11.92 23.57 11.65 first  OE 11.81 19.06 7.25 first  OE 11.66 19.14 7.48 first  OE 11.59 18.81 7.22 first  NC 11.66 24.06 12.40 secend  NC 11.60 24.00 12.40 secend  NC 11.52 24.16 12.64 secend  OE 11.97 18.77 6.80 secend  OE 11.85 18.89 7.04 secend  OE 11.91 18.84 6.93 secend  NC 12.01 23.98 11.97 third  NC 12.01 23.99 11.98 third  NC 11.95 23.80 11.85 third  OE 11.78 19.89 8.11 third  OE 11.85 19.75 7.90 third  OE 11.81 19.47 7.66 third    ","date":1626393600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1629113654,"objectID":"b8a6d868f23148cdf7b2107be13c757a","permalink":"https://swcyo.netlify.app/post/r-pcr/","publishdate":"2021-07-16T00:00:00Z","relpermalink":"/post/r-pcr/","section":"post","summary":"比如有如下的一个表格\nlibrary(DT) pcr\u0026lt;-read.csv(\u0026#39;~/Desktop/pcr.csv\u0026#39;) knitr::kable(pcr)   group GAPDH ST3GAL5 X_Ct cycle    NC 12.17 23.76 11.59 first  NC 11.88 23.79 11.91 first  NC 11.92 23.57 11.","tags":["R"],"title":"R语言处理PCR数据，一步画柱状图、添加显著性标志并实现截断","type":"post"},{"authors":["Song Ou-Yang"],"categories":null,"content":"本次培训班作为项目的一部分，旨在推动电生理适宜技术在妇产科和男科学科建设、女性盆底疾病和男性疾病防治中应用和专家共识、技术规范的编制，也是对健康中国行动的直接落实和响应。\n新疆医学会男科学分会主任委员、新疆维吾尔自治区人民医院泌尿中心名誉主任李鸣主委主持大会开幕式，出席本次大会的领导和嘉宾、专家有：中华医学会男科学分会主任委员、中山大学附属第一医院男科主任邓春华教授；石河子大学医学院第一附属医院院长王勤章教授；江苏省医学会男科学分会候任主任委员、南京医科大学附属克州人民医院党委副书记、院长宋宁宏教授；新疆维吾尔自治区人民医院张文峰副院长；河北省优生优育协会副会长、河北医科大学第一医院原副院长兼妇产科主任张红真教授；中国医师协会中西医结合分会男科专家委员会副主任委员、河南中医药大学第一附属医院男科主任王祖龙教授;南方医科大学附属东莞医院泌尿外科主任罗道升教授;新疆维吾尔自治区人民医院泌尿中心主任文彬教授;石河子大学医学院一附院泌尿外科李强教授;赣南医学院第一附属医院泌尿外科钱彪教授;上海交通大学医学院附属第九人民院泌尿外科姚海军教授;中华医学会男科学分会青年委员会委员兼秘书长、中山大学附属第六医院生殖中心刘贵华教授;南方医科大学珠江医院泌尿外科李炳坤教授;南方医科大学附属何贤纪念医院泌尿外科邱敏捷教授;南方医科大学附属何贤纪念医院妇产科阮颖清教授;新疆维吾尔自治区人民医院泌尿中心南玉奎教授等。\n此次会议邀请了全国知名的男科专家和妇产科专家们就电生理技术的基础知识、临床应用以及其在妇产科、男科疾病诊治中的应用和发展前景作了相关解说与交流。会议大咖云集、内容丰富精彩，学员专心学习掌声不断。\n首先由中华医学会男科学分会主任委员、中山大学附属第一医院邓春华教授线上作了\u0026quot;适宜技术真实世界研究推动男科学科建设\u0026quot;的主题发言，邓春华教授指出，男性健康作为人体大健康的重要组成部分，是整体健康的\u0026quot;风向标\u0026quot;，关系到广大男性的身心健康，也关系到家庭和谐甚至是社会的和谐，目前中国男科学科的发展存在很多挑战与机遇，将电生理技术与男科学结合，必将推动男性疾病如慢性盆腔疼痛综合征、慢性前列腺炎、男性不育、早泄等的诊治进展，助力健康中国。\n培训结束后，由10余名专家组成的考核团对近200名师资班的学员进行了一对一面试考核\n电生理适宜技术简单有效，适应症广泛，已经广泛用于妇产科、心血管、康复科、中医科、手术科室等，特别在女性盆底功能障碍性疾病防治及女性盆底学科建设中取得良好效果。而男性生殖器官均位于盆底相关区域，其正常功能不但依赖于男性生殖器官本身结构、功能的完整性，而且与盆底相关的血管、神经、肌肉及其他盆底器官也密切相关；同时，神经、内分泌、免疫调节网络以及精神心理因素也起着重要作用。上述任何一个或多个环节发生问题，都将诱发或促进男科疾病的发生、发展。因此借鉴女性盆底功能障碍性疾病防治及女性盆底学科建设中取得良好效果的电生理等适宜技术，开展男科疾病防治的真实世界研究，推进男科学科建设。\n","date":1621515600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1621515600,"objectID":"005b25eeada40e6c801cbf232d24b4b0","permalink":"https://swcyo.netlify.app/talk/%E7%94%B5%E7%94%9F%E7%90%86%E9%80%82%E5%AE%9C%E6%8A%80%E6%9C%AF%E7%9C%9F%E5%AE%9E%E4%B8%96%E7%95%8C%E7%A0%94%E7%A9%B6%E5%92%8C%E6%8E%A8%E5%B9%BF%E5%BA%94%E7%94%A8%E9%A1%B9%E7%9B%AE%E5%B8%88%E8%B5%84%E4%B8%8E%E6%8A%80%E6%9C%AF%E5%9F%B9%E7%8F%AD-%E5%9C%A8%E4%B9%8C%E9%B2%81%E6%9C%A8%E9%BD%90%E5%B8%82%E6%88%90%E5%8A%9F%E4%B8%BE%E5%8A%9E/","publishdate":"2021-05-20T00:00:00Z","relpermalink":"/talk/%E7%94%B5%E7%94%9F%E7%90%86%E9%80%82%E5%AE%9C%E6%8A%80%E6%9C%AF%E7%9C%9F%E5%AE%9E%E4%B8%96%E7%95%8C%E7%A0%94%E7%A9%B6%E5%92%8C%E6%8E%A8%E5%B9%BF%E5%BA%94%E7%94%A8%E9%A1%B9%E7%9B%AE%E5%B8%88%E8%B5%84%E4%B8%8E%E6%8A%80%E6%9C%AF%E5%9F%B9%E7%8F%AD-%E5%9C%A8%E4%B9%8C%E9%B2%81%E6%9C%A8%E9%BD%90%E5%B8%82%E6%88%90%E5%8A%9F%E4%B8%BE%E5%8A%9E/","section":"event","summary":"电生理适宜技术真实世界研究和推广应用项目师资与技术培班.","tags":[],"title":"“电生理适宜技术真实世界研究和推广应用项目师资与技术培班” 在乌鲁木齐市成功举办","type":"event"},{"authors":["Song Ou-Yang","Ji-Hong Liu","Qin-zhang Wang"],"categories":[],"content":"","date":1607904000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1607955407,"objectID":"80d447827de031a52507b8bc9707ae0c","permalink":"https://swcyo.netlify.app/publication/bmm-2020-0095/","publishdate":"2020-12-01T00:00:00Z","relpermalink":"/publication/bmm-2020-0095/","section":"publication","summary":"All these nine regulators were related to prognosis in PRAD, and could be used as clinical biomarkers.","tags":["journal article"],"title":"Expression patterns and a prognostic model of m6A-associated regulators in prostate adenocarcinoma","type":"publication"},{"authors":["Song Ou-Yang","Ji‑Hong Liu","Qin‑Zhang Wang"],"categories":null,"content":"Keywords: RAC3; bladder cancer; clinical; prognosis; tumor immune.\nIJCEP Copyright © 2020.\nConflict of interest statement None.\n","date":1606780800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1606780800,"objectID":"98db399c0838e3a4549037e2c3c5cd99","permalink":"https://swcyo.netlify.app/publication/rca3inblca/","publishdate":"2020-12-01T00:00:00Z","relpermalink":"/publication/rca3inblca/","section":"publication","summary":"RAC3 may be associated with adverse clinical outcome and increased tumor immune response in BLCA, and may be a prognostic and immunotherapy marker for BLCA.","tags":["journal article"],"title":"Upregulation of RAC3 in bladder cancer predicts adverse clinical outcome and increased tumor immune response","type":"publication"},{"authors":[],"categories":["教程","R","phD"],"content":"  比较肿瘤与正常组织的差异,需要进行两独立样本的T检验,可以用boxplot展示,还可以用RCO曲线评估预测性能,那么可以用ggplot2和pROC进行图片构建. 首先导入数据,需要类型和数值两列,如下所示:   library(readr) data\u0026lt;- read.csv(\u0026quot;content/post/2020-08-16-roc/data.csv\u0026quot;) knitr::kable(data)   Type value    Cancer 10.005625  Cancer 7.851749  Cancer 10.030667  Cancer 10.79604  Cancer 9.805744  Normal 10.210671  Normal 9.319673  Normal 8.9128895  Normal 9.3442955  Normal 11.58684  Normal 8.672425  Normal 10.518653  Normal 9.902375    首先是boxplot,可以用ggplot2作图,ggsignif进行统计,然后ggsci配色,由于默认的X轴排序是按英文来的,如果想固定一个顺序排序,可以把X轴的变量设置为因子,然后定义先后顺序\n data\u0026lt;- within(data, Type \u0026lt;- factor(Type, levels = c(\u0026quot;Normal\u0026quot;, \u0026quot;Cancer\u0026quot;))) shapiro.test(data$value) # 首先进行正态检验 # Shapiro-Wilk normality test # #data: data$value #W = 0.98318, p-value = 0.005502  可知p\u0026lt;0.05,不符合正态分布,选择非参数检验,默认的就是非参数检验,如果大于0.5就改用t.test   library(ggplot2) library(ggsignif) library(ggsci) p1\u0026lt;-ggplot(data,aes(x=Type,y=value,color=Type,shape=Type))+ #X轴为类型,Y轴为数值,按类型填色,按类型分形状 geom_boxplot()+geom_jitter()+#加柱状图,加点 theme_bw(base_size = 12)+#背景和字体大学 theme(legend.position = \u0026#39;none\u0026#39;)+#去掉标签 ggtitle(\u0026quot;Dataset\u0026quot;)+xlab(NULL)+#添加标题,去掉X轴 ylab(\u0026quot;Expression value\\nelog2(TPM+1)\u0026quot;)+ #\\n表示下一行 scale_color_lancet()+#lancet配色 geom_signif(comparisons = list(c(\u0026quot;Normal\u0026quot;,\u0026quot;Cancer\u0026quot;)),map_signif_level = T,textsize = 4)#显著标识 p1 接下来是ROC曲线的构建,需要用到pROC\n# library(pROC) roc\u0026lt;-roc(data$Type,data$value,ci=TRUE, smooth = TRUE) #进行roc计算,然后做曲线处理 roc$ci # 只有2.5,50和97.5%的置信区间,不是95% # 95% CI: 0.506-0.672 (2000 stratified bootstrap replicates) roc$auc #曲线下面积,一般大于0.5最好 # Area under the curve: 0.5878 画图  p2\u0026lt;-ggroc(roc,color=\u0026quot;#00468B\u0026quot;)+ggtitle(\u0026quot;ROC curver\u0026quot;)+ theme_bw(base_size = 12)+ geom_segment(aes(x = 1, xend = 0, y = 0, yend = 1), color=\u0026quot;grey\u0026quot;,linetype=\u0026quot;dashed\u0026quot;)+ ggplot2::annotate(\u0026#39;text\u0026#39;,x=0.12,y=0.25,label=paste(\u0026quot;AUC:\u0026quot;,round(roc$auc,4)))+ # 提取ACU结果,四位小数点 ggplot2::annotate(\u0026#39;text\u0026#39;,x=0.18,y=0.15,label=paste(\u0026quot;97.5%CI:\u0026quot;,round(roc$ci[1],4),\u0026quot;-\u0026quot;,round(roc$ci[3],4)))# 提取97.5%结果,四位小数点 p2 最后,将两张图拼起来  cowplot::plot_grid(p1,p2,labels = \u0026quot;AUTO\u0026quot;)  ","date":1597536000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1629099914,"objectID":"3adf5af36ec917108b86db6ab5d8c148","permalink":"https://swcyo.netlify.app/post/roc/","publishdate":"2020-08-16T00:00:00Z","relpermalink":"/post/roc/","section":"post","summary":"比较肿瘤与正常组织的差异,需要进行两独立样本的T检验,可以用boxplot展示,还可以用RCO曲线评估预测性能,那么可以用ggplot2和pROC进行图片构建. 首先导入数据,需要类型和数值两列,如下所示:   library(readr) data\u0026lt;- read.csv(\u0026quot;content/post/2020-08-16-roc/data.csv\u0026quot;) knitr::kable(data)   Type value    Cancer 10.005625  Cancer 7.851749  Cancer 10.030667  Cancer 10.79604  Cancer 9.","tags":"phD","title":"两独立样本进行统计,作箱式图和ROC曲线","type":"post"},{"authors":["Song Ou-Yang","Ji‑Hong Liu","Zhao Ni","Guo‑Fu Ding","Qin‑Zhang Wang"],"categories":null,"content":"Keywords: ST3 β-galactoside α-2,3-sialyltransferase 5; bladder cancer; high grade; methylation; muscle invasive; prognosis.\nIntroduction Bladder cancer (BC) is the 7th most common cancer affecting men in the world and the 11th most common cancer in the total population (1). BC affects ~3.4 million people worldwide, with 430,000 new cases diagnosed in 2015 (2). In the United States, 80,470 new cases of BC and 17,670 BC-associated mortality cases were expected to occur in 2019 (3). Furthermore, BC incidence and mortality rates vary across countries due to the differences in risk factors, detection and diagnostic practices and treatments availability (4). The most common type of BC is bladder urothelial carcinoma (BLCA), which accounts for ~90% of all cases (5). In addition, BLCA can be low grade or high grade (6). Low grade BLCA rarely results in cancer invasion in the bladder muscular wall or metastasis to other parts of the body, and patients rarely succumb to low grade BLCA; however, the majority of BLCA-associated mortality cases result from the high-grade disease (6). BC can also be stratified into muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC), according to invasion of the muscularis propria (6). In particular, ~75% of newly diagnosed BC cases are non-invasive, including Stages Ta, Tis or T1, based according to the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system (8th edition) (4). NMIBC exhibits a high prevalence due to the long-term survival rates and the lower risk of cancer-specific mortality compared with patients with MIBC (6). Furthermore, improvements in the early detection and treatment of BC have increased patient survival status; however, BC-associated mortality remains high. It is therefore crucial to identify novel biomarkers and potential therapeutic targets to improve the clinical treatment of patients with BLCA.\nST3 β-galactoside α-2,3-sialyltransferase 5 (ST3GAL5) is a protein coding gene, which catalyzes the formation of ganglioside monosialodihexosylganglioside (GM3) (7). Ganglioside GM3 is known to participate in the induction of cell differentiation, modulation of cell proliferation, maintenance of fibroblast morphology, signal transduction and integrin-mediated cell adhesion (8). Furthermore, ganglioside GM3 is associated with numerous types of tumor, including lung cancer, brain cancer and melanomas, and was reported to significantly influence cancer development and progression (9–12). GM3 is also upregulated in several types of cancer, such as lung and brain cancer, and melanoma, and can be used as a tumor-associated carbohydrate antigen in immunotherapy (9,10). In addition, GM3 inhibits tumor cell proliferation through angiogenesis inhibition or decrease in cell motility (9,11,13). However, the expression profile and functional role of ST3GAL5 in BLCA remain unclear. Therefore, to the best of our knowledge, the present study is the first data mining study to predict the potential role of ST3GAL5 in BLCA, based on publicly available gene expression and clinical outcome databases.\nIn the present study, the expression of ST3GAL5 and its clinical outcomes were investigated in patients with BLCA using various public gene expression and survival datasets. In addition, the DNA methylation and gene expression patterns of ST3GAL5 in BLCA were analyzed. Furthermore, enrichment analyses were performed on genes that were positively co-expressed with ST3GAL5 in BLCA, and gene set enrichment analysis (GSEA) was also used. The findings from the present study hypothesized that ST3GAL5 downregulation may influence BLCA carcinogenesis, suggesting that ST3GAL5 may represent a novel therapeutic target in BLCA.\nMaterials and methods Data set acquisition and processing All data were acquired and processed from the public bioinformatics databases Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo) (14), Oncomine (www.oncomine.org) (15,16), Tumor IMmune Estimation Resource (TIMER; cistrome.shinyapps.io/timer) (17,18), Gene Expression across Normal and Tumor tissue (GENT; medical-genome.kribb.re.kr/GENT) (19,20), University of California, Santa Cruz (UCSC) Xena (xenabrowser.net) (21), Gene expression Profiling Interactive Analysis 2 (GEPIA2; gepia2.cancer-pku.cn) (22) and Kaplan-Meier plotter (kmplot.com/analysis) (23). The BLCA microarray datasets GSE13507 (24), GSE120736 (25) and GSE31684 (25,26) were downloaded from the GEO database to analyze the expression of ST3GAL5. The Lee Bladder (27), Blaveri Bladder 2 (28), Sanchez-Carbayo Bladder 2 (29) and Stransky Bladder (30) datasets from the Oncomine database were extracted and processed using the R package ‘ROncomine’ v0.0.0.9 (github.com/yikeshu0611/ROncomine). The datasets from Genomic Data Commons (GDC; gdc.cancer.gov), The Cancer Genome Atlas (TCGA; cancergenome.nih.gov) and Genotype-Tissue Expression (GTEx; commonfund.nih.gov/GTEx) databases were downloaded using UCSC Xena browser tool (xenabrowser.net/). In the Oncomine database, the default settings were used and the threshold parameters were as follows: P\u0026lt;1×10−4, |fold change|\u0026gt;2 and gene rank in the top 10%. In the GENT database, data were analyzed using the Human Genome U133 Plus 2.0 Array platform (http://www.affymetrix.com/support/technical/byproduct.affx?product=hg-u133-plus).\nEnrichment analysis The Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were determined using the R package ‘clusterProfiler’ v3.14.3 (31), and the Reactome pathway enrichment analysis was performed using the R package ‘ReactomePA’ v1.30.0 (32). Subsequently, the gene-concept network analysis were performed using the R package ‘clusterProfiler’ and ‘ReactomePA’. Microarray datasets of accession number GSE83586 (33) were downloaded from the GEO database in order to investigate the relevant signaling pathways using GSEA. According to the mean expression value of ST3GAL5 in the GSE83586 dataset, the matrix file was divided into high- and low-expression groups, and GSEA was performed using GSEA 4.02 software (34) in order to determine the KEGG pathways (c2.cp.kegg.v7.0.symbols) associated with high and low expression of ST3GAL5. Gene set permutations were performed 1,000 times for each analysis. The false discovery rate \u0026lt;0.25, |normalized enrichment score| \u0026gt;1 and nominal P\u0026lt;0.05 were considered to indicate a statistically significant difference. Subsequently, replotting of the output from the GSEA report folder was conducted using the R package ‘Rtoolbox’ v1.4 (github.com/PeeperLab/Rtoolbox).\nData management and statistical analysis Cancer staging was assessed using the 8th edition of the UICC/AJCC cancer staging system. The gene expression profile and survival data were downloaded, converted, constructed and managed using Microsoft Office Excel 2016 (Microsoft Corporation). All statistical analyses were performed using R software (www.r-project.org; v3.6.1). The box plot was constructed using the R package ‘ggplot2’ v3.2.1 (35). The Cnetplot was constructed using the R package ‘clusterProfiler’ and ‘ReactomePA’. Student\u0026rsquo;s t-test was used to compare the means of two independent samples, and one-way ANOVA was used to compare the means of multiple independent samples followed by Bonferroni post hoc test for multiple comparisons. Kaplan-Meier analysis and Cox proportional hazard models were used for survival analysis by using R package ‘survival’ v3.1.8 and ‘survminer’ v0.4.6. A multivariate Cox proportional hazards regression model was performed to adjust for covariate effects, and stratification analysis was used to reduce the potential confounding effect on the estimation of hazard ratio (HR). Missing data were coded and excluded from the analysis. P\u0026lt;0.05 was considered to indicate a statistically significant difference.\nResults Expression of ST3GAL5 in different types of cancer The differences in ST3GAL5 expression between various types of cancer and paired healthy tissues were compared from three independent bioinformatics databases. In the Oncomine database, the comparison between each type of cancer and healthy tissues identified the downregulation of ST3GAL5 expression in bladder, lung, ovarian, prostate and ‘other’ cancers, and the upregulation of ST3GAL5 expression in esophageal cancer, head and neck cancer, kidney cancer, leukemia, lymphoma, melanoma and myeloma (Fig. 1A). ST3GAL5 expression was also analyzed in tumor and healthy tissues using TCGA data and the TIMER tool (Fig. 1B). Among the different types of cancer, 10 presented significantly lower ST3GAL5 expression, and five had significantly higher ST3GAL5 expression compared with paired healthy tissues (Fig. 1B). Furthermore, data from the GENT database indicated that ST3GAL5 expression was downregulated in certain cancer types, including bladder, blood, brain, breast, liver, ovary, prostate, stomach and testicular cancers (Fig. 1C). The three databases demonstrated the downregulation of ST3GAL5 in different cancer types. Furthermore, ST3GAL5 expression in BLCA tissues was significantly decreased in the three databases compared with paired healthy tissues.\n   Click on image to zoom  Figure 1.\nExpression of ST3GAL5 in different types of cancer. (A) Expression of ST3GAL5 in 20 types of cancer vs. healthy tissues from the Oncomine database. The cell color is determined by the best gene rank percentile for the analysis within the cell. Red color represents overexpression and blue color represents downregulation. (B) Expression of ST3GAL5 in different types of tumor vs. healthy tissues in data from the Tumor IMmune Estimation Resource website. Boxes represent the median, 25 and 75th percentiles, and each dot represents expression of samples. (C) Expression of ST3GAL5 in tumor vs. healthy tissues from the Gene Expression across Normal and Tumor tissue database. Boxes represent the median, 25 and 75th percentiles, and dots represent outliers. ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5.\nExpression of ST3GAL5 in BLCA and healthy bladder tissues To observe the expression of ST3GAL5 in BLCA, three independent datasets from TGCA + GTEx, Oncomine and GEO databases were analyzed. Data from TCGA + GTEx database were acquired using the USCS Xena browser tool. Moreover, data from the Oncomine Lee Bladder dataset were extracted and processed using the R package ‘ROncomine’. The GEO datasets were acquired from the accession number GSE13507. The results demonstrated a significant downregulation of ST3GAL5 in BLCA tissues compared with healthy bladder tissues (Fig. 2A-C).\n   Click on image to zoom  Figure 2.\nExpression of ST3GAL5 between BLCA and healthy bladder tissues. (A) Expression of ST3GAL5 in BLCA from TCGA + GTEx databases, the data was downloaded from UCSC Xena browser tool. (B) Expression of ST3GAL5 in BLCA from the Oncomine database, the threshold was designed using default settings parameters: P\u0026lt;1×10−4, |fold-change|\u0026gt;2, and gene rank in top 10%. (C) The expressions of ST3GAL5 in BLCA from the GEO database under accession numbers GSE13507. TCGA, The Cancer Genome Atlas; GTEx, Genotype-Tissue Expression; UCSC, University of California, Santa Cruz; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5.\nExpression of ST3GAL5 in MIBC and high-grade BLCA tissues To further determine of ST3GAL5 expression in MIBC and high-grade BLCA, four individual datasets from the Oncomine database were analyzed (Table I). The results from meta-analysis demonstrated that ST3GAL5 was significantly downregulated in MIBC across the four datasets (Table I). In these four datasets, ST3GAL5 was significantly downregulated in MIBC and high-grade BLCA (Fig. 3A-a1-4 and B-a1-4). The data acquired from the GEO datasets GSE120736, GSE31684 and GSE13507 also presented significantly lower expression of ST3GAL5 in MIBC and high-grade BLCA (Fig. 3A-b1-3 and B-b1-3, respectively). In addition, decreased expression of ST3GAL5 in high-grade BLCA tissues was reported in the GDC + TCGA BLCA datasets, using the USCS Xena browser tool (Fig. 3C). Taken together, these results demonstrated that ST3GAL5 downregulation was associated with MIBC and high-grade BLCA.\n   Click on image to zoom  Figure 3.\nExpression of ST3GAL5 in MIBC and high-grade BLCA. (A) Expression of ST3GAL5 in MIBC compared with NMIBC. (A-a-1) Stansky Bladder dataset from the Oncomine database reported lower expression of ST3GAL5 in MIBC. (A-a-2) Lee Bladder dataset from the Oncomine database reported lower expression of ST3GAL5 in MIBC. (A-a-3) Blaveri Bladder 2 dataset from the Oncomine database reported lower expression of ST3GAL5 in MIBC. (A-a-4) Sanchez-Carbayo Bladder 2 dataset from the Oncomine database reported lower expression of ST3GAL5 in MIBC. (A-b-1) GSE120736 dataset from the GEO database presented lower expression of ST3GAL5 in MIBC. (A-b-2) GSE31684 dataset from the GEO database presented lower expression of ST3GAL5 in MIBC. (A-b-3) GSE13507 dataset from the GEO database presented lower expression of ST3GAL5 in MIBC. (B) Expression of ST3GAL5 in high grade BLCA compared with low grade BLCA. (B-a-1) Stansky Bladder dataset from the Oncomine database demonstrated lower expression of ST3GAL5 in high grade BLCA. (B-a-2) Lee Bladder dataset from the Oncomine database demonstrated lower expression of ST3GAL5 in high grade BLCA. (B-a-3) Blaveri Bladder 2 dataset from the Oncomine database demonstrated lower expression of ST3GAL5 in high grade BLCA. (B-a-4) Sanchez-Carbayo Bladder 2 from the Oncomine database demonstrated lower expression of ST3GAL5 in high grade BLCA. (B-b-1) GSE120736 dataset from the GEO database presented lower expression of ST3GAL5 in high grade BLCA. (B-b-2) GSE31684 from the GEO database presented lower expression of ST3GAL5 in high grade BLCA. (B-b-3) GSE13507 from the GEO database presented lower expression of ST3GAL5 in high grade BLCA. (C) GDC + TCGA-BLCA dataset showed lower expression of ST3GAL5 in high grade BLCA. TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; MIBC, muscle invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer; GEO, Gene Expression Omnibus; GDC, Genomic Data Commons.\nTable I. Comparison of ST3 β-galactoside α-2,3-sialyltransferase 5 across four datasets in the downregulation analysis from the Oncomine database.\n   Dataset FC P-value Gene rank MIBC NMIBC     Sanchez-Carbayo Bladder 2 −9.324 2.43×10−9 315 (in top 3%) 32 25   Blaveri Bladder 2 −3.622 2.86×10−9 66 (in top 2%) 62 126   Stransky Bladder −5.276 3.02×10−10 3 (in top 1%) 22 19   Lee Bladder 2.627 2.43×10−12 7 (in top 1%) 81 28    Meta-analysis: Median Rank=36.5, P=2.64×10−9. FC, fold-change; MIBC, muscle invasive bladder cancer; NMIBC, non-muscle invasive bladder cancer.\nAssociation between ST3GAL5 expression and clinicopathological characteristics of patients with BLCA The present study investigated the association between ST3GAL5 mRNA expression, promoter methylation level and the clinicopathological characteristics of patients with BLCA from the TCGA-BLCA dataset by using the Xena web tool. Compared with healthy bladder tissues, the expression of ST3GAL5 was downregulated in tissues from primary tumors, Stage IV cancer, extreme weight, smoking for \u0026gt;15 years, non-papillary tumors and nodal metastasis status N1 (Table II). Furthermore, ST3GAL5 expression was downregulated in male and female patients with BLCA. However, the level of ST3GAL5 promoter methylation in patients with BLCA was significantly decreased, regardless of patient clinicopathological characteristics, including cancer stage, ethnicity, sex, age, weight, smoking status, nodal metastasis status and histological subtype compared with healthy patients (Fig. 4). Therefore, it was hypothesized that decreased ST3GAL5 promoter methylation may be positively associated with numerous clinicopathological characteristics of patients with BLCA.\n   Click on image to zoom  Figure 4.\nBox plots from TCGA clinical data according to categorization of the clinicopathological characteristics of patients with BLCA and healthy patients (normal). Promoter methylation of ST3GAL5 in BLCA (different color plot) and healthy (red plot) tissues based on (A) sample type, (B) individual cancer stages, (C) ethnicity, (D) sex, (E) age, (F) weight, (G) smoking status, (H) nodal metastasis status and (I) histological subtype. The β-value for assessment of methylation level ranged from 0 (least methylated) to 1 (most methylated). NW, normal weight; EW, extreme weight; EO, extreme obese; RS1, reformed smoker (\u0026lt;15 years); RS2, reformed smoker (\u0026gt;15 years); TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; Yrs, years; N1, metastases in 1–3 axillary lymph nodes; N2, metastases in 4–9 axillary lymph nodes; N3, metastases in ≥10 axillary lymph nodes.\nTable II. Association between ST3 β-galactoside α-2,3-sialyltransferase 5 expression and clinicopathological characteristics of patients with bladder urothelial carcinoma.\nIn multiple comparisons, the healthy group represented the reference group. Patients with body mass index (BMI) 18–24 were classified as ‘Normal weight’, those with BMI 25–29 were classified as ‘Extreme weight’, those with BMI 30–39 were classified as ‘Obese’ and those with BMI ≥40 as ‘Extreme obese’. Data regarding weight, smoking habits, nodal metastasis status and histological subtype were missing (NA) for some patients with primary tumor. N0, No regional lymph node metastasis; N1, Metastases in 1–3 axillary lymph nodes; N2, Metastases in 4–9 axillary lymph nodes; N3, Metastases in ≥10 axillary lymph nodes; NA, not available.\nAssociation between ST3GAL5 expression and survival prognosis in patients with BLCA To investigate the association between ST3GAL5 expression and survival prognosis in patients with BLCA, Kaplan-Meier survival analysis was performed using data from the GDC, TCGA and GEO databases via the UCSC Xena browser and Kaplan-Meier plotter web tools. The 5-year overall survival (OS), disease specific survival, progression free interval and relapse free survival were all positively associated with lower ST3GAL5 expression in patients with BLCA (Fig. 5A-E).\n   Click on image to zoom  Figure 5.\nAssessment of the 5-year overall survival according to ST3GAL5 expression in patients with BLCA. Survival plot data from the UCSC Xena browse tool, gene expression data and (A) overall survival, (B) disease specific survival and (C) progression free interval information were downloaded from TCGA-BLCA datasets. Survival plots from the KM plotter, gene expression data and (D) overall survival and (E) relapse free survival information were downloaded from the GEO, EGA and TCGA datasets. Analyses focused on ST3GAL5 expression in patients with BLCA. (F) Forest plots of the GEO datasets evaluating association of ST3GAL5 with the overall survival in patients with BLCA using GENT2 web tool. TCGA, The Cancer Genome Atlas; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; GEO, Gene Expression Omnibus; EGA, European Genome-phenome Archive; GENT, Gene Expression across Normal and Tumor tissue; UCSC, University of California, Santa Cruz; HR, hazard ratio.\nMeta-survival analysis of OS was performed using data from GENT2 web (gent2.appex.kr/gent2) tools and depicted as forest plots (Fig. 5F). The results demonstrated that low ST3GAL5 expression was associated with poor OS [P\u0026lt;0.001; HR, 2.934; 95% CI (1.916–4.493); τ2, 0.086; I2, 0.884]. These results indicated the prognostic relevance of ST3GAL5 expression in patients with BLCA.\nEnrichment analysis genes co-expressed with ST3GAL5 in BLCA samples The top 250 genes that were positively co-expressed with ST3GAL5 in BLCA samples were identified using Oncomine Stransky Bladder dataset and GEPIA2 and UALCAN web tools. The genes common to these three databases were selected for further analysis. In total, 33 genes were identified as positively co-expressed with ST3GAL5 in BLCA samples. The names of the genes were as follows: [methyltransferase like 7A, SMAD6, ATPase phospholipid transporting 8B1, sortilin related receptor 1, trafficking kinesin protein 1, pterin-4 α-carbinolamine dehydratase 1, cytochrome b5 type A, isocitrate dehydrogenase (NADP(+)) 1, fructose-bisphosphatase 1, GATA binding protein 3, cathepsin H, dual specificity phosphatase 2, TP53 target 1, inhibitor of DNA binding (ID) 1, phospholipase C eta 2, solute carrier family (SLC) 14 member 1 (Kidd blood group), arachidonate 5-lipoxygenase, PPFIA binding protein 2, transmembrane protein 63A, 4-aminobutyrate aminotransferase, intraflagellar transport 140, SLC23A2, zinc finger protein 211, keratin associated protein 5–9, oviductal glycoprotein 1, family with sequence similarity 13 member A, ID2, carbonyl reductase 4, glycerol-3-phosphate dehydrogenase 1 like, carnitine O-octanoyltransferase, tubulin tyrosine ligase like 3, aldehyde dehydrogenase 4 family member A1 and malic enzyme 3].\nSubsequently, GO, KEGG and Reactome pathway enrichment analyses, and gene-concept network analysis were performed with ST3GAL5 and the 33 positively co-expressed genes by using the R packages ‘clusterProfiler’ and ‘ReactomePA’. GO terms functional enrichment analysis was performed with ST3GAL5 and its associated genes to determine the functions associated with biological processes (BP), molecular functions (MF) and cellular components (CC). ST3GAL5 and its co-expressed genes were predominantly associated with ‘coenzyme metabolic process’, ‘organic hydroxy compound metabolic process’, ‘negative regulation of osteoblast differentiation’, ‘renal system development’, ‘tertiary granule lumen’, ‘tertiary granule’, ‘ficolin-1-rich granule lumen’, ‘coenzyme binding’, ‘NAD binding’ and ‘cofactor binding’ (Fig. 6A and B).\n   Click on image to zoom  Figure 6.\nEnrichment analysis of genes co-expressed with ST3GAL5 in BLCA samples. Bar plot showing the GO terms and signaling pathways of ST3GAL5 and its positively co-expressed genes in BLCA (left column). Cnetplot showing the links between genes and biological processes by using GO, KEGG pathways or Reactome pathways as networks (right column). (A) Bar plots of GO terms enrichment. (B) Cnetplot of GO terms. (C) Bar plots of KEGG pathways. (D) Cnetplot of KEGG pathways. (E) Bar plot of Reactome pathways. (F) Cnetplot of Reactome pathways. Length of the bar represents the gene count; the color represents the P-value or adjusted P-value. P Cutoff=0.05, Q Cutoff=0.2, P adjusted method=BH. BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BH, Benjamini-Hochberg.\nFurthermore, the KEGG pathways analysis for ST3GAL5 and its co-expressed genes demonstrated their association with ‘transforming growth factor (TGF)-β signaling pathway’, ‘carbon metabolism’, ‘alanine, aspartate and glutamate metabolism’, ‘peroxisome’, ‘glycosphingolipid biosynthesis-ganglio series’, ‘fatty acid biosynthesis’, ‘2-oxocarboxylic acid metabolism’ and ‘signaling pathways regulating pluripotency of stem cells’ (Fig. 6C and D).\nNext, Reactome pathway analysis of ST3GAL5 and its co-expressed genes identified highlighted their association with ‘protein localization’, ‘neutrophil degranulation’, ‘peroxisomal protein import’, ‘fatty acid metabolism’, ‘metabolism of vitamins and cofactors’, ‘interaction with cumulus cells and the zona pellucida’, ‘phenylalanine and tyrosine metabolism’ and ‘interleukin (IL)-4 and IL-13 signaling’ (Fig. 6E and F). All these pathways may therefore be associated with BLCA tumor progression and tumorigenesis.\nGSEA analysis between high and low ST3GAL5 expression in BLCA To further identify the signaling pathways that are differentially activated in BLCA, GSEA was performed to investigate the difference between high- (n=124) and low-ST3GAL5 (n=183) expression groups by using the GEO dataset GSE83586. Three tumor-associated pathways were identified as significantly associated with the downregulation of ST3GAL5 expression in BLCA tissues, including ‘NOD-like receptor (NLR) signaling pathway’, ‘cytokine-cytokine receptor interaction’ and ‘Janus kinase (JAK)-STAT signaling pathway’ (Table III; Fig. 7).\n   Click on image to zoom  Figure 7.\nGSEA analysis between high and low expression of ST3GAL5 in BLCA. In total, three tumor-related signaling pathways were identified as positively associated with ST3GAL5 downregulation in BLCA. (A) NOD-like receptor signaling pathway. (B) Cytokine-cytokine receptor interaction. (C) JAK-STAT signaling pathway. JAK, Janus kinase; BLCA, bladder urothelial carcinoma; ST3GAL5, ST3 β-galactoside α-2,3-sialyltransferase 5; ES, enrichment score; NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate.\nTable III. Gene set enrichment analysis in the group with low expression levels of ST3 β-galactoside α-2,3-sialyltransferase 5 in bladder urothelial carcinoma.\n   Gene set name NES NOM P-value FDR     KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 1.788003 0.00396 0.212486   KEGG_AUTOIMMUNE_THYROID_DISEASE 1.596979 0.027237 0.242572   KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 1.593668 0.028689 0.212411   KEGG_ALLOGRAFT_REJECTION 1.579419 0.044747 0.208527   KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE 1.577063 0.026923 0.189083   KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY 1.534106 0.035644 0.198596   KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 1.502448 0.042969 0.213385   KEGG_JAK_STAT_SIGNALING_PATHWAY 1.500872 0.042718 0.201288    Gene sets with |NES|\u0026gt;1, NOM P\u0026lt;0.05 and FDR\u0026lt;0.25 were considered as significant. NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate; JAK, Janus kinase; KEGG, Kyoto Encyclopedia of Genes and Genomes.\nDiscussion BC is the most common malignancy of the urinary system, and ~90% of BC cases are urothelial carcinoma (5). Furthermore, BC can be low grade or high grade and can also be divided into MIBC and NMIBC; low grade BC rarely invades the muscular wall of the bladder and patients rarely succumb to low grade BC, while high grade BC is more likely to result in mortality (6). Furthermore, patients with NMIBC exhibit a favorable outcome (5-year overall survival of 95 vs. 69% in MIBC) (36). However, 70% of patients with BC will experience recurrence following initial treatment (surgery, radiotherapy or chemotherapy), including 30% out of the 70% of patients presenting with muscle invasive disease (37). In addition, cancer recurrence and progression lead to a higher disease stage, ending therefore in a less favorable outcome (38). Currently, the etiology of muscle invasion and high-grade progression in BC remains unknown. It is therefore crucial to identify an effective biomarker that could predict muscle invasion, high grade and prognosis in patients with BC.\nTo the best of our knowledge, ST3GAL5 expression and its effect on muscle invasion, cancer grade and prognosis in patients with BLCA have not yet been investigated. The present study investigated therefore the potential role of ST3GAL5 in BLCA. In this study, bioinformatics analysis of multiple independent public databases was performed. The results demonstrated that ST3GAL5 was downregulated in various types of cancer, including BC, and that its expression in BLCA tissues was lower compared with healthy bladder tissues. In addition, ST3GAL5 downregulation was positively associated with muscle invasion, high grade and a poor prognosis in patients with BLCA. Collectively, these findings indicated that ST3GAL5 may be considered as a tumor suppressor gene in BLCA, and may therefore inhibit the progression of BC to MIBC and high grade BLCA. These results also highlighted the potential role of ST3GAL5 as a therapeutic target in BC. However, further investigation is required to determine the underlying mechanisms of ST3GAL5 in BC progression and in the prognosis of patients with BC.\nThe association between ST3GAL5 expression, promoter methylation level and the clinicopathological characteristics of patients with BLCA was examined using TCGA data from the Xena browser. The results demonstrated that ST3GAL5 expression was downregulated in high stages and moderate nodal metastasis status compared with healthy bladder tissues. However, the level of ST3GAL5 promoter methylation was significantly decreased in BCLA tissues compared with healthy bladder tissues regardless of the patients' clinicopathological characteristics, including cancer stage, ethnicity, sex, age, weight, smoking status, nodal metastasis status and histological subtype. Furthermore, analysis of ST3GAL5 expression and DNA methylation status indicated that ST3GAL5 gene expression may be associated with certain CpG island sites. CpG islands are CG-rich stretches in the genome concentrated near transcription start sites; in normal cells they are protected and therefore are in a non-methylated state, but in tumors they are specifically methylated. These findings suggested therefore that ST3GAL5 promoter methylation may be associated with the clinicopathological characteristics of patients with BC.\nST3GAL5 is a protein that catalyzes the formation of ganglioside GM3 (7). ST3GAL5 is upregulated in several types of cancer, such as lung and brain cancer, and melanoma, and can serve as a tumor-associated carbohydrate antigen in immunotherapy for cancer (9,10). Furthermore, ST3GAL5, which encodes GM3, inhibits tumor cell proliferation through angiogenesis inhibition or decrease in cell motility (9). Previous studies reported that ST3GAL5 exerts some anti-proliferative effects in colon cancer (39), breast cancer (40,41), liver cancer (42) and other types of tumor (9,10). Although some studies demonstrated that ST3GAL5 has anti-tumor effects in human bladder cancer (11,14,39,43), the underlying mechanisms remain unknown. Furthermore, it was reported that ST3GAL5 effects could be associated with tumor cell apoptosis and angiogenesis inhibition (9,12,44). However, the expression profile and functional role of ST3GAL5 in BLCA remain unknown.\nIn the present study, the biological effect of ST3GAL5 in BLCA was investigated by using bioinformatics analysis of multiple public databases. Co-expressed genes that were positively associated with ST3GAL5 expression were identified in three public databases, and intersecting genes from all databases were considered to be significantly co-expressed genes. R packages were then used to identify the signaling pathways associated with the genes that were positively co-expressed with ST3GAL5 in BLCA samples. Furthermore, from the perspective of functional classification, GO enrichment analysis of BP, CC and MF was performed on ST3GAL5 and its co-expressed genes. The results from KEGG pathway analysis revealed that the ‘TGF-β signaling pathway’ was significantly associated with ST3GAL5 expression. The deregulation of this pathway has been reported to result in tumor progression (45). In healthy and early-stage cancer, such as breast and prostate cancer cells, the TGF-β pathway exerts tumor-suppressive properties; however, its activation in late-stage cancer can promote tumor progression, via metastasis and chemoresistance (45,46). Furthermore, the dual function and pleiotropic nature of TGF-β signaling makes of it a challenging target; therefore, careful therapeutic dosage of TGF-β drugs and careful patient selection are required (46). In the present study, although ST3GAL5 expression was downregulated in BLCA tissues compared with healthy bladder tissues, ST3GAL5 expression was significantly downregulated in high grade and advanced stage BLCA in multiple databases. The significant downregulation in high grade and advanced stage BLCA may due to the associated activation of ST3GAL5 and its co-expressed genes following the increase in TGF-β signaling transduction. Another pathway associated with ST3GAL5 expression was ‘carbon metabolism’. Cells require one-carbon units for nucleotide synthesis, methylation and reductive metabolism, which support the high proliferative rate of cancer cells (47). A previous study reported that polymorphisms in one-carbon metabolism and susceptibility to BC suggested that variation in glutathione synthesis may contribute to the risk of BC (48). In the present study, Reactome pathway analysis demonstrated that the main pathway associated with ST3GAL5 expression was ‘protein localization’, and previous studies reported that changes in subcellular localization of tumor-associated proteins can influence protein structure and biological function, which are associated with tumorigenesis, tumor progression and patient prognosis (49–52). Another pathway associated with ST3GAL5 expression was ‘neutrophil degranulation’. Neutrophils have been shown to be the first responders to inflammation and infection (53). The role of neutrophils in cancer is multifactorial, but is not fully understood. Furthermore, neutrophils reflect a state of host inflammation, which is a hallmark of cancer (54), and can participate in different stages of the oncogenic process including tumor initiation, growth, proliferation and metastasis (55,56). Neutrophil granule proteins released upon cell activation have also been associated with tumor progression, and this differential granule mobilization may allow neutrophils and possibly associated cancer cells to exit the bloodstream and enter inflamed and infected tissues (53). Since neutrophils are immune cells, tumor immunity must also be considered in order to predict the prognosis of patients with BC. Takeuchi et al (55), reported that the Tumour-associated macrophage polarized M2 phenotype influences microangiogenesis, pathological outcome, tumor grade and tumor invasiveness in BC. In the present study, GO analysis of the BP and MF domains identified co-enzyme involvement in BP and MF, suggesting that co-enzymes may serve an important role in the tumorigenesis and tumor progression of BC. However, further in vitro and in vivo studies are required to elucidate the biological role of ST3GAL5 in BC. Taken together, these findings highlighted the important role of ST3GAL5 and its co-expressed genes in various carcinogenic processes.\nA large BLCA dataset from the GEO database was investigated in the present study. According to the mean value of ST3GAL5 expression, the dataset was divided into low- and high-expression groups, and GSEA was used to compare the two groups. The results identified three tumor-associated pathways that were associated with ST3GAL5 in BLCA, the ‘NLR signaling pathway’, ‘cytokine-cytokine receptor interaction’ and ‘JAK-STAT signaling pathway’. NLR signaling pathway is an immunology-signaling pathway, in which cytosolic NLRs are associated with certain diseases, including infections, cancer and autoimmune and inflammatory disorders (57). Furthermore, NLRs and their downstream signaling components can engage in an intricate crosstalk with cell death and autophagy pathways, which are critical processes for cancer progression (58). Kent and Blander (57) reported that chronic inflammation resulting from the activated NLRs signaling pathway is a powerful driver of carcinogenesis, which promotes gene mutation, tumor growth and progression. In the present study, results from KEGG analysis suggested that lower expression of ST3GAL5 were enriched in the ‘NLR signaling pathway’. Ozaki and Leonard (59) demonstrated that cytokines are crucial intercellular regulators and mobilizers of cells that are involved in innate and adaptive inflammatory host defenses, cell proliferation, cell differentiation, cell death, angiogenesis, and development and repair processes associated with the restoration of homeostasis. In the current study, the ‘cytokine-cytokine receptor interaction’ was positively associated with lower ST3GAL5 expression, suggesting that ST3GAL5 downregulation may promote oncogenesis by affecting the immune status of patients with BC. The JAK-STAT pathway is an essential signaling pathway involved with numerous cytokines and proliferation factors in mammals (60). Previous studies (60,61) assessing the JAK-STAT signaling pathway reported highly conserved programs linking cytokine signaling to the regulation of essential cellular mechanisms, including cell proliferation, cell invasion, cell survival, inflammation and immunity. Furthermore, aberrant active regulation of JAK-STAT signaling pathway has been reported to contribute to cancer progression and development of metastasis (60,61). In the present study, results from pathway analysis suggested that the low expression of ST3GAL5 may positively affect the progression of BLCA via tumor immunity, cytokine interaction and cytokine transduction. The results from this study suggested that immunotherapy may be used in the treatment of BLCA, and that ST3GAL5 may be considered as a novel target and potential biomarker in BLCA.\nAcknowledgements Not applicable.\nGlossary Abbreviations    BC bladder cancer     BLCA bladder urothelial carcinoma   MIBC muscle invasive bladder cancer   NMIBC non-muscle invasive bladder cancer    Funding The present study was supported by the Key Scientific and Technological Projects of Xinjiang Production and Construction Corps (grant no. 2018AB023).\nAvailability of data and materials The datasets generated and/or analyzed during the present study are available in the GEO (www.ncbi.nlm.nih.gov/geo), Oncomine (www.oncomine.org) and TGCA (cancergenome.nih.gov) repositories.\nAuthors' contributions JL and QW participated in the design of the present study, performed the statistical analysis and drafted the manuscript. SO, ZN and GD performed the study and collected background information and data. SO was a major contributor in writing the manuscript. All authors read and approved the final manuscript.\nEthics approval and consent to participate Not applicable.\nPatient consent for publication Not applicable.\nCompeting interests The authors declare that they have no competing interests.\nReferences  Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. doi: 10.1016/j.ejca.2018.07.005. [PubMed] [CrossRef] [Google Scholar] GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, corp-author. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond Engl. 2016;388:1545–1602. doi: 10.1016/S0140-6736(16)31678-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi: 10.3322/caac.21551. [PubMed] [CrossRef] [Google Scholar] Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, Vecchia CL, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012;63:234–241. doi: 10.1016/j.eururo.2012.07.033. [PubMed] [CrossRef] [Google Scholar] Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24:730–734. doi: 10.1111/iju.13376. [PubMed] [CrossRef] [Google Scholar] Witjes JA, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017;71:462–475. doi: 10.1016/j.eururo.2016.06.020. [PubMed] [CrossRef] [Google Scholar] Berselli P, Zava S, Sottocornola E, Milani S, Berra B, Colombo I. Human GM3 synthase: A new mRNA variant encodes an NH2-terminal extended form of the protein. Biochimica Biophysica Acta. 2006;1759:348–358. doi: 10.1016/j.bbaexp.2006.07.001. [PubMed] [CrossRef] [Google Scholar] Inokuchi JI, Inamori KI, Kabayama K, Nagafuku M, Uemura S, Go S, Suzuki A, Ohno I, Kanoh H, Shishido F. Biology of GM3 Ganglioside. Prog Mol Biol Transl. 2018;156:151–195. doi: 10.1016/bs.pmbts.2017.10.004. [PubMed] [CrossRef] [Google Scholar] Zheng C, Terreni M, Sollogoub M, Zhang Y. Ganglioside GM3 and its role in cancer. Curr Med Chem. 2019;26:2933–2947. doi: 10.2174/0929867325666180129100619. [PubMed] [CrossRef] [Google Scholar] Hakomori SI, Handa K. GM3 and cancer. Glycoconjugate J. 2015;32:1–8. doi: 10.1007/s10719-014-9572-4. [PubMed] [CrossRef] [Google Scholar] Satoh M, Ito A, Nojiri H, Handa K, Numahata K, Ohyama C, Saito S, Hoshi S, Hakomori SI. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells. Int J Oncol. 2001;19:723–731. [PubMed] [Google Scholar] Kawashima N, Nishimiya Y, Takahata S, Nakayama KI. Induction of Glycosphingolipid GM3 expression by valproic acid suppresses cancer cell growth. J Biol Chem. 2016;291:21424–21433. doi: 10.1074/jbc.M116.751503. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Ohyama C. Glycosylation in bladder cancer. Int J Clin Oncol. 2008;13:308–313. doi: 10.1007/s10147-008-0809-8. [PubMed] [CrossRef] [Google Scholar] Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207–210. doi: 10.1093/nar/30.1.207. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–180. doi: 10.1593/neo.07112. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pander A, Chinnaiyan AM. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1–6. doi: 10.1016/S1476-5586(04)80047-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al. Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. Genome Biol. 2016;17:174. doi: 10.1186/s13059-016-1028-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–e110. doi: 10.1158/0008-5472.CAN-17-0307. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Park SJ, Yoon BH, Kim SK, Kim SY. GENT2: An updated gene expression database for normal and tumor tissues. BMC Med Genomics. 2019;12(Suppl 5):101. doi: 10.1186/s12920-019-0514-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Shin G, Kang TW, Yang S, Baek SJ, Jeong YS, Kim SY. GENT: Gene expression database of normal and tumor tissues. Cancer Informatics. 2011;10:149–157. doi: 10.4137/CIN.S7226. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Goldman M, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, et al. The UCSC Xena platform for public and private cancer genomics data visualization and interpretation. 2019 Biorxiv 326470. [Google Scholar] Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102. doi: 10.1093/nar/gkx247. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Anaya J, Reon B, Chen WM, Bekiranov S, Dutta A. A pan-cancer analysis of prognostic genes. Peer J. 2016;3:e1499. doi: 10.7717/peerj.1499. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3. doi: 10.1186/1476-4598-9-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012;18:1323–1333. doi: 10.1158/1078-0432.CCR-11-2271. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O\u0026rsquo;Brien R, Schutz FA, et al. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014;20:1873–1883. doi: 10.1158/1078-0432.CCR-13-0759. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010;28:2660–2667. doi: 10.1200/JCO.2009.25.0977. [PubMed] [CrossRef] [Google Scholar] Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Pejavar S, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11:4044–4055. doi: 10.1158/1078-0432.CCR-04-2409. [PubMed] [CrossRef] [Google Scholar] Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778–789. doi: 10.1200/JCO.2005.03.2375. [PubMed] [CrossRef] [Google Scholar] Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R, de Rycke Y, Elvin P, Cassidy A, Spraggon C, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet. 2006;38:1386–1396. doi: 10.1038/ng1923. [PubMed] [CrossRef] [Google Scholar] Yu G, Wang LG, Han Y, He QY. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–287. doi: 10.1089/omi.2011.0118. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Yu G, He QY. ReactomePA: An R/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 2016;12:477–479. doi: 10.1039/C5MB00663E. [PubMed] [CrossRef] [Google Scholar] Sjödahl G, Eriksson P, Liedberg F, Höglund M. Molecular classification of urothelial carcinoma: Global mRNA classification versus tumour-cell phenotype classification. J Pathology. 2017;242:113–125. doi: 10.1002/path.4886. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc National Acad Sci. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Villanueva RAM, Chen ZJ. ggplot2: Elegant graphics for data analysis. Meas Interdiscip Res Perspectives. (2nd) 2019;17:160–167. doi: 10.1080/15366367.2019.1565254. [CrossRef] [Google Scholar] Nykopp TK, Batista da Costa J, Mannas M, Black PC. Current clinical trials in non-muscle invasive bladder cancer. Curr Urol Rep. 2018;19:101. doi: 10.1007/s11934-018-0852-6. [PubMed] [CrossRef] [Google Scholar] Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–249. doi: 10.1016/S0140-6736(09)60491-8. [PubMed] [CrossRef] [Google Scholar] Heijden AGvd, Witjes JA. Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer. Eur Urol Suppl. 2009;8:556–562. doi: 10.1016/j.eursup.2009.06.010. [CrossRef] [Google Scholar] Wang H, Isaji T, Satoh M, Li D, Arai Y, Gu J. Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model. Urology. 2012;81:210.e211–215. [PubMed] [Google Scholar] Li Q, Sun M, Yu M, Fu Q, Jiang H, Yu G, Li G. Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker. Glycoconjugate J. 2019;36:419–428. doi: 10.1007/s10719-019-09885-z. [PubMed] [CrossRef] [Google Scholar] Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vázquez AM, Fainboim L. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in High-Risk and metastatic breast cancer patients. J Immunother. 2006;29:215–223. doi: 10.1097/01.cji.0000188502.11348.34. [PubMed] [CrossRef] [Google Scholar] Cai H, Zhou H, Miao Y, Li N, Zhao L, Jia L. MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5. Lab Invest. 2017;97:530–542. doi: 10.1038/labinvest.2017.12. [PubMed] [CrossRef] [Google Scholar] Kawamura S, Ohyama C, Watanabe R, Satoh M, Saito S, Hoshi S, Gasa S, Orikasa S. Glycolipid composition in bladder tumor: A crucial role of GM3 ganglioside in tumor invasion. Int J Cancer. 2001;94:343–347. doi: 10.1002/ijc.1482. [PubMed] [CrossRef] [Google Scholar] Chung TW, Choi HJ, Kim SJ, Kwak CH, Song KH, Jin UH, Chang YC, Chang HW, Lee YC, Ha KT, Kim CH. The ganglioside GM3 is associated with cisplatin-induced apoptosis in human colon cancer cells. PLoS One. 2014;9:e92786. doi: 10.1371/journal.pone.0092786. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Massagué J. TGFβ in Cancer. Cell. 2008;134:215–230. doi: 10.1016/j.cell.2008.07.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer. 2017;3:56–71. doi: 10.1016/j.trecan.2016.11.008. [PubMed] [CrossRef] [Google Scholar] Newman AC, Maddocks ODK. One-carbon metabolism in cancer. Brit J Cancer. 2017;116:1499–1504. doi: 10.1038/bjc.2017.118. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Moore LE, Malats N, Rothman N, Real FX, Kogevinas M, Karami S, García-Closas R, Silverman D, Chanock S, Welch R, et al. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer. 2007;120:2452–2458. doi: 10.1002/ijc.22565. [PubMed] [CrossRef] [Google Scholar] Li X, Che K, Wang L, Zhang T, Wang G, Pang Z, Shen H, Du J. Subcellular localization of β-arrestin1 and its prognostic value in lung adenocarcinoma. Medicine. 2017;96:e8450. doi: 10.1097/MD.0000000000008450. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Liu J, Wang H, Huang C, Qian H. Subcellular localization of MTA proteins in normal and cancer cells. Cancer Metastasis Rev. 2014;33:843–856. doi: 10.1007/s10555-014-9511-7. [PubMed] [CrossRef] [Google Scholar] Kim HJ, Lee SY, Kim CY, Kim YH, Ju W, Kim SC. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells. Oncotarget. 2017;8:6608–6622. doi: 10.18632/oncotarget.14245. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Boudhraa Z, Bouchon B, Viallard C, D\u0026rsquo;Incan M, Degoul F. Annexin A1 localization and its relevance to cancer. Clin Sci (Lond) 2016;130:205–220. doi: 10.1042/CS20150415. [PubMed] [CrossRef] [Google Scholar] Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 2019;40:228–242. doi: 10.1016/j.it.2019.01.006. [PubMed] [CrossRef] [Google Scholar] Hanahan D, Weinberg Robert A. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. [PubMed] [CrossRef] [Google Scholar] Takeuchi H, Tanaka M, Tanaka A, Tsunemi A, Yamamoto H. Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness. Oncol Lett. 2016;11:3403–3408. doi: 10.3892/ol.2016.4392. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: Neutral no more. Nat Rev Cancer. 2016;16:431–446. doi: 10.1038/nrc.2016.52. [PubMed] [CrossRef] [Google Scholar] Kent A, Blander JM. Nod-like receptors: Key molecular switches in the conundrum of cancer. Front Immunol. 2014;5:185. doi: 10.3389/fimmu.2014.00185. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Saxena M, Yeretssian G. NOD-like receptors: Master regulators of inflammation and cancer. Front Immunol. 2014;5:327. doi: 10.3389/fimmu.2014.00327. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem. 2002;277:29355–29358. doi: 10.1074/jbc.R200003200. [PubMed] [CrossRef] [Google Scholar] Pencik J, Pham HTT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F, Kenner L. JAK-STAT signaling in cancer: From cytokines to non-coding genome. Cytokine. 2016;87:26–36. doi: 10.1016/j.cyto.2016.06.017. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Trivedi S, Starz-Gaiano M. Drosophila Jak/STAT signaling: Regulation and relevance in human cancer and metastasis. Int J Mol Sci. 2018;19:4056. doi: 10.3390/ijms19124056. [PMC free article] [PubMed] [CrossRef] [Google Scholar]  ","date":1593561600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1593561600,"objectID":"966884cc0d8ac9e31fab966c4534e973","permalink":"https://swcyo.netlify.app/publication/journal-article/","publishdate":"2020-07-01T00:00:00Z","relpermalink":"/publication/journal-article/","section":"publication","summary":"ST3GAL5 may be considered as an anti‑oncogene in BC, could represent a potential predictive and prognostic biomarker for BC and may be a molecular target for tumor therapy.","tags":["journal article"],"title":"Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer","type":"publication"},{"authors":null,"categories":null,"content":"1、石河子大学医学院2020年来华留学生医学本科（英语授课）试题库立项项目，留学生外科学II试题库，编号:YXLXSST202006，5000元，主持；\n2、石河子大学医学院2020年来华留学生医学本科（英语授课）教学改革立项项目，互联网时代医学留学生泌尿外科本科教学新模式探讨，编号:YXLXSJG202013，5000元，主持。\n","date":1587945600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1587945600,"objectID":"8f66d660a9a2edc2d08e68cc30f701f7","permalink":"https://swcyo.netlify.app/project/internal-project/","publishdate":"2020-04-27T00:00:00Z","relpermalink":"/project/internal-project/","section":"project","summary":"2020年来华留学生医学本科教学立项项目.","tags":["project"],"title":"石河子大学医学院立项项目","type":"project"},{"authors":["Chen Li","Biao Qian","Zhao Ni","Qin-Zhang Wang","Zi-Xiong Wang","Lu-Ping Ma","Zhi-Li Liu","Qiang Li","Xin-Min Wang"],"categories":null,"content":"Keywords: diabetic cystopathy; stem cell leukemia gene; lentiviral vectors; transfection; interstitial cells of Cajal\n1 Introduction Diabetic cystopathy (DCP) is one of the most common complications of late diabetes, and the incidence in diabetes patients is 19% ~ 84% [1, 2]. In late DCP, urinary tract infection and nephritis may occur and may develop into uremia [3, 4]. Many factors including decrease of nerve growth factor (NGF) levels, formation of oxidative free radicals, abnormal glucose metabolism, decrease of prostaglandin E2 (PGE2) levels, increase of mitochondrial reactive oxygen species (ROS), and reduction of the supply of blood vessels can lead to the occurrence of DCP [5, 6, 7]. However, the exact pathogenesis is still unclear. Recent studies have discovered a kind of specific cell type similar to the morphology of interstitial cells of Cajal (ICC) in the detrusor of humans, guinea pigs, and many other animals which is called bladder ICC [8, 9]. Studies confirm that spontaneous detrusor contractions completely regulated by ICCs occur, and thus ICCs may be possible bladder pacemaker cells [10, 11]. A tyrosine kinase receptor c-kit is present on the surface and cytoplasm of ICC cells and is considered to be a specific marker of ICC [12]. The SCL gene is an important regulatory gene upstream of c-kit, and it mainly acts on the gene promoter of c-kit, thereby regulating c-kit expression [13]. For DCP patients, ICCs continue to shrink or disappear due to the induction of hyperglycemia, which can damage the transmission functions of the stem cell factor (SCF)/growth factor receptor tyrosine kinase (c-kit) signaling pathway [14], lead to the reduction of bladder sensation, increase urine storage capacity, decrease detrusor contractility during urination, increase bladder residual urine and other discomforts, and result in bladder function becoming completely paralyzed or even failing [15].\nThere are two key receptors on ICCs, the specific protein receptor c-kit and its ligand stem cell factor (SCF). The specific binding of c-kit and SCF can start the SCF / c-kit signaling pathway [16]. Research has shown that the stem cell leukemia (SCL) gene is an upstream necessary regulator of c-kit which can increase the expression of c-kit and then promote the recovery of the ICC phenotype and function in DCP [17]. Therefore, the SCF/c-kit signaling pathway plays a key role in promoting ICC function reversal, which can guide the clinical treatment of DCP.\nRecombinant lentiviral vectors containing human SCL gene can be used to infect ICC cells with morphological and functional damage to increase the number and promote the functional recovery of ICCs. In this study, recombinant lentiviral vectors containing the SCL gene were constructed using genetic engineering techniques and used to transfect in vitro cultured ICCs. The transfection efficiency and expression of the SCL gene were investigated. Our findings may provide new ideas for the further use of lentiviral vectors containing the human SCL gene in transfection experiments in vivo and DCP treatment.\n2 Materials and Methods 2.1 Experimental animals A total of 40 guinea pigs of either gender was used for the study. Their ages were 6-12 months and weight was 250-400 g. All guinea pigs were purchased from the Animal Experimental Center of Xinjiang Medical University.\nEthical approval: The research related to animals use has been complied with all the relevant national regulations and institutional policies for the care and use of animals. All animal experiments were conducted according to the ethical guidelines of the First Affiliated Hospital of Shihezi University.\n2.2 Reagents Competent E. coli DH5α, 293T cells, and GV287-EGFP vector were purchased from Genechem (Shanghai) Co. (Shanghai, China). DMEM medium, fetal bovine serum (FBS), and Lipofectamine 2000 transfection kit were purchased from Invitrogen Co. (Carlsbad, CA, US). RT-PCR kit was purchased from Fermentas Co. (Waltham, MA, US).\n2.3 Construction and identification of lentiviral vectors containing the human SCL gene The recombinant lentiviral plasmid containing the human SCL gene was constructed by the assistance of Genechem (Shanghai) Co. (Shanghai, China). Briefly, the human SCL gene was amplified by PCR. The primers were as follows: upstream 5’-GAGGATCCCCGGGTACCGGTCGCCACCAT-GACCGAGCGGCCGCCGAG-3’ and downstream 5’-TCAC-CATGGTGGCGACCGGCCGAGGGCCGGCTCCATC-3’.\nThe primers were synthesized by Genechem (Shanghai) Co. The PCR procedure was as follows: denaturing at 94oC for 5 min, 30 cycles of denaturation at 94oC for 30 s, annealing at 55oC for 30 s, extension at 72oC for 2 min, and a final extension at 72oC for 10 min. The PCR product was verified by agarose gel electrophoresis. Then, the PCR product was purified and inserted into the GV287-EGFP vector by In-Fusion converting enzyme (QIAGEN Co., Valencia, CA, USA) to construct recombinant plasmid GV287-EGFP/SCL. The correctly constructed recombinant plasmid GV287-EGFP/SCL was identified by sequencing.\n2.4 Packaging of lentiviral vector and detection of virus titer In a 1.5 mL sterile EP tube, 1.5 μg of packaging helper plasmids (Helper 1.0 and Helper 2.0, Genechem Co. Shanghai, China), 0.5 μg of expression plasmid, and 250 μL serum-free medium were added, mixed, and incubated at room temperature for 5 min. At the same time, 9 μL of liposomes was mixed with 250 μL serum-free medium and incubated at room temperature for 5 min. Then, the above DNA solution and liposome suspension were mixed and incubated at room temperature for 20 min. The 293T cell line was used as the packaging cell. The mixture of DNA and liposome was put into a 6-well plate and supplied with 1 mL complete medium. 293T cell suspension (1 ml) was put into the 6-well plate and incubated at 37oC in an atmosphere with CO2 for 48-72 h. After that, the cells were centrifuged at 3000 r/min for 20 minutes, and the precipitate was filtered. The lentivirus stock solution was filtered with PVDF membrane. Virus-containing medium were grouped by 1: 100 dilutions and divided into standard solution and test solution. Both solutions were used for transfecting 293T cells simultaneously, and the virus titer was calculated by a fluorescent labeling method [8].\n2.5 In vitro culture of bladder ICCs of guinea pigs Four healthy guinea pigs were randomly selected and sacrificed by cervical dislocation. Their bladder tissues were removed in a sterile environment and cut into 1 mm3 pieces. The tissue pieces were digested with 1.0 mg/mL trypsin for 15 min at 37oC. DMEM medium (containing 1.0 mg/mL collagenase V, 100 U/mL penicillin, and 100 g/mL streptomycin) was added, and the tissues were further digested for 90 min at 37oC. Then, the digested tissues were filtered and centrifuged at 350 xg for 5 min. The supernatant was discarded, and the pellet was washed with 1% phosphate buffer solution (PBS). It was then centrifuged at 350 xg three times for 5 min each. Single cells were suspended by pipetting and then seeded in a 6-well plate. Low glucose DMEM medium containing 10% FBS and 1% double antibiotics (100 U/mL penicillin and 100 g/mL streptomycin) were added to each well, and the plate was then cultured at 37oC in an incubator. After 24 hours, the cells were observed under an inverted microscope, and the non-adhered smooth muscle cells were removed. The adhered ICCs were transferred to culture dishes and identified by immunofluorescence after 72 hours of incubation.\n2.6 Immunofluorescence In a 6-well plate, a sterile slide was put into each well, and the ICC suspension was dropped on the center of the slide. About 1 mL medium was added to each well, and another 1 mL medium was added after 8 hours of incubation. After 48 hours of incubation, the slides were taken out. The primary (rat anti-mouse c-kit monoclonal antibody) and secondary antibody (FITC-labeled rabbit anti-rat antibody) were diluted with antibody diluent to reach their working concentration 1: 100. The procedure of the immunohistochemical test was as follows: briefly, the slides were incubated in 100% acetone at room temperature for 10 minutes. After washing with 0.01 M PBS three times (5 minutes each time), the endogenous peroxidase was inactivated with 0.03% H2O2 for 20 minutes at room temperature. Then, the slides were blocked with 1% FBS albumin for 30 minutes at room temperature. After blocking, the slides were incubated with primary antibody of rat anti-mouse c-kit monoclonal antibody (1: 100, Merck Millipore Co., Germany) in a wet box for 2 hours at room temperature and then for 48 hours at 4oC. After washing, FITC-labeled secondary antibody (rabbit anti-rat antibody, 1: 100, Sigma Co., St. Louis, MO, USA) was added and incubated in the dark for 60 minutes. Finally, the slides were sealed with cover glass using 50% glycerol and observed under a fluorescence microscope and a laser scanning confocal microscope.\n2.7 Determination of the optimal MOI of the lentiviral vector containing human SCL gene into ICCs According to the manual for lentiviral transfection (provided by Genechem Co.), ICCs were added with 5×108 TU/mL lentiviral vectors containing the SCL gene at different MOIs (0.5, 1.0, 5.0, 10.0, 50.0, and 100.0), and 10 μg/mL polybrene was simultaneously added. After incubation for 8-12 h, the cells were observed under a microscope. After another 48 h incubation, the growth of ICCs was observed under a laser scanning confocal microscope, and the transfection efficiency was calculated [Transfection efficiency = (Number of cells expressing GFP/Total cell number) × 100%] to determine the optimal MOI.\n2.8 Determination of the optimal transfection time of the lentiviral vector containing the human SCL gene into ICCs ICCs were seeded in a 96-well plate at a concentration of 3×104~5×104/mL. The ICCs were divided into a normal control group, blank plasmid control group, and lentivirus transfection group using a random number table method. In the normal control group, 1% PBS was added. In the blank plasmid control group, blank lentivirus was added. In the lentivirus transfection group, the lentiviral vector containing human SCL gene was added at the optimal MOI together with 10 μg/mL polybrene. After 24 hours of incubation, the medium was removed, and the cells were washed with 1% PBS twice, and then 1 mL fresh DMEM medium containing 10% FBS was added for further incubation. The cells were observed using the laser scanning microscope at the 2, 3, and 5 d after transfection. A total of 20 continuous perpendicular to the horizontal views (about 0.77 mm2/view, 200 ×) were observed. The optimal transfection time was determined by observing the expression intensity of GFP.\n2.9 RT-PCR The total RNA of ICCs was extracted at 2, 3, and 5 d after transfection, and the expression of SCL mRNA was analyzed using RT-PCR. The primers of SCL and GAPDH were as follows:\nSCL: Upstream: 5’-GAGGATCCCCGGTACCGGTCGC-CACCATGCGAGCGGCCGCCGAG-3’; Downstream: 5’-TCAC-CATGGTGGCGACCGACCGGCCGAGGGCCGGCTCCATC-3’.\nGAPDH: Upstream: 5’-ACCACAGTCCATGCCATCAC-3’; Downstream: 5’-TCCACCACCCTGTTGCTGTA-3’.\nThe size of SCL is 1036 bp, while that of GADPH is 456 bp. The PCR reaction procedure was as follows: denaturing at 94oC for 5 min, 30 cycles of denaturation at 94oC for 30 s, annealing at 53oC for 30 s, and extension at 72oC for 1 min and a final extension at 72oC for 10 min. The products were detected with agarose gel electrophoresis. Gel imaging and gray intensity analysis were performed using a gel analysis system, and the expression of SCL mRNA in each group of ICCs was detected.\n2.10 Statistical analysis Data analysis was performed with the statistical software SPSS 17.0. The data was expressed as mean ± standard deviation (SD). ANOVA was used for the comparison among groups, and SNK-q test was used for the comparison between two groups. A P\u0026lt; 0.05 was considered to be statistically significant.\n3 Results 3.1 Separation, culture and identification of guinea pig ICCs To confirm whether the cultured cells were ICCs, c-kit antibody was used to identify the ICCs. After 24 hours of seeding, some spindle cells were observed with both sides and had obvious convex. Their nuclei were large, and there were some black glycogen particles in the cytoplasm. They had regular shapes, and most of them grew adherently (Figure 1A). After incubation for another 72 hours, the above cells were identified by immunofluorescence using the antibody of c-kit, which is an ICC-specific marker. The ICC-specific receptor tyrosine kinase (c-kit) was successfully expressed (Figure 1B). This result verified that the cultured cells were ICCs.\n   Figure 1 Identification of ICCs after GFP-SCL transfection. (A) After 2 days of incubation, adherent spindle cells with two projections on the two poles were observed under an inverted microscope (200×). (B) Tyrosine kinase (c-kit) receptor positive cells detected by immunofluorescence assays (200×).\n3.2 The optimal MOI for the lentiviral transfection into ICCs The GV287-SCL recombinant lentivirus vector was successfully constructed. The virus titer was 5 × 108 TU/ mL. To determine the optimal MOI for the lentiviral vector containing the human SCL gene to transfect cells, transfection efficiency of different MOI was measured. After 48 h of transfection, green fluorescence was observed under the laser scanning confocal microscope. As shown in Figure 2, when MOI was 0.5, 1.0, 5.0, 10.0, 50.0, and 100.0, the transfection efficiencies were 35.42% ± 0.12%, 58.04% ± 2.28%, 74.47% ± 3.22%, 85.62% ± 0.33%, 90.39% ± 0.67%, 90.77 ± 0.40%, respectively. When MOI ≥ 10.0, the transfection efficiencies all maintained above 85%, and there were statistically significant differences from those at MOI \u0026lt; 10.0 (P \u0026lt; 0.05, Table 1). When MOI ≤ 10.0, the cell growth was good and had no cell death. When MOI ≥ 50.0, although the transfection efficiencies were high, part of the cells were dead, and the cell activity decreased. Taking into consideration the transfection efficiency and cell activity at each MOI value, the optimal MOI for the lentiviral vector containing the human SCL gene was determined to be 10.0.\n   Figure 2 ICCs transfected with lentivirus at different MOIs for 48 h observed by an inverted phase contrast microscope (200×). The representative images at different MOI (MOI = 0.5; MOI = 1.0; MOI = 5.0; MOI = 10.0; MOI = 50.0; MOI = 100.0) were shown.\nTable 1Transfection efficiencies of the lentivirus into ICCs at different MOI values (mean ± SD, n=4).\n   MOI Transfection efficiency (%)     0.5 35.42 ± 0.12**[a]**   1.0 58.04 ± 2.28**[b]**   5.0 74.47± 3.22**[c]**   10.0 85.62 ± 0.33   50.0 90.39 ± 0.67**[d]**   100.0 90.77 ± 0.40**[e]**   F value 326.30   P value \u0026lt;0.001     Note: MOI, multiplicity of infection\n3.3 The optimal transfection time for the lentiviral vector into ICCs To determine the optimal transfection time for the lentiviral vector containing the human SCL gene to ICCs, comparison of the green fluorescence in ICCs at different days was performed. The bladder ICC-like cells were transfected at the optimal MOI, and the transfection efficiencies were observed at 2 d, 3 d, and 5 d after transfection (Figure 3). After 3 days of transfection, the green fluorescence was the most obvious with the highest intensity, and after that the expression of GFP was weakened. After 3 d of lentiviral transfection, GFP expression in the ICCs was higher than in ICCs with 2d and 5d of transfection. Hence, the optimal transfection time for the lentiviral vector containing the human SCL gene in ICCs was 3 d.\n   Figure 3 The expression intensity of GFP in the lentivirus transfection group. The representative images at day 2, day 3, and day 5 are shown (200×).\n3.4 The expression of SCL mRNA To determine whether the SCL gene was successfully introduced into ICCs, RT-PCR was performed to determine the expression of mRNA in each group. The amplification product of the lentiviral group was consistent with the target fragment in size, while there was no expression of the specific band in the normal control group and blank plasmid control group (Figure 4). This indicated that the SCL gene was successfully introduced into ICCs.\n   Figure 4 The expression of SCL mRNA analyzed by agarose gel electrophoresis. Lane 1: Normal control group; Lane 2: Blank plasmid control group; Lane M: Marker; Lane 4 and 5: Lentivirus transfection groups.\n4 Discussion Studies [18, 19, 20] have indicated that ICCs can control the spontaneous excitement and contraction of the detrusor. It has been shown that bladder ICCs can spontaneously generate action potentials using patch clamp [21]. Blocking ICC action potentials significantly inhibits the contraction of detrusor cells [22]. Some researchers believe that ICCs are capable of neural information conduction and may serve as the bladder pacemaker [22, 23, 24]. However, ICC levels in the bladder detrusor of diabetic patients are low and show abnormal distribution or weakened spontaneous excitement, thus promoting the formation of DCP [25]. Related studies [26, 27] have found that the growth of ICCs is closely related to their specific tyrosine kinase receptor, c-kit. When the SCF/c-kit signaling pathway is successfully activated, the appearance and physiological characteristics of ICCs can be maintained [28]. SCL is a transcription factor that can regulate the expression and function of c-kit, but it cannot bind to DNA directly [29]. In the present study, the lentiviral vector containing the human SCL gene was constructed and transfected into in vitro cultured ICCs. After transfection, the expression of SCL in ICCs was enhanced. These results may provide relevant information to further explore gene therapy for DCP.\nIn this study, target cells were collected according to the adhesion time of bladder smooth muscle cells to bladder. After 24 h of incubation, ICCs were found to adhere to the culture plates, while bladder smooth muscle cells did not adhere. The non-adhered bladder muscle cells were filtered, and relatively pure bladder ICCs were obtained. Some characteristic spindle cells were observed under an inverted microscope. These cells had obvious convex branches on their sides, large nuclei, regular shapes, and were neatly adhered, while most of the non-adhered cells were oval, without projections on both poles and had overall flat shapes. The expression of the c-kit receptor was successful. Therefore, the cultured cells were confirmed to be bladder ICCs. The bladder ICCs obtained using this differential adherence method were of a relatively higher number and purer quality, but smooth muscle cells were still observed. This method is simple and time-cost effective and can provide enough cells for subsequent experiments.\nLentivirus is a commonly used gene vector adapted from the human immunodeficiency virus -1. It retains biological activity but has inactivated toxicity, low immunogenicity, and good biosafety [30]. Viral vectors can efficiently integrate target genes into host cells by gene recombination, unlikely to cause insertional mutagenesis [31]. The target genes can express sustainably and stably [32, 33]. Viral vectors have high transfection efficiencies for both dividing and non-dividing cells [34]. Thus, they are an ideal tool for gene transfection both in vitro and in vivo. In this study, lentivirus was packaged by a three plasmid system which included one recombinant virus plasmid encoding lentivirus and its two secondary packaging element vector plasmids. The encoding plasmid and the helper plasmids have cis-trans complementary functions. In addition, the structures of the secondary packaging plasmids were constructed by pHelper1.0 and pHelper2.0 vectors. This method is relatively simple, the lentivirus recombination rate and yield are acceptable, and the expression of the target gene is high. During the experiment, the supernatant rich in lentiviral particles was collected and concentrated and purified repeatedly to obtain high-titer lentiviral stock solution. The expression of the target gene was determined after transfecting 293T cells, and the virus titer was determined by fluorescence. The results showed that the titer of the lentivirus was 5 × 108 TU /mL, which could meet the needs of most transfection experiments.\nAlthough the toxic genes of lentivirus have been excluded, its biological risk is not completely lost. Lentivirus is a “suicide” virus with certain cytotoxicity [35, 36]. Studies have found that the transfection efficiency of lentivirus is closely related to its MOI, and high MOI can lead to some cell death [37, 38, 39, 40]. Therefore, a proper MOI is important. In the current experiment, we found that the lentiviral transfection efficiency in ICCs was best at MOI = 10.0, and cell activity was good with no cell death. Considering the transfection efficiency and growth state of the cells, the optimal MOI value was determined to be 10.0. GFP is a bioluminescent protein that can steadily emit green fluorescence under the excitation of blue light and has no cytotoxicity. It is now widely used in cell biology and biopsy as a molecular marker or reporter gene. In this study, GFP was used as a marker gene of the lentivirus because of its stable and clear fluorescence. Under a fluorescence microscope, real-time and in situ observation of living cells can be realized. Therefore, the transfection of the three plasmids into 293T cells to generate virus could be observed in real time, and accurate and intuitive results could be obtained. The ICCs were transfected with the lentivirus at the optimal MOI value and the expression of GFP was observed under a confocal microscope. The results showed that there was no GFP expressions in the normal control group and blank plasmid control group after 2 days of transfection. The GFP expression intensity in ICCs after 3 days of lentivirus transfection was higher than that after 2 days and 5 days, so the optimal transfection time for the lentivirus containing the human SCL gene into ICCs was 3 days. Comprehensively, for the transfection of lentivirus containing the human SCL gene into ICCs, the optimal MOI was 10.0, and the transfection efficiency, biological activity, and safety were highest after 72 hours of transfection. The results of RT-PCR indicated that the amplification product in the lentivirus transfection group had the same size as that of the target fragment, which was 1036 bp, while there was no expression of the specific band in the normal control group and blank plasmid control group. This suggested that the SCL gene was successfully introduced into ICCs.\nThere are some limitations to the present study. In vitro culture of cells is different from the body’s internal environment and might lose cell maintenance or auxiliary signals as well as interactions with other cells and proteins. In vitro experiments cannot completely replicate the in vivo situation, thus whether the transfection of DCP guinea pig bladder using a lentiviral vector containing the human SCL gene or other in vivo experiments can obtain the same results needs further study.\nIn conclusion, this study successfully constructed a recombinant lentiviral vector containing the human SCL gene by gene technology and molecular biological techniques. The titer of the lentivirus was 5 × 108 TU/ mL. In vitro cultured ICCs were transfected with the lentiviral vector containing the human SCL gene, and SCL was successfully expressed in the ICCs. Our findings may provide a foundation for further in vivo transfection studies using the SCL gene.\nAcknowledgements This work was supported by National Natural Science Foundation [grant number 81360120].\n Conflict of interest: Authors state no conflict of interest.\nReferences [1] Liu G, Daneshgari F. Diabetic bladder dysfunction. Chin Med J (Engl) 2014; 127: 1357-1364 Search in Google Scholar\n[2] Xu Y, Wang L, He J, Bi Y, Li M, Wang T et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013; 310: 948-959 Search in Google Scholar\n[3] Gomez CS, Kanagarajah P, Gousse AE. Bladder dysfunction in patients with diabetes. Current urology reports 2011; 12: 419-426 Search in Google Scholar\n[4] Lin TL, Chen GD, Chen YC, Huang CN, Ng SC. Aging andrecurrent urinary tract infections are associated with bladder dysfunction in type 2 diabetes. Taiwan J Obstet Gynecol 2012; 51: 381-386 Search in Google Scholar\n[5] Leiria LO, Monica FZ, Carvalho FD, Claudino MA, Franco-Penteado CF, Schenka A et al. Functional, morphological and molecular characterization of bladder dysfunction in streptozotocin-induced diabetic mice: evidence of a role for L-type voltage-operated Ca2+ channels. Br J Pharmacol 2011; 163: 1276-1288 Search in Google Scholar\n[6] Li Y, Sun Y, Zhang Z, Feng X, Meng H, Li S et al. Cannabinoid receptors 1 and 2 are associated with bladder dysfunction in an experimental diabetic rat model. BJU Int 2013; 112: E143-150 Search in Google Scholar\n[7] Oberbach A, Jehmlich N, Schlichting N, Heinrich M, Lehmann S, Wirth H et al. Molecular fingerprint of high fat diet induced urinary bladder metabolic dysfunction in a rat model. PLoS One 2013; 8: e66636 Search in Google Scholar\n[8] Briggs Boedtkjer D, Rumessen J, Baandrup U, Skov Mikkelsen M, Telinius N, Pilegaard H et al. Identification of interstitial Cajal-like cells in the human thoracic duct. Cells Tissues Organs 2013; 197: 145-158 Search in Google Scholar\n[9] Wang JP, Ding GF, Wang QZ. Interstitial cells of Cajal mediate excitatory sympathetic neurotransmission in guinea pig prostate. Cell Tissue Res 2013; 352: 479-486 Search in Google Scholar\n[10] Yin Z, Yang J. Bladder interstitial cells and pathophysiology. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2014; 39: 644-648 Search in Google Scholar\n[11] Zhang YG, X.W. H, W. Z, Ma WQ, Wu YS, Wu Q et al. Excitability change and significance of interstitial cells of Cajal in rat bladder with detrusor hyperreflexia. Journal of Clinical Urology 2015: 168-171 Search in Google Scholar\n[12] Wang L, Liang Y, Chen Q, et al. Identification and distribution of the interstitial cells of cajal in the abomasum of goats[J]. Cell Transplant, 2018, 27(2): 335-344. Search in Google Scholar\n[13] Lang R J, Tonta M A, Zoltkowski B Z, et al. Pyeloureteric peristalsis: role of atypical smooth muscle cells and interstitial cells of Cajal-like cells as pacemakers.[J]. J Physiol, 2006, 576(3):695-705. Search in Google Scholar\n[14] Wang QZ, Shi-Qi JI, Zhu GD, Yun-Fei LI, Cai ZQ, Ying-Long LI et al. The morphologic changes and significance of interstitial cells of Cajal-like cells in the bladder of diabetic guinea pig. Chinese Journal of Clinical \u0026amp; Experimental Pathology 2009; Search in Google Scholar\n[15] Liu YG, Wang QZ, Ding GF, Liu XJ, Zhou JM, Ying-Long LI et al. Effects of SCF on the expressions of c-kit mRNA and protein of interstitial cells of Cajal-like cells in the bladder of guinea pig in the high glucose environment. Chinese Journal of Clinical \u0026amp; Experimental Pathology 2011; 27: 282-285 Search in Google Scholar\n[16] Tan YY, Ji ZL, Zhao G, Jiang JR, Wang D, Wang JM. Decreased SCF/c-kit signaling pathway contributes to loss of interstitial cells of Cajal in gallstone disease. Int J Clin Exp Med 2014; 7: 4099-4106 Search in Google Scholar\n[17] Kart Y, Karakus OZ, Ates O, Hakguder G, Olguner M, Akgur FM. Altered expression of interstitial cells of Cajal in primary obstructive megaureter. J Pediatr Urol 2013; 9: 1028-1031 Search in Google Scholar\n[18] Feng J, Liu Y, Gao J, Zhong Y, Shu Y, Meng M et al. Effect of exogenous stem cell factor on numbers of interstitial cells of Cajal and detrusor contraction in rats with underactive bladder. Journal of Third Military Medical University 2016; Search in Google Scholar\n[19] Juszczak K, Maciukiewicz P, Drewa T, Thor PJ. Cajal–like interstitial cells as a novel target in detrusor overactivity treatment: true or myth? Central European Journal of Urology 2014; 66: 413 Search in Google Scholar\n[20] Kim SO, Song SH, Ahn KY, Kwon DD. Distribution of interstitial cells of cajal in menopausal rat urinary bladder showing detrusor overactivity. Int Neurourol J 2010; 14: 48-53 Search in Google Scholar\n[21] Kim BJ, Kim HW, Lee GS, Choi S, Jun JY, So I et al. Poncirus trifoliate fruit modulates pacemaker activity in interstitial cells of Cajal from the murine small intestine. J Ethnopharmacol 2013; 149: 668-675 Search in Google Scholar\n[22] Zuo DC, Choi S, Shahi PK, Kim MY, Park CG, Kim YD et al. Inhibition of pacemaker activity in interstitial cells of Cajal by LPS via NF-kappaB and MAP kinase. World J Gastroenterol 2013; 19: 1210-1218 Search in Google Scholar\n[23] Han S, Kim JS, Jung BK, Han SE, Nam JH, Kwon YK et al. Effects of ginsenoside on pacemaker potentials of cultured interstitial cells of Cajal clusters from the small intestine of mice. Mol Cells 2012; 33: 243-249 Search in Google Scholar\n[24] Lee J, Kim YD, Park CG, Kim MY, Chang IY, Zuo DC et al. Neurotensin modulates pacemaker activity in interstitial cells of Cajal from the mouse small intestine. Mol Cells 2012; 33: 509-516 Search in Google Scholar\n[25] Sanders KM, Koh SD, Ward SM. Interstitial cells of cajal as pacemakers in the gastrointestinal tract. Annu Rev Physiol 2006; 68: 307-343 Search in Google Scholar\n[26] Sung R, Kim YC, Yun HY, Choi W, Kim HS, Kim H et al. Interstitial cells of Cajal (ICC)-like-c-Kit positive cells are involved in gastritis and carcinogenesis in human stomach. Oncol Rep 2011; 26: 33-42 Search in Google Scholar\n[27] Wang XY, Chen JH, Li K, Zhu YF, Wright GW, Huizinga JD. Discrepancies between c-Kit positive and Ano1 positive ICC-SMP in the W/Wv and wild-type mouse colon; relationships with motor patterns and calcium transients. Neurogastroenterol Motil 2015; 26: 1298-1310 Search in Google Scholar\n[28] Ward SM, Sanders KM. Physiology and pathophysiology of the interstitial cell of Cajal: from bench to bedside. I. Functional development and plasticity of interstitial cells of Cajal networks. Am J Physiol Gastrointest Liver Physiol 2001; 281: G602-611 Search in Google Scholar\n[29] Li F, Zhang L, Li C, Ni B, Wu Y, Huang Y et al. Adenovirus-mediated stem cell leukemia gene transfer induces rescue of interstitial cells of Cajal in ICC-loss mice. Int J Colorectal Dis 2010; 25: 557-566 Search in Google Scholar\n[30] Rusu MC, Pop F, Hostiuc S, Curca GC, Streinu-Cercel A. Extrahepatic and intrahepatic human portal interstitial Cajal cells. Anat Rec (Hoboken) 2011; 294: 1382-1392 Search in Google Scholar\n[31] Ranzani M, Annunziato S, Calabria A, Brasca S, Benedicenti F, Gallina P et al. Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies. Mol Ther 2014; 22: 2056-2068 Search in Google Scholar\n[32] Xie B, Yu G, Ling S, Ma Z, Bai J. Establishment of MDCK cell lines which stably express FRT-LacZ gene by lentiviral system. Biotechnology 2016; Search in Google Scholar\n[33] Zhang J, Wang D, Hu N, Wang Q, Yu S, Wang J. The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line. Tumour Biol 2016; 37: 5847-5855 Search in Google Scholar\n[34] Pelascini LP, Janssen JM, Goncalves MA. Histone deacetylase inhibition activates transgene expression from integration-defective lentiviral vectors in dividing and non-dividing cells. Hum Gene Ther 2013; 24: 78-96 Search in Google Scholar\n[35] Hossain JA, Ystaas LR, Mrdalj J, Välk K, Riecken K, Fehse B et al. Lentiviral HSV‐Tk.007‐mediated suicide gene therapy is not toxic for normal brain cells. J Gene Med 2016; 18: 234-243 Search in Google Scholar\n[36] Mohammadi Z, Shariati L, Khanahmad H, Kolahdouz M, Kianpoor F, Ghanbari JA et al. A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy. Mol Biotechnol 2015; 57: 793-800 Search in Google Scholar\n[37] Hu Y, Zhang Q, Zhang L, Tang XX, He HY. Basic fibroblast growth factor lentiviral vector-transfected sheep bone marrow mesenchymal stem cells and non-specific osteogenic gene expression. Mol Med Rep 2015; 12: 267-272 Search in Google Scholar\n[38] Huang GH, Yang XT, Chen K, Xing J, Zhu L, Hong-Jiang LI et al. Construction of lentiviral vector with over-expression of Porf-2 gene and transfection of neural cells. Journal of Shanghai Jiaotong University 2015; 87: 480 Search in Google Scholar\n[39] Jiao ZZ, Xue WJ, Tian XH, Li Y, Zheng J. Construction of VEGF165 lentivirus vectors and expression in adipose tissue-derived stem cells after transfection. Chin Pharm J 2016; Search in Google Scholar\n[40] Wang X, Mani P, Sarkar DP, Roychowdhury N, Roychowdhury J. Ex vivo gene transfer into hepatocytes. Methods Mol Biol 2009; 481: 117 Search in Google Scholar\nReceived: 2018-08-29\nAccepted: 2019-10-21\nPublished Online: 2020-03-25\n© 2020 Biao Qian et al. published by De Gruyter\nThis work is licensed under the Creative Commons Attribution 4.0 International License.\n","date":1585094400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1585094400,"objectID":"a939e51f53267bab4e89f8453755cc8d","permalink":"https://swcyo.netlify.app/publication/lichen1/","publishdate":"2020-03-25T00:00:00Z","relpermalink":"/publication/lichen1/","section":"publication","summary":"the recombinant lentiviral vector GV287-SCL was successfully constructed and transfected into the in vitro cultured ICCs. The successful expression of SCL in ICCs may provide an experimental basis for the in vivo transfection of the SCL gene.","tags":["journal article"],"title":"Construction of recombinant lentiviral vector containing human stem cell leukemia gene and its expression in interstitial cells of cajal","type":"publication"},{"authors":[],"categories":[],"content":"公示网址:http://kjj.xjbt.gov.cn/c/2019-11-12/7300748.shtml?COLLCC=2095363529\u0026amp;\n决定网址:http://kjj.xjbt.gov.cn/c/2019-12-24/7314407.shtml?COLLCC=2095363529\u0026amp;\n接兵团科技局官方网站最新内容“关于2019年度兵团科学技术奖励的决定”公示，我院泌尿外科荣获兵团科技进步奖二等奖一项，此次兵团科技进步奖共设一等奖5项，二等奖11项，三等奖15项，其中我科获奖题目为“T1b期肾肿瘤实施腹腔镜下肾部分切除术的临床应用研究”，我院副院长、第三师医院院长王勤章教授为第一完成人，特此祝贺。\n我院泌尿外科自2011年申报兵团杰出青年基金课题“T1b期肾癌实施腹腔镜下肾部分切除术的临床应用研究”以来，不仅顺利完成了原课题计划设计内容，并且在此基础上不断深入研究创新，解决了以往对于4-7cm的肾肿瘤切除肾脏的技术瓶颈，保留了患者肾脏，改善了患者生存治疗，并且以此制定了相关理论及技术规范并向新疆多家基层医院进行帮扶及技术转换，现将成果汇报如下：\n  * 应用推广情况 系统评价了T1b期肾肿瘤行保留肾单位手术的治疗效果后，确定了腹腔镜下肾部分切除术的可行性，统计分析了T1b期肾肿瘤临床、影像学及病理学与腹腔镜下肾部分切除术具体操作相关联的内在规律，并以此制定腹腔镜下肾部分切除术的相关理论和技术操作体系；最后依据所制定的技术操作体系选择T1b期肾肿瘤患者实施腹腔镜下肾部分切除术并向基层医院推广，疗效及远期随访良好。 应用产出情况 通过临床可行性及需求性研究，统计分析了T1b期肾肿瘤流行性病学特点及预后相关影响因素，确定了肿瘤安全切除边距，制定了腹腔镜下肾部分切除术相关理论和技术操作体系，建立了相关手术风险评估系统，与兵团第四师、第五师、第七师、第九师、乌苏市等五家基层医院进行成果转化项目申报，将成果转出，产生了较大的社会效益，本研究共授权专利2项，主编著作1部，发表文章22篇，其中SCI 2篇，中文核心期刊18篇，培养博士研究生3名，硕士研究生7名。         ","date":1577145600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628943884,"objectID":"7abf9232877da19d8ee05a562568bb1a","permalink":"https://swcyo.netlify.app/talk/2019/","publishdate":"2019-12-24T00:00:00Z","relpermalink":"/talk/2019/","section":"event","summary":"公示网址:http://kjj.xjbt.gov.cn/c/2019-11-12/7300748.shtml?COLLCC=2095363529\u0026amp;\n决定网址:http://kjj.xjbt.gov.cn/c/2019-12-24/7314407.shtml?COLLCC=2095363529\u0026amp;\n接兵团科技局官方网站最新内容“关于2019年度兵团科学技术奖励的决定”公示，我院泌尿外科荣获兵团科技进步奖二等奖一项，此次兵团科技进步奖共设一等奖5项，二等奖11项，三等奖15项，其中我科获奖题目为“T1b期肾肿瘤实施腹腔镜下肾部分切除术的临床应用研究”，我院副院长、第三师医院院长王勤章教授为第一完成人，特此祝贺。\n我院泌尿外科自2011年申报兵团杰出青年基金课题“T1b期肾癌实施腹腔镜下肾部分切除术的临床应用研究”以来，不仅顺利完成了原课题计划设计内容，并且在此基础上不断深入研究创新，解决了以往对于4-7cm的肾肿瘤切除肾脏的技术瓶颈，保留了患者肾脏，改善了患者生存治疗，并且以此制定了相关理论及技术规范并向新疆多家基层医院进行帮扶及技术转换，现将成果汇报如下：\n  * 应用推广情况 系统评价了T1b期肾肿瘤行保留肾单位手术的治疗效果后，确定了腹腔镜下肾部分切除术的可行性，统计分析了T1b期肾肿瘤临床、影像学及病理学与腹腔镜下肾部分切除术具体操作相关联的内在规律，并以此制定腹腔镜下肾部分切除术的相关理论和技术操作体系；最后依据所制定的技术操作体系选择T1b期肾肿瘤患者实施腹腔镜下肾部分切除术并向基层医院推广，疗效及远期随访良好。 应用产出情况 通过临床可行性及需求性研究，统计分析了T1b期肾肿瘤流行性病学特点及预后相关影响因素，确定了肿瘤安全切除边距，制定了腹腔镜下肾部分切除术相关理论和技术操作体系，建立了相关手术风险评估系统，与兵团第四师、第五师、第七师、第九师、乌苏市等五家基层医院进行成果转化项目申报，将成果转出，产生了较大的社会效益，本研究共授权专利2项，主编著作1部，发表文章22篇，其中SCI 2篇，中文核心期刊18篇，培养博士研究生3名，硕士研究生7名。         ","tags":[],"title":"我科获2019年兵团科技进步二等奖","type":"event"},{"authors":[],"categories":[],"content":"【项目名称】 Cx43与ICC细胞交互作用在DCP膀胱发生中的作用及其机制研究\n【学科分类】：医学科学部(H) -\u0026gt; 泌尿系统(H05) -\u0026gt; 膀胱疾病(H0514)\n【执行时间】：2020-01至2023-12\n   项目负责人 王勤章 职称      依托单位 石河子大学 依托单位 石河子大学   研究期限 2020-01至2023-12 研究期限 2020-01至2023-12   资助金额 32.00万元 项目类别 地区科学基金项目   批准号 81960147 学科分类 膀胱疾病   中文主题词  中文主题词    英文主题词  英文主题词     ","date":1565740800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628944438,"objectID":"8915f6be060fb893097ee76def2eb46b","permalink":"https://swcyo.netlify.app/project/nfc2018/","publishdate":"2019-08-14T00:00:00Z","relpermalink":"/project/nfc2018/","section":"project","summary":"Cx43与ICC细胞交互作用在DCP膀胱发生中的作用及其机制研究","tags":["Project"],"title":"国家自然地区科学基金项目(81960147)","type":"project"},{"authors":null,"categories":null,"content":"南疆地区盆底功能障碍性疾病诊疗新技术的集成推广与相关临床应用研究\n项目来源: 新疆生产建设兵团科技攻关项目\n编号: 2018AB023\n经费: 96万\n年限: 2019年-\n","date":1556323200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628944438,"objectID":"e04b2eb6691ebaf80cb09633d3c9f8a6","permalink":"https://swcyo.netlify.app/project/2018ab023/","publishdate":"2019-04-27T00:00:00Z","relpermalink":"/project/2018ab023/","section":"project","summary":"南疆地区盆底功能障碍性疾病诊疗新技术的集成推广与相关临床应用研究.","tags":["Project"],"title":"新疆生产建设兵团科技攻关项目(2018AB023)","type":"project"},{"authors":[],"categories":[],"content":"Create slides in Markdown with Wowchemy Wowchemy | Documentation\n Features  Efficiently write slides in Markdown 3-in-1: Create, Present, and Publish your slides Supports speaker notes Mobile friendly slides   Controls  Next: Right Arrow or Space Previous: Left Arrow Start: Home Finish: End Overview: Esc Speaker notes: S Fullscreen: F Zoom: Alt + Click PDF Export: E   Code Highlighting Inline code: variable\nCode block:\nporridge = \u0026quot;blueberry\u0026quot; if porridge == \u0026quot;blueberry\u0026quot;: print(\u0026quot;Eating...\u0026quot;)   Math In-line math: $x + y = z$\nBlock math:\n$$ f\\left( x \\right) = ;\\frac{{2\\left( {x + 4} \\right)\\left( {x - 4} \\right)}}{{\\left( {x + 4} \\right)\\left( {x + 1} \\right)}} $$\n Fragments Make content appear incrementally\n{{% fragment %}} One {{% /fragment %}} {{% fragment %}} **Two** {{% /fragment %}} {{% fragment %}} Three {{% /fragment %}}  Press Space to play!\nOne  Two  Three \n A fragment can accept two optional parameters:\n class: use a custom style (requires definition in custom CSS) weight: sets the order in which a fragment appears   Speaker Notes Add speaker notes to your presentation\n{{% speaker_note %}} - Only the speaker can read these notes - Press `S` key to view {{% /speaker_note %}}  Press the S key to view the speaker notes!\n Only the speaker can read these notes Press S key to view    Themes  black: Black background, white text, blue links (default) white: White background, black text, blue links league: Gray background, white text, blue links beige: Beige background, dark text, brown links sky: Blue background, thin dark text, blue links    night: Black background, thick white text, orange links serif: Cappuccino background, gray text, brown links simple: White background, black text, blue links solarized: Cream-colored background, dark green text, blue links   Custom Slide Customize the slide style and background\n{{\u0026lt; slide background-image=\u0026quot;/media/boards.jpg\u0026quot; \u0026gt;}} {{\u0026lt; slide background-color=\u0026quot;#0000FF\u0026quot; \u0026gt;}} {{\u0026lt; slide class=\u0026quot;my-style\u0026quot; \u0026gt;}}   Custom CSS Example Let\u0026rsquo;s make headers navy colored.\nCreate assets/css/reveal_custom.css with:\n.reveal section h1, .reveal section h2, .reveal section h3 { color: navy; }   Questions? Ask\nDocumentation\n","date":1549324800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1549324800,"objectID":"0e6de1a61aa83269ff13324f3167c1a9","permalink":"https://swcyo.netlify.app/slides/example/","publishdate":"2019-02-05T00:00:00Z","relpermalink":"/slides/example/","section":"slides","summary":"An introduction to using Wowchemy's Slides feature.","tags":[],"title":"Slides","type":"slides"},{"authors":[],"categories":[],"content":"石河子大学成果转化与技术推广计划项目\n微创保肾在泌尿外科中的应用\n编号：CGZH201706\n经费: 20万\n","date":1502668800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628945433,"objectID":"e539e6890228026e995a281de295f018","permalink":"https://swcyo.netlify.app/project/cgzh201706/","publishdate":"2017-08-14T00:00:00Z","relpermalink":"/project/cgzh201706/","section":"project","summary":"微创保肾在泌尿外科中的应","tags":["project"],"title":"石河子大学成果转化与技术推广计划项目(CGZH201706)","type":"project"},{"authors":null,"categories":null,"content":"","date":1461715200,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1461715200,"objectID":"d1311ddf745551c9e117aa4bb7e28516","permalink":"https://swcyo.netlify.app/project/external-project/","publishdate":"2016-04-27T00:00:00Z","relpermalink":"/project/external-project/","section":"project","summary":"石河子大学.","tags":["Project"],"title":"石河子大学","type":"project"},{"authors":["Biao Qian","Li-Ying Zheng","Qin-Zhang Wang","Guo-Fu Ding"],"categories":null,"content":"Keywords: Uyghur population; apolipoprotein E gene polymorphism; dyslipidemia; urolithiasis.\nIntroduction Urolithiasis is a common urinary disease, with increasing incidence worldwide. The occurrence of urolithiasis varies among geographical regions and ethnic groups. A high incidence of urolithiasis has been observed in Xinjiang, China, particularly among the Uyghur population of south Xinjiang that follows a high-fat diet. High levels of blood lipids have been reported to affect lipid metabolism and may be a risk factor for urolithiasis (1,2). Blood lipid levels are affected by genetic factors and lifestyle, and lipid metabolism processes are regulated by a set of genes. Different blood lipid levels have been detected among ethnic groups as early as childhood, which indicates that the differences may be based on genetic factors (3). In addition, genetic factors have been identified as a possible cause of a number of abnormalities in blood lipid metabolism (4). The present study focused on the apolipoprotein E (ApoE) gene, which is one of the components of plasma lipoproteins. ApoE regulates blood lipid metabolism by binding with a receptor protein (5). Epidemiological investigations have revealed that ApoE gene polymorphisms are closely associated with lipid metabolism abnormalities (6).\nApoE is a major plasma lipoprotein that plays an important role in lipoprotein metabolism. Lipoproteins with different ApoE isomers have been reported to exhibit distinct kinetic characteristics and affect the blood lipid levels differently (7). Kong et al (8) reported that cholesterol crystallization in the gall bladder was associated with ApoE polymorphism, and hypothesized that ApoE may be a promoter of nucleation, and thus, a susceptibility factor for cholesterol crystallization in the gall bladder. In the present study, lipid metabolism was investigated in urolithiasis patients among the Uyghur population. Using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, the associations between ApoE gene polymorphisms and lipid metabolism abnormalities were analyzed.\nMaterials and methods Subjects In total, 90 Uyghur patients with urolithiasis from the Aksu Prefecture, hospitalized between January and July 2007, were enrolled in this study (male, 51; female, 39; age range, 7–67 years). In addition, 90 healthy Uyghur individuals with no blood relation to the patients were randomly selected as the control group (male, 51; female, 39; age range, 8–69 years). Individuals from the control group had similar occupations and resided in the same area as the patient group individuals. B-type ultrasonography was performed to ensure that the control group did not suffer from a urinary calculus or any other relevant diseases. Patients diagnosed with a urinary calculus who did not undergo removal of the calculus, even following extracorporeal shock wave lithotripsy, as well as patients with chronic urinary infections and renal insufficiency, were excluded from the study. Qualitative analysis of the calculus components was conducted using standard calculus qualitative analytical chemical reagents supplied by the Institute of Urology, Peking University (Peking, China). The reagents included calcium phosphate, calcium oxalate, ammonium magnesium phosphate, uric acid, carbapatite, and cystine. The stone samples were powdered and analyzed by Fourier transform infrared spectrophotometry (Tensor 27; Bruker Optics GmbH, Ettlingen, Germany).\nPrior written and informed consent was obtained from all the patients and the study was approved by the Ethics Review Board of Shihezi University (Shihezi, China).\nMeasurement of blood lipid profiles Blood lipids levels were analyzed on an Olympus AU400 Automated Chemistry analyzer (Olympus Optical Co., Ltd., Tokyo, Japan). Blood samples were collected from the peripheral vein of each individual without fasting and frozen in liquid nitrogen. Aliquots of frozen serum were thawed on ice for 2 h. The samples were thus frozen and thawed twice in total. Lipid metabolites were extracted from 100 μl of serum. Blood levels of cholesterol and triglycerides were analyzed in the patients and control groups using the cholesterol oxidase method. In addition, the levels of apolipoprotein A-I and total lipoprotein were determined by an immunoturbidimetric assay. The levels of high-density lipoprotein and low-density lipoprotein were measured using a routine Hitachi 7600 autoanalyzer (Hitachi High-Technologies Corporation, Tokyo, Japan).\nPCR-RFLP analysis A 5-ml blood sample was collected from the peripheral vein of each individual and was anticoagulated with EDTA. DNA was extracted from the blood sample using a Genomic DNA Extraction kit (Sangon Biotech Co., Ltd., Shanghai, China), according to the manufacturer’s instructions. The ApoE gene was amplified in a total volume of 30 μl. The primerswere synthesized by Sangon Biotech Co., Ltd. and their sequences as follows: forward: 5′-ACA GAA TTC GCC CCG GCC TGG TAC AC-3′ and reverse: 5′-TAA GCT TGG CAC GGC TGT CCA AGG A-3′. Each PCR cycle included 3 μl 10X PCR buffer (with 15 mM MgCl2), 2 units Taq DNA polymerase (Takara Bio, Inc., Tokyo, Japan), 2 μl dNTP (2.5 mM), 0.4 μl each of the forward and reverse primers (20 mM) and 0.5–0.6 μg DNA templates. The following PCR procedure was used: initial denaturation at 97°C for 7 min; 35 cycles of denaturation at 95°C for 45 sec; annealing at 65°C for 45 sec and extension at 72°C for 1 min; and a final extension at 72°C for 10 min. PCR was performed in a C1000 Touch™ PCR thermal cycler (Bio-Rad, Hercules, California, USA)\nFollowing PCR, a 1-μg sample of the ApoE gene amplification product was digested with 20 μl restriction endonuclease (Sangon Biotech Co., Ltd.). Following digestion, the DNA fragments were separated by electrophoresis on a polyacrylamide gel for 2 h at 90 V. The genotypes were identified using a Gel Doc™ XR gel imaging and analysis system (Bio-Rad). A sample was randomly selected from each genotype identified during the RFLP analysis, and sequenced by Sangon Biotech Co., Ltd.\nStatistical analysis The frequencies of the genotypes and gene alleles were calculated separately in the patient and control groups using a gene counting method as described previously (9). The data were tested for Hardy-Weinberg equilibrium and statistical analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). The genotypic and allelic differences between the control and patient groups were examined with the χ2 test, where P\u0026lt;0.05 was considered to indicate a statistically significant difference.\nResults Analysis of calculus composition To determine the percentage of each component in the calculi of the patients, calculus composition was analyzed using standard calculus qualitative analytical chemical reagents. The results indicated that the major component of the calculi was calcium oxalate in 90.0% of the patients (81/90). Among the 81 patients with calcium oxalate calculi, the calculus composition detected was as follows: Pure calcium oxalate (67.9%, 55/81); calcium oxalate and calcium phosphate (4.9%, 4/81); calcium oxalate and ammonium magnesium phosphate (2.5%, 2/81); calcium oxalate and uric acid or ammonium urate (18.5%, 15/81); calcium oxalate, ammonium magnesium phosphate and dahllite (2.5%; 2/81); calcium oxalate and dahllite (2.5%, 2/81); and calcium oxalate and cystine (1.2%, 1/81). Among the other nine urolithiasis cases, the calculus composition included pure calcium phosphate (2.2%, 2/90), pure uric acid (5.6%, 5/90) and pure ammonium magnesium phosphate (2.2%, 2/90). These results indicated that the major component of calculi in urolithiasis cases among the Uyghur population of south Xinjiang was calcium oxalate.\nNumber of cases with abnormal levels of total cholesterol, triglycerides and high-density lipoproteins is higher in urolithiasis patients Blood lipid levels were measured to investigate the role of blood lipids in urolithiasis. The blood lipids detected included total cholesterol, triglycerides, high-density lipoproteins, low-density lipoproteins, apolipoprotein A-I and lipoproteins. As shown in Table I, abnormal levels of total cholesterol were detected in 38 urolithiasis patients (42.2%) and 21 individuals from the control group (23.3%). In addition, abnormal levels of triglycerides were observed in 33 patients (36.7%) and 15 cases from the control group (16.7%). In total, 29 cases (32.2%) in the patient group exhibited abnormal levels of high-density lipoproteins, whereas abnormal levels were detected in only 16 cases from the control group (17.8%). Abnormal levels of apolipoprotein A-I were detected in 67 cases (74.4%) in the patient group and 60 cases (66.7%) in the control group. The number of cases exhibiting abnormal levels of low-density lipoproteins was 57 in the patient group (63.3%) and 53 in the control group (58.9%). Only one case (1.1%) was detected with abnormal levels of lipoproteins in the patient group, while no cases were detected in the control group. Statistically, the number of cases with abnormal levels of total cholesterol, triglycerides and high-density lipoproteins was significantly higher in the patient group when compared with the control group. However, the difference in the number of cases with abnormal levels of apolipoprotein A-I, low-density lipoproteins and lipoproteins between the two groups was not found to be statistically significant. These results indicated that dyslipidemia may be a significant factor in the development of urolithiasis among the Uyghur population of south Xinjiang.\nTable I Blood lipid level analysis in the patient and control groups. P\u0026lt;0.05, vs. control group.\nAssociations between ApoE gene polymorphisms and the occurrence of urolithiasis To determine the associations between the polymorphisms of ApoE and the occurrence of urolithiasis, ApoE gene polymorphisms were analyzed using PCR-RFLP. The ApoE gene was successfully amplified in the 180 subjects (90 patients and 90 controls) and the product size of the gene was 244 bp. In theory, due to the presence of different bases at sites 112 and 158 of the ApoE gene, three alleles and six genotypes can be generated following digestion with the Hha I restriction endonuclease. However, in this study, only three genotypes were identified in the subjects, namely, the E3/3, E4/4 and E3/4 genotypes (Fig. 1). Through Hardy-Weinberg equilibrium testing, these genotypes of ApoE were found to be consistent with the theoretical expectations.\n[   An external file that holds a picture, illustration, etc. Object name is ETM-09-01-0183-g00.jpg  Apolipoprotein E gene polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism. Following digestion with the restriction endonuclease, Hha I, the DNA fragments were run on a polyacrylamide gel and the representative electrophoresis results of the E3/4 (91, 72 and 48 bp), E3/3 (91 and 48 bp) and E4/4 (72 and 48 bp) genotypes are shown.\nThe associations between ApoE gene polymorphisms and the occurrence of urolithiasis were analyzed. As shown in Table II, 28 cases with E3/3 (30.1%), 58 cases with E3/4 (64.4%) and four cases with the E4/4 genotype (4.5%) were detected in the patient group. By contrast, 52 individuals with E3/3 (57.8%), 35 individuals with E3/4 (38.9%) and three individuals with the E4/4 genotype (3.3%) were identified in the control group. The frequency of the E3/4 genotype in the patient group was significantly higher when compared with the control group (χ2=12.96; P\u0026lt;0.001). The number of E3 and E4 alleles in the patient group was 114 (64.8%) and 62 (35.2%), respectively, while the number of these alleles in the control group was 139 (79.0%) and 41 (21.0%), respectively. Statistically, the frequency of the E4 allele in the patient group was significantly higher when compared with the control group (χ2=6.61; P\u0026lt;0.025). The results indicated that the E3/4 genotype and E4 allele may be susceptibility factors for urolithiasis among the Uyghur population of south Xinjiang.\nTable II Associations between ApoE gene polymorphisms and the occurrence of urolithiasis.\naP\u0026lt;0.001 and\nbP\u0026lt;0.025, vs. control group.\nApoE, apolipoprotein E.\nDiscussion The occurrence of urolithiasis has been shown to increase with age and the increasing incidence of obesity (10). In addition to the high risk of developing obesity, coronary heart disease, dyslipidemia and abnormal glucose tolerance, individuals with metabolic syndromes also experience a high risk of urolithiasis (11). Zhang (12) reported that high levels of triglycerides, high-density lipoproteins, cholesterol and ApoE in the blood were risk factors for developing urolithiasis. Clinical control of urolithiasis may relieve the symptoms, promote the removal of calculi, lower the risk of recurrence and reduce the effect on the kidneys. Accordingly, the present study revealed that the levels of triglycerides, high-density lipoproteins and cholesterol were significantly higher in the urolithiasis patient group when compared with the control group.\nA previous study demonstrated that ApoE polymorphisms were associated with human longevity in a Han Chinese population (13). In the current study, however, the association between ApoE polymorphisms and the age of the patients was not analyzed. In another study, the allele frequencies of the ApoE polymorphism in Zambian populations were 13.8, 59.5 and 26.7% for the E2, E3 and E4 alleles, respectively (14). Genotype frequencies of E3/3 were 32.8% in Zambian populations. The allele and genotype frequencies in Uyghur populations were different to those in Zambian populations. This may be due to the difference in ethnic background.\nIn the present study, the polymorphisms of ApoE were investigated among the Uyghur population of south Xinjiang using PCR-RFLP analysis. The number of cases with the E3/4 genotype was significantly higher in the patient group when compared with the control group (χ2=12.96; P\u0026lt;0.001). In addition, the number of cases with the E4 allele was significantly higher in the patient group when compared with the control group (χ2=6.61; P\u0026lt;0.025). Therefore, the E4 allele of the ApoE gene may be used as a potential indicator in the diagnosis and screening of urolithiasis.\nAcknowledgements This study was supported by a grant from the Xinjiang Production and Construction Corps Doctor Fund (no. 2007JC14).\nReferences  Gu Y, Wang GZ, He W, Zhang J, Yang JW, Yang F, Ye M. Analysis of relative factors of urinary stones between patients of urinary stone and the health people in Shanghai Pudong area. Lin Chang Mi Niao Wai Ke Za Zhi. 2011;26:702–705. (In Chinese) [Google Scholar] Li LD. A primer on causes, prevention and treatment of urolithiasis. Hang Kong Hang Tian Yi Xue Za Zhi. 2011;22:688–689. (In Chinese) [Google Scholar] Ye RG. Internal Medicine. 5th Edition. People’s Medical Publishing House; Beijing: 2002. Dyslipidemia and Dyslipoproteinemia; pp. 834–837. [Google Scholar] Wilkinson IB, Prasad K, Hall IR, et al. Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol. 2002;39:1005–1011. doi: 10.1016/S0735-1097(02)01723-0. [PubMed] [CrossRef] [Google Scholar] Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology. 2004;62:1869–1871. doi: 10.1212/01.WNL.0000125323.15458.3F. [PubMed] [CrossRef] [Google Scholar] Lin SK, Kao JT, Tsai SM, Tsai LY, Lin MN, Lai CJ, Zhong WL. Association of apolipoprotein E genotypes with serum lipid profiles in a healthy population of Taiwan. Ann Clin Lab Sci. 2004;34:443–448. [PubMed] [Google Scholar] Rall SC, Jr, Mahley RW. The role of apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med. 1992;231:653–659. doi: 10.1111/j.1365-2796.1992.tb01254.x. [PubMed] [CrossRef] [Google Scholar] Kong FM, Guo RX, Liu YC. The study of relationship between cholesterol crystalization and ApoE. Zhonghua Shi Yan Wai Ke Za Zhi. 2000;17:520–521. (In Chinese) [Google Scholar] Thomas A. Accelerated gene counting for haplotype frequency estimation. Ann Hum Genet. 2003;67:608–612. doi: 10.1046/j.1529-8817.2003.00054.x. [PubMed] [CrossRef] [Google Scholar] Abate N, Chandalia M, Cabo-Chan AV, Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65:386–392. doi: 10.1111/j.1523-1755.2004.00386.x. [PubMed] [CrossRef] [Google Scholar] Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol. 2006;17:2026–2033. doi: 10.1681/ASN.2006030262. [PubMed] [CrossRef] [Google Scholar] Zhang GH. Risk factors of blood lipid level in urinary calculi. Zhongguo Xing Ke Xue. 2012;21:34–37. (In Chinese) [Google Scholar] Lu F, Guan H, Gong B, Liu X, et al. Genetic variants in PVRL2-TOMM40-APOE region are associated with human longevity in a Han Chinese population. PLoS One. 2014;9:e99580. doi: 10.1371/journal.pone.0099580. [PMC free article] [PubMed] [CrossRef] [Google Scholar] Atadzhanov M, Mwaba MH, Mukomena PN, Lakhi S, et al. Frequency of APOE, MTHFR and ACE polymorphisms in the Zambian population. BMC Res Notes. 2014;7:194. doi: 10.1186/1756-0500-7-194. [PMC free article] [PubMed] [CrossRef] [Google Scholar]  ","date":1416873600,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1416873600,"objectID":"8eaf927abf2a60389ac38a2c60ad3214","permalink":"https://swcyo.netlify.app/publication/apoe/","publishdate":"2014-11-25T00:00:00Z","relpermalink":"/publication/apoe/","section":"publication","summary":"the occurrence of urolithiasis was found to be associated with ApoE gene polymorphisms, and the E4 allele may be a potential susceptibility factor for urolithiasis.","tags":["journal article"],"title":"Correlation between ApoE gene polymorphisms and the occurrence of urolithiasis","type":"publication"},{"authors":[],"categories":[],"content":"项目名称：SCL慢病毒转染重塑膀胱ICC治疗DCP的实验研究 【学科分类】：医学科学部(H) -\u0026gt; 泌尿系统(H05) -\u0026gt; 膀胱疾病(H0514) 【执行时间】：2014-01至2017-12 【关键词】 ：糖尿病膀胱;Cajal间质细胞;c-kit;SCL基因;慢病毒\n   项目负责人 王勤章 职称 主任医师     依托单位 石河子大学           研究期限 2014-01至2017-12     资助金额 48.00万元 项目类别 地区科学基金项目   批准号 81360120 学科分类 膀胱疾病   中文主题词 糖尿病膀胱;Cajal间质细胞;c-kit;SCL基因;慢病毒     英文主题词 diabetic cystopathy;interstitial cells of Cajal;c-kit;SCL gene;lentiviral         中文摘要 糖尿病膀胱病变（dcp）是糖尿病引起的泌尿系统并发症之一，我们前期研究证实高糖环境可引起膀胱cajal 间质细胞(icc)数量减少,形态改变，起搏和神经信号传导功能降低，进而引起膀胱逼尿肌兴奋和收缩功能下降，导致dcp，而通过构建scl基因重组腺病毒载体，采用 scl基因转染上调c-kit，显著改善了体外高糖环境下培养的已受损害的icc形态和功能。为了观察经膀胱灌注进行scl基因转染对在体dcp膀胱中 icc表型、形态、功能损害的重塑作用及治疗dcp的可行性及有效性，本研究拟构建scl基因重组慢病毒载体，评估慢病毒载体的体外转染效率及安全性后，经尿道将scl基因慢病毒载体灌注入dcp膀胱，通过尿流动力学和肌条实验检测膀胱功能恢复情况，并进一步通过免疫组化、细胞膜片钳、电镜、rt-pcr、western-blot等技术观察icc表型及形态、功能重塑情况，从而为dcp的临床治疗探索一条新途径。     英文摘要 diabetic cystopathy (dcp) is a complication of diabetes in urinary system. we previously demonstrated that high glucose can reduce the number of the interstitial cells of cajal (icc) in bladder and the pacing and signal-transducting function of icc. the result was related to the decrease of detrusor function, resulting in dcp. we further demonstrated gene transfection of scl can promote c-kit and restore redifferentiated icc in vitro. so we want to investigate whether gene transfection of scl can also restore redifferentiated icc and detrusor function of dcp in vivo. at first, this study is designed to assess the efficiency and safety of scl gene lentiviral vector after it constructed successfully. then , we will fill scl gene lentiviral vector into bladders of the dcp animal models through urethras. bladder function will be tested by urodynamic and accessed by contraction of detrusor strips. phenotype and function of icc will further tested by immunohistochemistry , cell patch clamp, rt-pcr、western-blot and other assays.   结题摘要 ' + item.close_summary + '    项目成果\n    序号 标题 类型 作者     1 含人干细胞白血病基因的重组慢病毒表达载体的构建及鉴定 期刊 于建超王江平李应龙钱彪倪钊王新敏李强王文晓王勤章.   2 经尿道灌注干细胞白血病基因慢病毒转染豚鼠糖尿病膀胱病变的效果研究[J] 期刊 魏艳青马路平王江平钱彪王勤章.    ","date":1376438400,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628944969,"objectID":"c6e890172e02437d5fdb4a9971ff17b3","permalink":"https://swcyo.netlify.app/project/nfsc2013/","publishdate":"2013-08-14T00:00:00Z","relpermalink":"/project/nfsc2013/","section":"project","summary":"项目名称：SCL慢病毒转染重塑膀胱ICC治疗DCP的实验研究 【学科分类】：医学科学部(H) -\u0026gt; 泌尿系统(H05) -\u0026gt; 膀胱疾病(H0514) 【执行时间】：2014-01至2017-12 【关键词】 ：糖尿病膀胱;Cajal间质细胞;c-kit;SCL基因;慢病毒\n   项目负责人 王勤章 职称 主任医师     依托单位 石河子大学           研究期限 2014-01至2017-12     资助金额 48.","tags":["project"],"title":"国家自然地区科学基金项目(81360120)","type":"project"},{"authors":[],"categories":[],"content":"项目名称：膀胱逼尿肌中一种新型二聚体Cajal样间质细胞起搏作用研究 【学科分类】：医学科学部(H) -\u0026gt; 泌尿系统(H05) -\u0026gt; 尿动力学(H0515) 【执行时间】：2011-01至2013-12 【关键词】 ：Cajal间质细胞；膀胱；逼尿肌；起搏细胞；\n   项目负责人 王勤章 职称 主任医师     依托单位 石河子大学 依托单位 石河子大学   研究期限 2011-01至2013-12 研究期限 2011-01至2013-12   资助金额 25.00万元 项目类别 地区科学基金项目   批准号 81060064 学科分类 尿动力学   中文主题词 Cajal间质细胞；膀胱；逼尿肌；起搏细胞； 中文主题词 Cajal间质细胞；膀胱；逼尿肌；起搏细胞；   英文主题词 interstitial cells of Cajal；bladder；detrusor；pacemaker cell； 英文主题词 interstitial cells of Cajal；bladder；detrusor；pacemaker cell；    ","date":1281744000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628945184,"objectID":"2bb6a3ac2f94b3608869defdf079da28","permalink":"https://swcyo.netlify.app/project/81060064/","publishdate":"2010-08-14T00:00:00Z","relpermalink":"/project/81060064/","section":"project","summary":"膀胱逼尿肌中一种新型二聚体Cajal样间质细胞起搏作用研究","tags":["project"],"title":"国家科学自然基金项目(81060064)","type":"project"},{"authors":[],"categories":[],"content":"项目名称：高糖环境下逼尿肌中SCF/c-kit信号变化及其对膀胱Cajal样间质细胞的影响 【学科分类】：医学科学部(H) -\u0026gt; 泌尿系统(H05) -\u0026gt; 继发性肾脏疾病(H0510) 【执行时间】：2009-01至2011-12 【关键词】 ：糖尿病；膀胱功能障碍；Cajal样间质细胞；c-kit；SCF；\n   项目负责人 王勤章 职称 主任医师     依托单位 石河子大学 依托单位 石河子大学   研究期限 2009-01至2011-12 研究期限 2009-01至2011-12   资助金额 23.00万元 项目类别 地区科学基金项目   批准号 30860281 学科分类 继发性肾脏疾病   中文主题词 糖尿病；膀胱功能障碍；Cajal样间质细胞；c-kit；SCF； 中文主题词 糖尿病；膀胱功能障碍；Cajal样间质细胞；c-kit；SCF；   英文主题词  英文主题词     项目成果    序号 标题 类型 作者     1 c-Kit和n-NOS2双重染色在豚鼠膀胱Cajal样间质细胞的表达 期刊 丁国富   2 糖尿病豚鼠膀胱Cajal样间质细胞形态学变化及意义 期刊 王勤章   3 高糖环境对豚鼠膀胱ICCs细胞形态及电生理的影响 期刊 李云飞   4 豚鼠膀胱Cajal样细胞在高糖环境中的形态学变化 期刊 范勇洪   5 高糖环境对豚鼠膀胱ICCs细胞超微结构的影响 期刊 王勤章   序号 标题 类型 作者    ","date":1218672000,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":1628945285,"objectID":"691731e1891170ae7334c273efd56cb7","permalink":"https://swcyo.netlify.app/project/30860281/","publishdate":"2008-08-14T00:00:00Z","relpermalink":"/project/30860281/","section":"project","summary":"高糖环境下逼尿肌中SCF/c-kit信号变化及其对膀胱Cajal样间质细胞的影响","tags":["project"],"title":"国家科学自然基金项目(30860281)","type":"project"},{"authors":null,"categories":null,"content":"","date":-62135596800,"expirydate":-62135596800,"kind":"page","lang":"en","lastmod":-62135596800,"objectID":"f26b5133c34eec1aa0a09390a36c2ade","permalink":"https://swcyo.netlify.app/admin/config.yml","publishdate":"0001-01-01T00:00:00Z","relpermalink":"/admin/config.yml","section":"","summary":"","tags":null,"title":"","type":"wowchemycms"}]